US20230357433A1 - Inflammatory cytokines and fatigue in subject with a complement mediated disease - Google Patents
Inflammatory cytokines and fatigue in subject with a complement mediated disease Download PDFInfo
- Publication number
- US20230357433A1 US20230357433A1 US18/164,521 US202318164521A US2023357433A1 US 20230357433 A1 US20230357433 A1 US 20230357433A1 US 202318164521 A US202318164521 A US 202318164521A US 2023357433 A1 US2023357433 A1 US 2023357433A1
- Authority
- US
- United States
- Prior art keywords
- antibody
- amino acid
- seq
- acid sequence
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000295 complement effect Effects 0.000 title claims abstract description 74
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 71
- 230000001404 mediated effect Effects 0.000 title claims abstract description 70
- 201000010099 disease Diseases 0.000 title claims abstract description 68
- 102000004127 Cytokines Human genes 0.000 title description 37
- 108090000695 Cytokines Proteins 0.000 title description 37
- 230000002757 inflammatory effect Effects 0.000 title description 30
- 238000000034 method Methods 0.000 claims abstract description 91
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 188
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 179
- 102000004889 Interleukin-6 Human genes 0.000 claims description 61
- 108090001005 Interleukin-6 Proteins 0.000 claims description 61
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 54
- 108090000174 Interleukin-10 Proteins 0.000 claims description 54
- 102000003814 Interleukin-10 Human genes 0.000 claims description 54
- 208000011038 Cold agglutinin disease Diseases 0.000 claims description 50
- 206010009868 Cold type haemolytic anaemia Diseases 0.000 claims description 50
- 230000006872 improvement Effects 0.000 claims description 16
- 230000002829 reductive effect Effects 0.000 claims description 11
- 210000004369 blood Anatomy 0.000 claims description 9
- 239000008280 blood Substances 0.000 claims description 9
- 208000017667 Chronic Disease Diseases 0.000 claims description 7
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 6
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 238000012544 monitoring process Methods 0.000 claims description 4
- 230000008859 change Effects 0.000 claims description 2
- 206010016256 fatigue Diseases 0.000 description 78
- 235000001014 amino acid Nutrition 0.000 description 60
- 150000001413 amino acids Chemical class 0.000 description 56
- 229940024606 amino acid Drugs 0.000 description 54
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 36
- 108010074051 C-Reactive Protein Proteins 0.000 description 27
- 102100032752 C-reactive protein Human genes 0.000 description 27
- 206010061218 Inflammation Diseases 0.000 description 25
- 230000004054 inflammatory process Effects 0.000 description 25
- 230000000694 effects Effects 0.000 description 23
- 229940121331 sutimlimab Drugs 0.000 description 23
- 230000027455 binding Effects 0.000 description 22
- 229920001213 Polysorbate 20 Polymers 0.000 description 20
- 230000024203 complement activation Effects 0.000 description 20
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 20
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 20
- 239000012634 fragment Substances 0.000 description 19
- 229960002885 histidine Drugs 0.000 description 19
- 239000000203 mixture Substances 0.000 description 19
- 208000024891 symptom Diseases 0.000 description 19
- 239000000427 antigen Substances 0.000 description 17
- 108091007433 antigens Proteins 0.000 description 17
- 102000036639 antigens Human genes 0.000 description 17
- 239000000090 biomarker Substances 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- 230000035772 mutation Effects 0.000 description 15
- 241000282414 Homo sapiens Species 0.000 description 13
- 238000009472 formulation Methods 0.000 description 13
- 235000002639 sodium chloride Nutrition 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
- -1 IL-1β Proteins 0.000 description 11
- 230000007423 decrease Effects 0.000 description 11
- 239000012530 fluid Substances 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 238000011068 loading method Methods 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 238000006467 substitution reaction Methods 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 102000009109 Fc receptors Human genes 0.000 description 9
- 108010087819 Fc receptors Proteins 0.000 description 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 9
- 229930006000 Sucrose Natural products 0.000 description 9
- 206010065579 multifocal motor neuropathy Diseases 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- 229920001184 polypeptide Polymers 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 239000005720 sucrose Substances 0.000 description 9
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 8
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 8
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 7
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 7
- 102000015696 Interleukins Human genes 0.000 description 7
- 108010063738 Interleukins Proteins 0.000 description 7
- 208000005777 Lupus Nephritis Diseases 0.000 description 7
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 7
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 7
- 208000007502 anemia Diseases 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 238000001990 intravenous administration Methods 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000003381 stabilizer Substances 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 206010018910 Haemolysis Diseases 0.000 description 5
- 102000013691 Interleukin-17 Human genes 0.000 description 5
- 108050003558 Interleukin-17 Proteins 0.000 description 5
- 108090001007 Interleukin-8 Proteins 0.000 description 5
- 102000004890 Interleukin-8 Human genes 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 230000008588 hemolysis Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 230000000770 proinflammatory effect Effects 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000012384 transportation and delivery Methods 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 102100037850 Interferon gamma Human genes 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 108010065805 Interleukin-12 Proteins 0.000 description 4
- 108090000171 Interleukin-18 Proteins 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- 208000012192 Mucous membrane pemphigoid Diseases 0.000 description 4
- 206010034277 Pemphigoid Diseases 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 4
- 201000010002 cicatricial pemphigoid Diseases 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 4
- 239000008121 dextrose Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 206010028417 myasthenia gravis Diseases 0.000 description 4
- 208000008795 neuromyelitis optica Diseases 0.000 description 4
- 229920001983 poloxamer Polymers 0.000 description 4
- 229920000136 polysorbate Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000003442 weekly effect Effects 0.000 description 4
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 3
- 102000016917 Complement C1 Human genes 0.000 description 3
- 108010028774 Complement C1 Proteins 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 206010047115 Vasculitis Diseases 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 239000006172 buffering agent Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 3
- 230000004154 complement system Effects 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 201000003278 cryoglobulinemia Diseases 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 229940047122 interleukins Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000012669 liquid formulation Substances 0.000 description 3
- 239000012931 lyophilized formulation Substances 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 235000006109 methionine Nutrition 0.000 description 3
- 229960004452 methionine Drugs 0.000 description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 208000033808 peripheral neuropathy Diseases 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 239000012929 tonicity agent Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 2
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 2
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 description 2
- 108010091326 Cryoglobulins Proteins 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 208000010428 Muscle Weakness Diseases 0.000 description 2
- 206010028372 Muscular weakness Diseases 0.000 description 2
- YNLCVAQJIKOXER-UHFFFAOYSA-N N-[tris(hydroxymethyl)methyl]-3-aminopropanesulfonic acid Chemical compound OCC(CO)(CO)NCCCS(O)(=O)=O YNLCVAQJIKOXER-UHFFFAOYSA-N 0.000 description 2
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 2
- 206010067776 Ocular pemphigoid Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 2
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 206010039509 Scab Diseases 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 208000027094 acute motor and sensory axonal neuropathy Diseases 0.000 description 2
- 208000027137 acute motor axonal neuropathy Diseases 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 150000005215 alkyl ethers Chemical class 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 238000009175 antibody therapy Methods 0.000 description 2
- 239000013011 aqueous formulation Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 208000000594 bullous pemphigoid Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 229960002433 cysteine Drugs 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 229960001259 diclofenac Drugs 0.000 description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
- 229960000616 diflunisal Drugs 0.000 description 2
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 2
- MUCZHBLJLSDCSD-UHFFFAOYSA-N diisopropyl fluorophosphate Chemical compound CC(C)OP(F)(=O)OC(C)C MUCZHBLJLSDCSD-UHFFFAOYSA-N 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 229960005293 etodolac Drugs 0.000 description 2
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229960001419 fenoprofen Drugs 0.000 description 2
- 229960005051 fluostigmine Drugs 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 208000007475 hemolytic anemia Diseases 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 2
- 229960000991 ketoprofen Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 229960004270 nabumetone Drugs 0.000 description 2
- 229960002009 naproxen Drugs 0.000 description 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 2
- 229920002113 octoxynol Polymers 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 2
- 229960002739 oxaprozin Drugs 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
- 229960002702 piroxicam Drugs 0.000 description 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 2
- 230000004983 pleiotropic effect Effects 0.000 description 2
- 229960000502 poloxamer Drugs 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 230000006337 proteolytic cleavage Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 2
- 229960000894 sulindac Drugs 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- LDDMACCNBZAMSG-BDVNFPICSA-N (2r,3r,4s,5r)-3,4,5,6-tetrahydroxy-2-(methylamino)hexanal Chemical compound CN[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO LDDMACCNBZAMSG-BDVNFPICSA-N 0.000 description 1
- XJOTXKZIRSHZQV-RXHOOSIZSA-N (3S)-3-amino-4-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S,3S)-1-[[(1R,6R,12R,17R,20S,23S,26R,31R,34R,39R,42S,45S,48S,51S,59S)-51-(4-aminobutyl)-31-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]-20-benzyl-23-[(2S)-butan-2-yl]-45-(3-carbamimidamidopropyl)-48-(hydroxymethyl)-42-(1H-imidazol-4-ylmethyl)-59-(2-methylsulfanylethyl)-7,10,19,22,25,33,40,43,46,49,52,54,57,60,63,64-hexadecaoxo-3,4,14,15,28,29,36,37-octathia-8,11,18,21,24,32,41,44,47,50,53,55,58,61,62,65-hexadecazatetracyclo[32.19.8.26,17.212,39]pentahexacontan-26-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)[C@@H](C)O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](Cc5ccccc5)NC(=O)[C@@H](NC1=O)[C@@H](C)CC)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1cnc[nH]1)NC3=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N2)C(=O)NCC(=O)N4)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XJOTXKZIRSHZQV-RXHOOSIZSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- GBBSUAFBMRNDJC-MRXNPFEDSA-N (5R)-zopiclone Chemical compound C1CN(C)CCN1C(=O)O[C@@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-MRXNPFEDSA-N 0.000 description 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010089414 Anaphylatoxins Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000035913 Atypical hemolytic uremic syndrome Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 206010018370 Glomerulonephritis membranoproliferative Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 206010020974 Hypocomplementaemia Diseases 0.000 description 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010005714 Interferon beta-1b Proteins 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 208000004451 Membranoproliferative Glomerulonephritis Diseases 0.000 description 1
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010028293 Muscle contractions involuntary Diseases 0.000 description 1
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 208000010476 Respiratory Paralysis Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108700028909 Serum Amyloid A Proteins 0.000 description 1
- 102000054727 Serum Amyloid A Human genes 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000004732 Systemic Vasculitis Diseases 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002391 anti-complement effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 108010008730 anticomplement Proteins 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960004823 armodafinil Drugs 0.000 description 1
- YFGHCGITMMYXAQ-LJQANCHMSA-N armodafinil Chemical compound C=1C=CC=CC=1C([S@](=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-LJQANCHMSA-N 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000037424 autonomic function Effects 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229940021459 betaseron Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- JURKNVYFZMSNLP-UHFFFAOYSA-N cyclobenzaprine Chemical compound C1=CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 JURKNVYFZMSNLP-UHFFFAOYSA-N 0.000 description 1
- 229960003572 cyclobenzaprine Drugs 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 206010061811 demyelinating polyneuropathy Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 229960005426 doxepin Drugs 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- HCFDWZZGGLSKEP-UHFFFAOYSA-N doxylamine Chemical compound C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 HCFDWZZGGLSKEP-UHFFFAOYSA-N 0.000 description 1
- 229960005178 doxylamine Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000012893 effector ligand Substances 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 201000001505 hemoglobinuria Diseases 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 102000018511 hepcidin Human genes 0.000 description 1
- 108060003558 hepcidin Proteins 0.000 description 1
- 229940066919 hepcidin Drugs 0.000 description 1
- 244000038280 herbivores Species 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 1
- 229960000240 hydrocodone Drugs 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000000819 hypertonic solution Substances 0.000 description 1
- 239000000815 hypotonic solution Substances 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- BQINXKOTJQCISL-GRCPKETISA-N keto-neuraminic acid Chemical compound OC(=O)C(=O)C[C@H](O)[C@@H](N)[C@@H](O)[C@H](O)[C@H](O)CO BQINXKOTJQCISL-GRCPKETISA-N 0.000 description 1
- 208000027905 limb weakness Diseases 0.000 description 1
- 231100000861 limb weakness Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000001617 median nerve Anatomy 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229960001344 methylphenidate Drugs 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 229960001785 mirtazapine Drugs 0.000 description 1
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229960001165 modafinil Drugs 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000001538 myasthenic effect Effects 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- CERZMXAJYMMUDR-UHFFFAOYSA-N neuraminic acid Natural products NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO CERZMXAJYMMUDR-UHFFFAOYSA-N 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 239000013631 noncovalent dimer Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 229960001158 nortriptyline Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 244000054334 omnivore Species 0.000 description 1
- 235000020912 omnivore Nutrition 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 229960002085 oxycodone Drugs 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 238000002616 plasmapheresis Methods 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920005606 polypropylene copolymer Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 244000062645 predators Species 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960001233 pregabalin Drugs 0.000 description 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229960003910 promethazine Drugs 0.000 description 1
- 230000001003 psychopharmacologic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 210000002979 radial nerve Anatomy 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 208000012263 renal involvement Diseases 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000009774 resonance method Methods 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 210000002972 tibial nerve Anatomy 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 229960004380 tramadol Drugs 0.000 description 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 1
- 229960003991 trazodone Drugs 0.000 description 1
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000000658 ulnar nerve Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 229960001475 zolpidem Drugs 0.000 description 1
- ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 description 1
- 229960000820 zopiclone Drugs 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5412—IL-6
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5428—IL-10
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/22—Haematology
- G01N2800/224—Haemostasis or coagulation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
- G01N2800/306—Chronic fatigue syndrome
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Definitions
- the present application relates to methods for treating complement-mediated diseases and associated conditions.
- CAD Cold agglutinin disease
- a pro-inflammatory state secondary to complement activation has been demonstrated in other hemolytic diseases such as paroxysmal nocturnal hemoglobinuria and atypical-hemolytic uremic syndrome.
- Complement cascade activation stimulates cytokine production (TNF, IL-6, IL-8, IL-17) via anaphylatoxins C3a and C5a and increases vascular inflammatory markers, consistent with complement-mediated inflammation.
- complement activation and chronic inflammation may contribute to patient fatigue in cold agglutinin disease (CAD), apart from anemia.
- CAD cold agglutinin disease
- Some aspects of the present disclosure provide a method comprising administering to a subject an anti-C1s antibody (e.g., the anti-C1s antibody of Table 1 or Table 2) and measuring a level of C reactive protein (CRP), IL-6, and/or IL-10 in a sample (e.g., blood, e.g., serum) from the subject.
- the method further comprises assessing fatigue (e.g., measuring FACIT-F score) in the subject.
- aspects of the present disclosure provide a method comprising measuring a level of CRP, IL-6, and/or IL-10 in a sample from a subject being treated with an anti-C1s antibody (e.g., sutimlimab). In some embodiments, the method further comprises assessing fatigue in the subject.
- an anti-C1s antibody e.g., sutimlimab
- a level of CRP is measured.
- CRP in some embodiments, is used as a surrogate for IL-6.
- a level of IL-6 is measured.
- IL-10 is measured.
- the subject has a complement-mediated disease. In some embodiments, the subject has CAD.
- the subject has fatigue.
- Yet other aspects of the present disclosure provide a method comprising treating a subject with an anti-C1s antibody therapy (e.g., sutimlimab therapy), wherein the subject has fatigue, and measuring a level of CRP, IL-6, and/or IL-10 in a sample from the subject.
- the method further comprises assessing fatigue in the subject.
- the subject has a complement-mediated disease, for example, CAD.
- the method further comprises assessing fatigue in the subject.
- the subject has fatigue.
- the subject has a baseline level of CRP, IL-6, and/or IL-10 prior to treatment with an anti-C1s antibody (e.g., sutimlimab), and/or wherein the subject has a baseline level of fatigue prior to treatment with an anti-C1s antibody.
- an anti-C1s antibody e.g., sutimlimab
- the method further comprises continuing with a current anti-C1s antibody treatment (e.g., sutimlimab treatment).
- the method further comprises altering a current anti-C1s antibody treatment. In some embodiments, if the level of CRP, IL-6, and/or IL-10 in the sample is within 5% or within 10% of baseline, the method further comprises altering a current anti-C1s antibody treatment. In some embodiments, if fatigue the subject is maintained or worsens relative to baseline, the method further comprises altering a current anti-C1s antibody treatment.
- altering the current anti-C1s antibody treatment comprises adjusting the dosage and/or frequency of the treatment with the anti-C1s antibody.
- altering the current anti-C1s antibody treatment comprises further treatment of the subject with an anti-inflammatory agent.
- altering the current anti-C1s antibody treatment comprises further treatment of the subject to improve fatigue.
- a method further comprises monitoring levels (e.g., reassessing levels) of CRP, IL-6, and/or IL-10 in the subject over a period of time (e.g., hours, days, weeks, or months).
- the subject has undergone a blood transfusion. In some embodiments, the subject has undergone a blood transfusion prior to commencing treatment with an anti-C1s antibody, e.g., within a month, within 3 weeks, within 2 weeks, or within 1 week.
- the fatigue is assessed based on a Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) score.
- FACIT-F Functional Assessment of Chronic Illness Therapy-Fatigue
- an improvement in fatigue is a change by at least 3 (e.g., at least 4, 5, 6, 7, 8, 9, or 10) points on a FACIT-F score relative to baseline.
- the anti-C1s antibody comprises a heavy chain (HC) complementarity determining region 1 (CDR1) comprising the amino acid sequence of SEQ ID NO: 5, an HC complementarity determining region 2 (CDR2) comprising the amino acid sequence of SEQ ID NO: 6, an HC complementarity determining region 3 (CDR3) comprising the amino acid sequence of SEQ ID NO: 7, a light chain (LC) CDR1 that comprises the amino acid sequence of SEQ ID NO: 8, an LC CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and an LC CDR3 comprising the amino acid sequence of SEQ ID NO: 10.
- HC heavy chain
- CDR1 comprising the amino acid sequence of SEQ ID NO: 5
- CDR2 comprising the amino acid sequence of SEQ ID NO: 6
- CDR3 comprising the amino acid sequence of SEQ ID NO: 7
- LC CDR1 that comprises the amino acid sequence of SEQ ID NO: 8
- an LC CDR2 comprising the amino acid sequence of SEQ ID NO
- the anti-C1s antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 3 and comprises a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 4.
- the anti-C1s antibody comprises an HC comprising the amino acid sequence of SEQ ID NO: 1 and an LC comprising the amino acid sequence of SEQ ID NO: 2.
- the anti-C1s antibody comprises an HC CDR1 comprising the amino acid sequence of SEQ ID NO: 15, an HC CDR2 comprising the amino acid sequence of SEQ ID NO: 16, an HC CDR3 comprising the amino acid sequence of SEQ ID NO: 17, an LC CDR1 comprising the amino acid sequence of SEQ ID NO: 18, an LC CDR2 comprising the amino acid sequence of SEQ ID NO: 19, and an LC CDR3 comprising the amino acid sequence of SEQ ID NO: 20.
- the anti-C1s antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 13 and comprises a VL comprising the amino acid sequence of SEQ ID NO: 14.
- the anti-C1s antibody comprises an HC comprising the amino acid sequence of SEQ ID NO: 11 and an LC comprising the amino acid sequence of SEQ ID NO: 12.
- the anti-C1s antibody comprises an IgG4 constant region.
- WO 2014/071206, filed Nov. 2, 2012, entitled Anti-Complement C1s Antibodies and Uses Thereof, WO 2016/164358, filed Apr. 6, 2015, entitled Humanized Anti-C1s Antibodies and Methods of Use Thereof, and in WO 2018/170145, filed Mar. 14, 2017, entitled Methods for Treating Complement-Mediated Diseases and Disorders is herein incorporated by reference in its entirety.
- FIG. 1 shows changes in proinflammatory cytokine IL-6 levels (B) and FACIT-F (A) scores at baseline and over time in patients with cold agglutinin disease (CAD).
- FACIT-F functional assessment of chronic illness therapy-fatigue
- SEM standard error of the mean
- TAT treatment assessment timepoint.
- Mean and SEM values from week 25 were used to represent the TAT. Normal control values for IL-6 were ⁇ 3.2 pg/mL.
- FIG. 2 shows changes in regulatory cytokine IL-10 levels (B) and FACIT-F (A) scores at baseline and over time in patients with CAD.
- FACIT-F functional assessment of chronic illness therapy-fatigue
- SEM standard error of the mean
- TAT treatment assessment timepoint.
- Mean and SEM values from week 25 were used to represent the TAT.
- FIG. 3 shows effect of sutimlimab treatment on mean IL-6 level (A), fatigue (B), mean total C4 (C), and classical complement pathway activity (D) in patients with CAD.
- Mean and SEM values from Week 25 were used to represent the TAT. Normal values for IL-6 were ⁇ 3.2 pg/mL.
- CAD cold agglutinin disease
- CP classical complement pathway
- FACIT-Fatigue Functional Assessment of Chronic Illness Therapy-Fatigue
- IL interleukin
- SEM standard error of the mean
- TAT treatment assessment time point.
- FIG. 4 shows effect of sutimlimab treatment on mean IL-10 level (A), fatigue (B), mean total C4 (C), and classical complement pathway activity (D) in patients with CAD.
- Mean and SEM values from Week 25 were used to represent the TAT.
- CAD cold agglutinin disease
- CP classical complement pathway
- FACIT-Fatigue Functional Assessment of Chronic Illness Therapy-Fatigue
- IL interleukin
- SEM standard error of the mean
- TAT treatment assessment time point.
- the complement system is a well-known effector mechanism of the immune response, providing not only protection against pathogens and other harmful agents but also recovery from injury.
- the complement pathway comprises proteins that typically exist in the body in inactive form.
- the classical complement pathway is triggered by activation of the first component of complement, referred to as the C1 complex, which includes C1q, C1r, and C1s proteins.
- the C1s component a diisopropyl fluorophosphate (DFP)-sensitive serine protease, cleaves complement components C4 and C2 to initiate activation of the classical complement pathway.
- DFP diisopropyl fluorophosphate
- the classical complement pathway plays a role in cold agglutinin disease, for example.
- CAD Cold agglutinin disease
- AIHA chronic autoimmune hemolytic anemia
- Symptoms of CAD can include chronic hemolysis, anemia and related symptoms (e.g., dyspnea), hemoglobinuria, jaundice, and circulatory symptoms.
- Some people who have cold agglutinin disease also may get a cold, numb feeling and loss of color in their fingers or toes, known as Raynaud's phenomenon.
- the data provided herein demonstrated a relationship between inflammatory cytokine expression (e.g., IL-6 and IL-10) and fatigue in CAD patients treated with the humanized monoclonal anti-C1s antibody, sutimlimab.
- inflammatory cytokine expression e.g., IL-6 and IL-10
- fatigue in CAD patients treated with the humanized monoclonal anti-C1s antibody, sutimlimab.
- IL-6 is a pro-inflammatory cytokine featuring pleiotropic activity; it induces synthesis of acute phase proteins such as CRP, serum amyloid A, fibrinogen, and hepcidin in hepatocytes, whereas it inhibits production of albumin.
- IL-6 also plays an important role on acquired immune response by stimulation of antibody production and of effector T-cell development. Moreover, IL-6 can promote differentiation or proliferation of several nonimmune cells. Because of the pleiotropic activity, dysregulated continual production of IL-6 leads to the onset or development of various diseases.
- IL-10 formerly known as cytokine synthesis inhibitory factor and namesake of the corresponding cytokine family, is regarded as a key immunoregulatory cytokine capable of curbing overt inflammation in various pathophysiological settings.
- IL-10 has the capability to curb production of key effector mediators involved in development of tissue damage, among others reactive oxygen species (and matrix metalloproteinases.
- Fatigue is a common symptom of CAD. While not solely caused by anemia, the fatigue in CAD is presumed to be secondary to the hemolytic anemia, which refers to low numbers of RBCs as a result of their destruction. RBCs are responsible for delivering oxygen to all parts of the body, and for removing carbon dioxide that is generated because of metabolic activity. When RBC numbers are low due to hemolytic anemia, the organs receive less oxygen than required for their normal function. This affects all organs of the body, especially those that require high energy for their function. The result is tiredness and fatigue because the body is not able to keep up with the energy demand of daily tasks.
- the present disclosure is based in part, on the observation that subjects with a complement-mediated disease (e.g., CAD), who are receiving treatment with an anti-C1s antibody, show a decrease in the levels of inflammatory cytokines along with a concomitant improvement in symptoms of fatigue.
- CAD complement-mediated disease
- the present disclosure provides methods of monitoring and/or treating inflammation and/or fatigue in subjects with complement-mediated disorders, by analyzing the status of one or more inflammatory cytokines (e.g., IL-6, IL-8, IL-10, IL-12, IL-17, IL-18, IL-1 ⁇ , IFN- ⁇ , TNF- ⁇ , TNF-receptor, etc.) in said patients.
- the status of one or more inflammatory cytokines is determined by measuring the level of one or more biomarkers of inflammation.
- the levels of inflammatory cytokines and/or biomarkers of inflammation provide an objective measure of fatigue. Methods of measuring levels of inflammatory cytokines and/or biomarkers of inflammation are known in the art.
- the level of an inflammatory cytokine or biomarker of inflammation may be measured using standard electrophoretic and immunodiagnostic techniques, including but not limited to immunoassays such as competition, direct reaction, or sandwich type assays. Such techniques include, but are not limited to, Western blots; agglutination tests; enzyme-labeled and mediated immunoassays, such as an ELISA; biotin/avidin assays; radioimmunoassays; immunoelectrophoresis; immunoprecipitation, etc.
- the methods may include plasmon resonance methods, or any method that detects the presence of an inflammatory cytokine or biomarker of inflammation by the binding of an antibody, aptamer, or other binding molecule.
- the present disclosure provides a method comprising administering to a subject an anti-C1s antibody (e.g., the anti-C1s antibody of Table 1 or Table 2); measuring a level of one or more biomarkers of inflammation (e.g., CRP), or one or more inflammatory cytokines (e.g., IL-6, and/or IL-10) in a sample (e.g., blood, e.g., serum) from the subject.
- the subject has a complement-mediated disease, such as CAD.
- the subject has fatigue.
- the present disclosure provides a method comprising measuring a level of one or more biomarkers of inflammation (e.g., CRP), or one or more inflammatory cytokines (e.g., IL-6, and/or IL-10) in a sample from a subject being treated with an anti-C1s antibody (e.g., the anti-C1s antibody of Table 1 or Table 2).
- the subject in some embodiments, has a complement-mediated disease (e.g., CAD). In some embodiments, the subject has fatigue.
- Yet other aspects of the present disclosure provide a method comprising treating a subject with an anti-C1s antibody (e.g., the anti-C1s antibody of Table 1 or Table 2), wherein the subject has fatigue, and measuring a level of one or more biomarkers of inflammation (e.g., CRP), or one or more inflammatory cytokines (e.g., IL-6, and/or IL-10) in a sample from the subject.
- an anti-C1s antibody e.g., the anti-C1s antibody of Table 1 or Table 2
- the subject has fatigue
- a level of one or more biomarkers of inflammation e.g., CRP
- one or more inflammatory cytokines e.g., IL-6, and/or IL-10
- the subject has a complement-mediated disease, such as CAD.
- an anti-C1s antibody e.g., the anti-C1s antibody of Table 1 or Table 2
- the subject has a complement mediated disease (e.g., CAD)
- CAD complement mediated disease
- CRP biomarkers of inflammation
- IL-6 inflammatory cytokines
- IL-6 inflammatory cytokines
- a level of CRP is measured.
- CRP in some embodiments, is used as a surrogate for IL-6.
- a level of IL-6 is measured.
- a level of IL-10 is measured.
- a method of the present disclosure further comprises assessing fatigue in the subject.
- the fatigue is assessed based on a FACIT-F score.
- the FACIT-F is a 13-item patient-reported outcome instrument that was designed to assess fatigue-related symptoms and impacts on daily functioning (Cella et al. Cancer 94(2):528-238 (2002)); Yellen et al., J Pain Symptom Manage 13(2):63-74 (1997); Lai et al., J Rheumatol 38(4):672-9 (2011); Reddy et al., J Palliat Med 19(5):1068-75 (2007)). Other methods of assessing fatigue may be used.
- Fatigue Severity Scale FSS
- Fatigue Impact Scale FIS
- BFI Brief Fatigue Inventory
- FSI Fatigue Symptom Inventory
- MAF Multidimensional Assessment of Fatigue
- MFSI Multidimensional Fatigue Symptom Inventory
- the subject has a baseline level of CRP, IL-6, and/or IL-10 prior to treatment with an anti-C1s antibody.
- the subject has a baseline level of CRP of greater than 3 mg/mL (e.g., greater than 4 mg/mL, greater than 5 mg/mL, greater than 6 mg/mL, greater than 7 mg/mL, greater than 8 mg/mL, greater than 9 mg/mL, or greater than 10 mg/mL, greater than 20 mg/mL, greater than 50 mg/mL, etc.).
- the subject has a baseline level of IL-6 of greater than 1.8 pg/mL (e.g., greater than 2 pg/mL, greater than 2.5 pg/mL, greater than 3 pg/mL, between about 1.8 pg/mL and about 2 pg/mL, between about 2 pg/mL to about 2.5 pg/mL, between about 2.5 to about 3 pg/mL, between about 3 pg/mL to about 3.5 pg/mL, between about 3.5 pg/mL to about 4 pg/mL, etc.).
- 1.8 pg/mL e.g., greater than 2 pg/mL, greater than 2.5 pg/mL, greater than 3 pg/mL, between about 1.8 pg/mL and about 2 pg/mL, between about 2 pg/mL to about 2.5 pg/mL, between about 2.5 to about 3 pg/mL, between about 3
- the subject has a baseline level of IL-10 of greater than 1 pg/mL (e.g., greater than 1.1 pg/mL, greater than 1.2 pg/mL, greater than 1.3 pg/mL, greater than 1.4 pg/mL, greater than 1.5 pg/mL, 2 pg/mL, greater than 2.5 pg/mL, greater than 3 pg/mL, between about 1 pg/mL to about 1.5 pg/mL, between about 1 pg/mL and about 2 pg/mL, between about 2 pg/mL to about 2.5 pg/mL, between about 2.5 to about 3 pg/mL, between about 3 pg/mL to about 3.5 pg/mL, between about 3.5 pg/mL to about 4 pg/mL, etc.).
- 1 pg/mL e.g., greater than 1.1 pg/mL, greater than 1.2 p
- the subject has a baseline level of fatigue prior to treatment with an anti-C1s antibody.
- the baseline level of fatigue is assessed based on a FACIT-F score.
- the baseline FACIT-F score of a subject ranges from 20-25, 25-30, 30-35, or 35-40.
- the baseline FACIT-F score of a subject is 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40.
- the levels of one or more biomarkers of inflammation are monitored over a period of time (e.g., 1 week, one month, 6-8 weeks, three months, six months, a year, two years, etc.).
- the levels are assessed once a week, biweekly, bimonthly, or monthly over the course of several months (e.g., at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, etc.) or over the course of several years (e.g., at least 2, 3, 4, 5, etc.).
- the method further comprises continuing with a current anti-C1s antibody treatment.
- an improvement in fatigue is an improvement of at least at 3 points (e.g., at least 4 points, at least 5 points, at least 6 points, at least 7 points, at least 8 points, at least 9 points, at least 10 points, at least 11 points, at least 12 points, at least 13 points, at least 14 points, at least 15 points, 3-15 points, 3-10 points, 3-5 points, 5-15 points, 5-10 points, etc.) on the FACIT-F score relative to baseline.
- 3 points e.g., at least 4 points, at least 5 points, at least 6 points, at least 7 points, at least 8 points, at least 9 points, at least 10 points, at least 11 points, at least 12 points, at least 13 points, at least 14 points, at least 15 points, 3-15 points, 3-10 points, 3-5 points, 5-15 points, 5-10 points, etc.
- the method further comprises altering a current anti-C1s antibody treatment.
- the fatigue is assessed based on a FACIT-F score.
- a worsening in fatigue is a decrease of at least at 3 points (e.g., at least 4 points, at least 5 points, at least 6 points, at least 7 points, at least 8 points, at least 9 points, at least 10 points, at least 11 points, at least 12 points, at least 13 points, at least 14 points, at least 15 points, 3-15 points, 3-10 points, 3-5 points, 5-15 points, 5-10 points, etc.) on the FACIT-F score relative to baseline.
- 3 points e.g., at least 4 points, at least 5 points, at least 6 points, at least 7 points, at least 8 points, at least 9 points, at least 10 points, at least 11 points, at least 12 points, at least 13 points, at least 14 points, at least 15 points, 3-15 points, 3-10 points, 3-5 points, 5-15 points, 5-10 points, etc.
- the levels of one or more biomarkers of inflammation are measured at a first point in time and a second point in time after commencing treatment with the anti-C1s antibody.
- the first point in time and the second point in time are a few days apart (e.g., less than 1 week), 1 week apart, 2 weeks apart, 3 weeks apart, 1 month apart, 2 months apart, or several months apart (e.g., at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, etc.).
- the method further comprises if the level of one or more biomarkers of inflammation (e.g., CRP), or one or more inflammatory cytokines (e.g., IL-6, and/or IL-10) in the sample is reduced, for example, by at least 5% or by at least 10% (e.g., at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, or at least 80%, between about 5% to about 10%, between about 10% to about 15%, between about 15% to about 20%, between about 20% to about 25%, between about 25% to about 30%, between about 30% to about 40%, between about 40% to about 50%, between about 50% to about 60%, between about 60% to about 80%, etc., or if the levels are reduced to a level that is within the normal range for that biomarker or inflammatory cytokine) at the second time point relative to the first time point and/or fatigue in the subject is improved relative to the first time point, the method further comprises
- the method further comprises altering a current anti-C1s antibody treatment.
- one or more biomarkers of inflammation e.g., CRP
- one or more inflammatory cytokines e.g., IL-6, and/or IL-10
- a worsening in fatigue is a decrease of at least at 3 points (e.g., at least 4 points, at least 5 points, at least 6 points, at least 7 points, at least 8 points, at least 9 points, at least 10 points, at least 11 points, at least 12 points, at least 13 points, at least 14 points, at least 15 points, 3-15 points, 3-10 points, 3-5 points, 5-15 points, 5-10 points, etc.) on the FACIT-F score relative to baseline.
- 3 points e.g., at least 4 points, at least 5 points, at least 6 points, at least 7 points, at least 8 points, at least 9 points, at least 10 points, at least 11 points, at least 12 points, at least 13 points, at least 14 points, at least 15 points, 3-15 points, 3-10 points, 3-5 points, 5-15 points, 5-10 points, etc.
- continuing with a current anti-C1s antibody treatment comprises: a) administering an effective dose of about 6.5 g of the anti-C1s antibody on Day 1; b) administering an effective dose of about 6.5 g of the anti-C1s antibody on Day 8; and c) administering an effective dose of about 6.5 g of the anti-C1s antibody every other week following the Day 8 administration.
- an effective dose of about 6.5 g of the anti-C1s antibody is administered to the individual every other week for a period of time from about 4 weeks to 1 year, e.g., from about 4 weeks to about 8 weeks, from about 2 months to about 6 months, or from about 6 months to 1 year.
- an effective dose of about 6.5 g of the anti-C1s antibody is administered to the individual every other week for a period of time of more than 1 year.
- an effective dose of about 6.5 g of the anti-C1s antibody is administered to the individual every other week for a period of time from 1 year to 50 years, e.g., from 1 year to 2 years, from 2 years to 5 years, from 5 years to 10 years, from 10 years to 20 years, from 20 years to 30 years, from 30 years to 40 years, or from 40 years to 50 years.
- continuing with a current anti-C1s antibody treatment comprises: a) administering an effective dose of about 7.5 g of the anti-C1s antibody on Day 1; b) administering an effective dose of about 7.5 g of the anti-C1s antibody on Day 8; and c) administering an effective dose of about 7.5 g of the anti-C1s antibody every other week following the Day 8 administration.
- an effective dose of about 7.5 g of the anti-C1s antibody is administered to the individual every other week for a period of time from about 4 weeks to 1 year, e.g., from about 4 weeks to about 8 weeks, from about 2 months to about 6 months, or from about 6 months to 1 year.
- an effective dose of about 7.5 g of the anti-C1s antibody is administered to the individual every other week for a period of time of more than 1 year.
- an effective dose of about 7.5 g of the anti-C1s antibody is administered to the individual every other week for a period of time from 1 year to 50 years, e.g., from 1 year to 2 years, from 2 years to 5 years, from 5 years to 10 years, from 10 years to 20 years, from 20 years to 30 years, from 30 years to 40 years, or from 40 years to 50 years.
- altering treatment with the anti-C1s antibody comprises adjusting the dosage and/or frequency of the treatment with the anti-C1s antibody.
- adjusting the dosage and/or frequency of the treatment with the anti-C1s antibody involves increasing the dosage and/or frequency of the treatment with the anti-C1s antibody.
- the effective dose of the anti-C1s antibody is increased by about 0.1 g to about 0.5 g, about 0.5 g to about 1 g, about 1 g to about 1.5 g, about 1.5 g to about 2.0 g, about 2.0 to about 2.5 g, about 2.5 g to about 3 g, or about 3 g to about 3.5 g.
- the effective dose of the anti-C1s antibody is increased by about 0.1 g, about 0.2 g, about 0.3 g, about 0.4 g, about 0.5 g, about 0.6 g, about 0.7 g, about 0.8 g, about 0.9 g, about 1 g, about 1.5 g, about 2 g, about 2.5 g, about 3 g, or about 3.5 g.
- the frequency of the treatment is increased to monthly, bi-weekly, weekly, every other day, or daily.
- the anti-C1s antibody is administered as one or more loading doses followed by dosing at dosing intervals.
- the frequency of the loading doses is increased to monthly, bi-weekly, weekly, every other day, or daily.
- the dosing interval following the initial one or more loading doses is reduced (e.g., reduced to monthly, bi-weekly, weekly, every other day, daily, etc.).
- the number of loading doses is increased (e.g., by 1, 2, 3, 4, or more).
- altering treatment with the anti-C1s antibody comprises further treatment of the subject with an anti-inflammatory agent.
- an anti-inflammatory agent is selected from one or more of: a glucocorticoid (e.g., cortisol, prednisolone, methyl-prednisolone, dexamethasone); a nonsteroidal anti-inflammatory drug (NSAID) (e.g., aspirin, ibuprofen, fenoprofen, naproxen, sulindac, diclofenac, piroxicam, ketoprofen, diflunisal, nabumetone, etodolac, or oxaprozin, indomethacin); Cox-2 inhibitors (e.g., rofecoxib and celecoxib); interferon, interferon derivatives including betaseron, beta-interferon; soluble TNF-receptors; anti-TNF-antibodies;
- altering treatment with the anti-C1s antibody comprises further treatment of the subject to improve fatigue.
- the further treatment to improve fatigue comprises administering one or more of: an NSAID (e.g., aspirin, ibuprofen, fenoprofen, naproxen, sulindac, diclofenac, piroxicam, ketoprofen, diflunisal, nabumetone, etodolac, oxaprozin, or indomethacin); an antihistamine (diphenhydramine or doxylamine); a stimulant (e.g., modafinil, armodafinil, methylphenidate, dexamphetamine, or amphetamine salts); a sleep aid (e.g., melatonin, cyclobenzaprine, clonazepam, zolpidem, zopiclone, or promethazine), an antiseizure drug (e.
- an NSAID
- the subject has undergone a blood transfusion. In some embodiments, the subject has undergone a blood transfusion prior to commencing treatment with an anti-C1s antibody, e.g., within a month, within 3 weeks, within 2 weeks, or within 1 week.
- Anti-C1s Antibody #1 (Sutimlimab) Anti- SEQ body ID Region Sequence NO: HC EVQLVESGGGLVKPGGSLRLSCAASGFTFSNYAMSWVR 1 QAPGKGLEWVATISSGGSHTYYLDSVKGRFTISRDNSK NTLYLQMNSLRAEDTALYYCARLFTGYAMDYWGQGTLV TVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFP EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP SSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCP APEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQ EDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVL TVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPR EPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIA
- a humanized anti-C1s antibody comprises a heavy chain complementarity determining region 1 (HC CDR1) comprising the amino acid sequence of SEQ ID NO: 5. In some embodiments, a humanized anti-C1s antibody comprises a heavy chain complementarity determining region 2 (HC CDR2) comprising the amino acid sequence of SEQ ID NO: 6. In some embodiments, a humanized anti-C1s antibody comprises a heavy chain complementarity determining region 3 (HC CDR3) comprising the amino acid sequence of SEQ ID NO: 7.
- a humanized anti-C1s antibody comprises an HC CDR1 comprising the amino acid sequence of SEQ ID NO: 5, an HC CDR2 comprising the amino acid sequence of SEQ ID NO: 6, and an HC CDR3 comprising the amino acid sequence of SEQ ID NO: 7.
- a humanized anti-C1s antibody comprises a light chain complementarity determining region 1 (LC CDR1) comprising the amino acid sequence of SEQ ID NO: 8. In some embodiments, a humanized anti-C1s antibody comprises a light chain complementarity determining region 2 (LC CDR2) comprising the amino acid sequence of SEQ ID NO: 9. In some embodiments, a humanized anti-C1s antibody comprises a light chain complementarity determining region 3 (LC CDR3) comprising the amino acid sequence of SEQ ID NO: 10.
- LC CDR1 light chain complementarity determining region 1
- a humanized anti-C1s antibody comprises a light chain complementarity determining region 2 (LC CDR2) comprising the amino acid sequence of SEQ ID NO: 9. In some embodiments, a humanized anti-C1s antibody comprises a light chain complementarity determining region 3 (LC CDR3) comprising the amino acid sequence of SEQ ID NO: 10.
- a humanized anti-C1s antibody comprises an LC CDR1 comprising the amino acid sequence of SEQ ID NO: 8, an LC CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and an LC CDR3 comprising the amino acid sequence of SEQ ID NO: 10.
- a humanized anti-C1s antibody comprises an HC CDR1 comprising the amino acid sequence of SEQ ID NO: 5, an HC CDR2 comprising the amino acid sequence of SEQ ID NO: 6, an HC CDR3 comprising the amino acid sequence of SEQ ID NO: 7, an LC CDR1 comprising the amino acid sequence of SEQ ID NO: 8, an LC CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and an LC CDR3 comprising the amino acid sequence of SEQ ID NO: 10.
- a humanized anti-C1s antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 3.
- a humanized anti-C1s antibody comprises a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 4.
- a humanized anti-C1s antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 3 and a VL comprising the amino acid sequence of SEQ ID NO: 4.
- a humanized anti-C1s antibody comprises a heavy chain (HC) comprising the amino acid sequence of SEQ ID NO: 1.
- a humanized anti-C1s antibody comprises a light chain (LC) comprising the amino acid sequence of SEQ ID NO: 2.
- a humanized anti-C1s antibody comprises a HC comprising the amino acid sequence of SEQ ID NO: 1 and a LC comprising the amino acid sequence of SEQ ID NO: 2.
- a humanized anti-C1s antibody comprises an HC CDR1 comprising an amino acid sequence containing no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation(s)) relative to the HC CDR1 amino acid sequence of SEQ ID NO: 5.
- a humanized anti-C1s antibody comprises an HC CDR2 comprising an amino acid sequence containing no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation(s)) relative to the HC CDR2 amino acid sequence of SEQ ID NO: 6.
- a humanized anti-C1s antibody comprises an HC CDR3 comprising an amino acid sequence containing no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation(s)) relative to the HC CDR3 amino acid sequence of SEQ ID NO: 7.
- affinity maturation may be used to identify CDR variations that preserve binding specificity.
- a humanized anti-C1s antibody comprises an LC CDR1 comprising an amino acid sequence containing no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation(s)) relative to the LC CDR1 amino acid sequence of SEQ ID NO: 8.
- a humanized anti-C1s antibody comprises an LC CDR2 comprising an amino acid sequence containing no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation(s)) relative to the LC CDR2 amino acid sequence of SEQ ID NO: 9.
- a humanized anti-C1s antibody comprises an LC CDR3 comprising an amino acid sequence containing no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation(s)) relative to the LC CDR3 amino acid sequence of SEQ ID NO: 10.
- a humanized anti-C1s antibody comprises a VH comprising an amino acid sequence containing no more than 20 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation(s)) relative to the VH amino acid sequence of SEQ ID NO: 3.
- amino acid variations e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation(s)
- a humanized anti-C1s antibody comprises a VL comprising an amino acid sequence containing no more than 20 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation(s)) relative to the VL amino acid sequence of SEQ ID NO: 4.
- a humanized anti-C1s antibody comprises a VH comprising an HC CDR1 comprising the amino acid sequence of SEQ ID NO: 5, an HC CDR2 comprising the amino acid sequence of SEQ ID NO: 6, an HC CDR3 comprising the amino acid sequence of SEQ ID NO: 7, and comprises framework regions that contain no more than 20 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation(s)) relative to the VH sequence of SEQ ID NO: 3.
- framework regions that contain no more than 20 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation(s)) relative to the VH sequence of SEQ ID NO: 3.
- a humanized anti-C1s antibody comprises a VL comprising an LC CDR1 comprising the amino acid sequence of SEQ ID NO: 8, an LC CDR2 comprising the amino acid sequence of SEQ ID NO: 9, an LC CDR3 comprising the amino acid sequence of SEQ ID NO: 10, and comprises framework regions that contain no more than 20 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation(s)) relative to the VL sequence of SEQ ID NO: 4.
- framework regions that contain no more than 20 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation(s)) relative to the VL sequence of SEQ ID NO: 4.
- a humanized anti-C1s antibody comprises (a) a VH comprising an HC CDR1 comprising the amino acid sequence of SEQ ID NO: 5, an HC CDR2 comprising the amino acid sequence of SEQ ID NO: 6, an HC CDR3 comprising the amino acid sequence of SEQ ID NO: 7, and comprises framework regions that contain no more than 20 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation(s)) relative to the VH sequence of SEQ ID NO: 3, and (b) a VL comprising an LC CDR1 comprising the amino acid sequence of SEQ ID NO: 8, an LC CDR2 comprising the amino acid sequence of SEQ ID NO: 9, an LC CDR3 comprising the amino acid sequence of SEQ ID NO: 10, and comprises framework regions that contain no more than 20 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1
- a humanized anti-C1s antibody comprises a VH comprising an amino acid sequence having at least 80% (e.g., 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) identity to the VH amino acid sequence of SEQ ID NO: 3.
- a humanized anti-C1s antibody comprises a VL comprising an amino acid sequence having at least 80% (e.g., 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) identity to the VL amino acid sequence of SEQ ID NO: 4.
- a humanized anti-C1s antibody comprises a VH comprising an HC CDR1 comprising the amino acid sequence of SEQ ID NO: 5, an HC CDR2 comprising the amino acid sequence of SEQ ID NO: 6, an HC CDR3 comprising the amino acid sequence of SEQ ID NO: 7, and comprises framework regions that have at least 80% (e.g., 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) identity to the framework regions of the VH sequence of SEQ ID NO: 3.
- a humanized anti-C1s antibody comprises a VL comprising an LC CDR1 comprising the amino acid sequence of SEQ ID NO: 8, an LC CDR2 comprising the amino acid sequence of SEQ ID NO: 9, an LC CDR3 comprising the amino acid sequence of SEQ ID NO: 10, and comprises framework regions that have at least 80% (e.g., 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) identity to the framework regions of the VL sequence of SEQ ID NO: 4.
- a humanized anti-C1s antibody comprises (a) a VH comprising an HC CDR1 comprising the amino acid sequence of SEQ ID NO: 5, an HC CDR2 comprising the amino acid sequence of SEQ ID NO: 6, an HC CDR3 comprising the amino acid sequence of SEQ ID NO: 7, and comprises framework regions that have at least 80% (e.g., 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) identity to the framework regions of the VH sequence of SEQ ID NO: 3, and (b) a VL comprising an LC CDR1 comprising the amino acid sequence of SEQ ID NO: 8, an LC CDR2 comprising the amino acid sequence of SEQ ID NO: 9, an LC CDR3 comprising the amino acid sequence of SEQ ID NO: 10, and comprises framework regions that have at least 80% (e.g., 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) identity to the framework regions of the VL
- a humanized anti-C1s antibody comprises a heavy chain complementarity determining region 1 (HC CDR1) comprising the amino acid sequence of SEQ ID NO: 15. In some embodiments, a humanized anti-C1s antibody comprises a heavy chain complementarity determining region 2 (HC CDR2) comprising the amino acid sequence of SEQ ID NO: 16. In some embodiments, a humanized anti-C1s antibody comprises a heavy chain complementarity determining region 3 (HC CDR3) comprising the amino acid sequence of SEQ ID NO: 17.
- a humanized anti-C1s antibody comprises an HC CDR1 comprising the amino acid sequence of SEQ ID NO: 15, an HC CDR2 comprising the amino acid sequence of SEQ ID NO: 16, and an HC CDR3 comprising the amino acid sequence of SEQ ID NO: 17.
- a humanized anti-C1s antibody comprises a light chain complementarity determining region 1 (LC CDR1) comprising the amino acid sequence of SEQ ID NO: 18. In some embodiments, a humanized anti-C1s antibody comprises a light chain complementarity determining region 2 (LC CDR2) comprising the amino acid sequence of SEQ ID NO: 19. In some embodiments, a humanized anti-C1s antibody comprises a light chain complementarity determining region 3 (LC CDR3) comprising the amino acid sequence of SEQ ID NO: 20.
- LC CDR1 light chain complementarity determining region 1
- a humanized anti-C1s antibody comprises a light chain complementarity determining region 2 (LC CDR2) comprising the amino acid sequence of SEQ ID NO: 19. In some embodiments, a humanized anti-C1s antibody comprises a light chain complementarity determining region 3 (LC CDR3) comprising the amino acid sequence of SEQ ID NO: 20.
- a humanized anti-C1s antibody comprises an LC CDR1 comprising the amino acid sequence of SEQ ID NO: 18, an LC CDR2 comprising the amino acid sequence of SEQ ID NO: 19, and an LC CDR3 comprising the amino acid sequence of SEQ ID NO: 20.
- a humanized anti-C1s antibody comprises an HC CDR1 comprising the amino acid sequence of SEQ ID NO: 15, an HC CDR2 comprising the amino acid sequence of SEQ ID NO: 16, an HC CDR3 comprising the amino acid sequence of SEQ ID NO: 17, an LC CDR1 comprising the amino acid sequence of SEQ ID NO: 18, an LC CDR2 comprising the amino acid sequence of SEQ ID NO: 19, and an LC CDR3 comprising the amino acid sequence of SEQ ID NO: 20.
- a humanized anti-C1s antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 13.
- a humanized anti-C1s antibody comprises a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 14.
- a humanized anti-C1s antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 13 and a VL comprising the amino acid sequence of SEQ ID NO: 14.
- a humanized anti-C1s antibody comprises a heavy chain (HC) comprising the amino acid sequence of SEQ ID NO: 11.
- a humanized anti-C1s antibody comprises a light chain (LC) comprising the amino acid sequence of SEQ ID NO: 12.
- a humanized anti-C1s antibody comprises a HC comprising the amino acid sequence of SEQ ID NO: 11 and a LC comprising the amino acid sequence of SEQ ID NO: 12.
- a humanized anti-C1s antibody comprises an HC CDR1 comprising an amino acid sequence containing no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation(s)) relative to the HC CDR1 amino acid sequence of SEQ ID NO: 15.
- a humanized anti-C1s antibody comprises an HC CDR2 comprising an amino acid sequence containing no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation(s)) relative to the HC CDR2 amino acid sequence of SEQ ID NO: 16.
- a humanized anti-C1s antibody comprises an HC CDR3 comprising an amino acid sequence containing no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation(s)) relative to the HC CDR3 amino acid sequence of SEQ ID NO: 7.
- a humanized anti-C1s antibody comprises an LC CDR1 comprising an amino acid sequence containing no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation(s)) relative to the LC CDR1 amino acid sequence of SEQ ID NO: 18.
- a humanized anti-C1s antibody comprises an LC CDR2 comprising an amino acid sequence containing no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation(s)) relative to the LC CDR2 amino acid sequence of SEQ ID NO: 19.
- a humanized anti-C1s antibody comprises an LC CDR3 comprising an amino acid sequence containing no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation(s)) relative to the LC CDR3 amino acid sequence of SEQ ID NO: 20.
- a humanized anti-C1s antibody comprises a VH comprising an amino acid sequence containing no more than 20 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation(s)) relative to the VH amino acid sequence of SEQ ID NO: 13.
- a humanized anti-C1s antibody comprises a VL comprising an amino acid sequence containing no more than 20 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation(s)) relative to the VL amino acid sequence of SEQ ID NO: 14.
- a humanized anti-C1s antibody comprises a VH comprising an HC CDR1 comprising the amino acid sequence of SEQ ID NO: 15, an HC CDR2 comprising the amino acid sequence of SEQ ID NO: 16, an HC CDR3 comprising the amino acid sequence of SEQ ID NO: 17, and comprises framework regions that contain no more than 20 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation(s)) relative to the VH sequence of SEQ ID NO: 13.
- framework regions that contain no more than 20 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation(s)) relative to the VH sequence of SEQ ID NO: 13.
- a humanized anti-C1s antibody comprises a VL comprising an LC CDR1 comprising the amino acid sequence of SEQ ID NO: 18, an LC CDR2 comprising the amino acid sequence of SEQ ID NO: 19, an LC CDR3 comprising the amino acid sequence of SEQ ID NO: 20, and comprises framework regions that contain no more than 20 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation(s)) relative to the VL sequence of SEQ ID NO: 14.
- framework regions that contain no more than 20 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation(s)) relative to the VL sequence of SEQ ID NO: 14.
- a humanized anti-C1s antibody comprises (a) a VH comprising an HC CDR1 comprising the amino acid sequence of SEQ ID NO: 15, an HC CDR2 comprising the amino acid sequence of SEQ ID NO: 16, an HC CDR3 comprising the amino acid sequence of SEQ ID NO: 17, and comprises framework regions that contain no more than 20 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation(s)) relative to the VH sequence of SEQ ID NO: 13, and (b) a VL comprising an LC CDR1 comprising the amino acid sequence of SEQ ID NO: 18, an LC CDR2 comprising the amino acid sequence of SEQ ID NO: 19, an LC CDR3 comprising the amino acid sequence of SEQ ID NO: 20, and comprises framework regions that contain no more than 20 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1
- a humanized anti-C1s antibody comprises a VH comprising an amino acid sequence having at least 80% (e.g., 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) identity to the VH amino acid sequence of SEQ ID NO: 13.
- a humanized anti-C1s antibody comprises a VL comprising an amino acid sequence having at least 80% (e.g., 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) identity to the VL amino acid sequence of SEQ ID NO: 14.
- a humanized anti-C1s antibody comprises a VH comprising an HC CDR1 comprising the amino acid sequence of SEQ ID NO: 15, an HC CDR2 comprising the amino acid sequence of SEQ ID NO: 16, an HC CDR3 comprising the amino acid sequence of SEQ ID NO: 17, and comprises framework regions that have at least 80% (e.g., 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) identity to the framework regions of the VH sequence of SEQ ID NO: 13.
- a humanized anti-C1s antibody comprises a VL comprising an LC CDR1 comprising the amino acid sequence of SEQ ID NO: 18, an LC CDR2 comprising the amino acid sequence of SEQ ID NO: 19, an LC CDR3 comprising the amino acid sequence of SEQ ID NO: 20, and comprises framework regions that have at least 80% (e.g., 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) identity to the framework regions of the VL sequence of SEQ ID NO: 14.
- a humanized anti-C1s antibody comprises (a) a VH comprising an HC CDR1 comprising the amino acid sequence of SEQ ID NO: 15, an HC CDR2 comprising the amino acid sequence of SEQ ID NO: 16, an HC CDR3 comprising the amino acid sequence of SEQ ID NO: 17, and comprises framework regions that have at least 80% (e.g., 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) identity to the framework regions of the VH sequence of SEQ ID NO: 13, and (b) a VL comprising an LC CDR1 comprising the amino acid sequence of SEQ ID NO: 18, an LC CDR2 comprising the amino acid sequence of SEQ ID NO: 19, an LC CDR3 comprising the amino acid sequence of SEQ ID NO: 20, and comprises framework regions that have at least 80% (e.g., 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) identity to the framework regions of the VL
- Antibody encompasses antibodies or immunoglobulins of any isotype, including but not limited to humanized antibodies and chimeric antibodies.
- An antibody may be a single-chain antibody (scAb) or a single domain antibody (dAb) (e.g., a single domain heavy chain antibody or a single domain light chain antibody; see Holt et al. (2003) Trends Biotechnol. 21:484).
- scAb single-chain antibody
- dAb single domain antibody
- the term “antibody” also encompasses fragments of antibodies (antibody fragments) that retain specific binding to an antigen.
- Antibody further includes single-chain variable fragments (scFvs), which are fusion proteins of the variable regions of the heavy (V H ) and light chains (V L ) of antibodies, connected with a short linker peptide, and diabodies, which are noncovalent dimers of scFv fragments that include the VH and VL connected by a small peptide linker (Zapata et al., Protein Eng. 8(10): 1057-1062 (1995)).
- scFvs single-chain variable fragments
- V H variable regions of the heavy
- V L light chains
- diabodies which are noncovalent dimers of scFv fragments that include the VH and VL connected by a small peptide linker
- Antibody fragments comprise a portion of an intact antibody, for example, the antigen binding or variable region of the intact antibody.
- antibody fragments include an antigen-binding fragment (Fab), Fab′, F(ab′) 2 , a variable domain Fv fragment (Fv), an Fd fragment, and an antigen binding fragment of a chimeric antigen receptor.
- Papain digestion of antibodies produces two identical antigen-binding fragments, referred to as “Fab” fragments, each with a single antigen-binding site, and a residual “Fc” fragment, a designation reflecting the ability to crystallize readily.
- Pepsin treatment yields an F(ab′) 2 fragment that has two antigen combining sites and is still capable of cross-linking antigen.
- “Fv” is the minimum antibody fragment that contains a complete antigen-recognition and -binding site. This region includes a dimer of one heavy-chain variable domain and one light-chain variable domain in tight, non-covalent association. It is in this configuration that the three CDRs of each variable domain interact to define an antigen-binding site on the surface of the V H -V L dimer. Collectively, the six CDRs confer antigen-binding specificity to the antibody. However, even a single variable domain (or half of an Fv comprising only three CDRs specific for an antigen) has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site.
- Fab fragments contain the constant domain of the light chain and the first constant domain (CH 1 ) of the heavy chain. Fab fragments differ from Fab′ fragments by the addition of a few residues at the carboxyl terminus of the heavy chain CH 1 domain including at least one cysteine from the antibody hinge region.
- Fab′-SH is the designation herein for Fab′ in which the cysteine residue(s) of the constant domains bear a free thiol group.
- F(ab′) 2 antibody fragments originally were produced as pairs of Fab′ fragments which have hinge cysteines between them. Other chemical couplings of antibody fragments are also known.
- scFv antibody fragments comprise the V H and V L of an antibody, wherein these regions are present in a single polypeptide chain.
- the Fv polypeptide further comprises a polypeptide linker between the V H and V L regions, which enables the scFv to form the desired structure for antigen binding.
- Diabody refers to a small antibody fragment with two antigen-binding sites, which fragments comprise a V H connected to a V L in the same polypeptide chain (V H -V L ). By using a linker that is too short to allow pairing between the two domains on the same chain, the domains are forced to pair with the complementary domains of another chain and create two antigen-binding sites. Diabodies are described more fully in, for example, Hollinger et al. Proc. Natl. Acad. Sci. USA 90: 6444-6448 (1993).
- An antibody can be monovalent or bivalent.
- An antibody can be an Ig monomer, which is a “Y-shaped” molecule that consists of four polypeptide chains: two heavy chains and two light chains connected by disulfide bonds.
- Antibodies can be detectably labeled, e.g., with a radioisotope, an enzyme that generates a detectable product, and/or a fluorescent protein. Antibodies can be further conjugated to other moieties, such as members of specific binding pairs, e.g., biotin member of biotin-avidin specific binding pair. Antibodies can also be bound to a solid support, including, but not limited to, polystyrene plates and/or beads.
- an “isolated” antibody is one that has been identified and separated and/or recovered from a component of its natural environment (i.e., is not naturally occurring). Contaminant components of its natural environment are materials that would interfere with uses (e.g., diagnostic or therapeutic uses) of the antibody, and can include enzymes, hormones, and other proteinaceous or nonproteinaceous solutes.
- an antibody is purified (1) to greater than 90%, greater than 95%, or greater than 98% by weight of antibody as determined by the Lowry method, for example, more than 99% by weight, (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (3) to homogeneity by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) under reducing or non-reducing conditions using Coomassie blue or silver stain.
- Isolated antibodies encompass antibodies in situ within recombinant cells, as at least one component of the antibody's natural environment will not be present.
- an isolated antibody is prepared by at least one purification step.
- a “monoclonal antibody” is an antibody produced by a group of identical cells, all of which were produced from a single cell by repetitive cellular replication. That is, the clone of cells only produces a single antibody species. While a monoclonal antibody can be produced using hybridoma production technology, other production methods known to those skilled in the art can also be used (e.g., antibodies derived from antibody phage display libraries).
- CDR complementarity determining region
- LC CDR1 refers, respectively, to the first, second, and third CDRs in a light chain variable region.
- HC CDR1”, “HC CDR2”, and “HC CDR3” refer, respectively, to the first, second, and third CDRs in a heavy chain variable region.
- CDR1”, “CDR2”, and “CDR3” refer, respectively, to the first, second and third CDRs of either chain's variable region.
- a “framework” when used in reference to an antibody variable region includes all amino acid residues outside the CDR regions within the variable region of an antibody.
- a variable region framework is generally a discontinuous amino acid sequence that includes only those amino acids outside of the CDRs.
- a “framework region” includes each domain of the framework that is separated by the CDRs.
- a “humanized antibody” is an antibody comprising portions of antibodies of different origin, wherein at least one portion comprises amino acid sequences of human origin.
- the humanized antibody can comprise portions derived from an antibody of nonhuman origin with the requisite specificity, such as a mouse, and from antibody sequences of human origin (e.g., chimeric immunoglobulin), joined together chemically by conventional techniques (e.g., synthetic) or prepared as a contiguous polypeptide using genetic engineering techniques (e.g., DNA encoding the protein portions of the chimeric antibody can be expressed to produce a contiguous polypeptide chain).
- humanized antibody is an antibody containing at least one chain comprising a CDR derived from an antibody of nonhuman origin and a framework region derived from a light and/or heavy chain of human origin (e.g., CDR-grafted antibodies with or without framework changes).
- Chimeric or CDR-grafted single chain antibodies are also encompassed by the term humanized immunoglobulin. See, e.g., Cabilly et al., U.S. Pat. No. 4,816,567; Cabilly et al., European Patent No. 0,125,023 B1; Boss et al., U.S. Pat. No. 4,816,397; Boss et al., European Patent No.
- a humanized antibody is produced using synthetic and/or recombinant nucleic acids to prepare genes (e.g., cDNA) encoding the desired humanized chain.
- genes e.g., cDNA
- nucleic acid (e.g., DNA) sequences coding for humanized variable regions can be constructed using PCR mutagenesis methods to alter DNA sequences encoding a human or humanized chain, such as a DNA template from a previously humanized variable region (see e.g., Kamman, M., et al., Nucl. Acids Res., 17: 5404 (1989)); Sato, K., et al., Cancer Research, 53: 851-856 (1993); Daugherty, B. L.
- variants can also be readily produced.
- cloned variable regions can be mutagenized, and sequences encoding variants with the desired specificity can be selected (e.g., from a phage library; see e.g., Krebber et al., U.S. Pat. No. 5,514,548; Hoogenboom et al., WO 93/06213, published Apr. 1, 1993).
- a humanized anti-C1s antibody described herein is a full-length IgG, an Ig monomer, a Fab fragment, a F(ab′)2 fragment, a Fd fragment, a scFv, a scAb, or a Fv.
- a humanized anti-C1s antibody described herein is a full-length IgG.
- the heavy chain of any of the humanized anti-C1s antibodies as described herein comprises a heavy chain constant region (CH) or a portion thereof (e.g., CH1, CH2, CH3, or a combination thereof).
- the heavy chain constant region can of any suitable origin, e.g., human, mouse, rat, or rabbit.
- the heavy chain constant region is from a human IgG (a gamma heavy chain), e.g., IgG1, IgG2, or IgG4.
- mutations can be introduced into the heavy chain constant region of any one of the humanized anti-C1s antibodies described herein.
- one, two or more mutations e.g., amino acid substitutions
- are introduced into the heavy chain constant region e.g., in a CH2 domain (residues 231-340 of human IgG1) and/or CH3 domain (residues 341-447 of human IgG1) and/or the hinge region, with numbering according to the Kabat numbering system (e.g., the EU index in Kabat)) to increase or decrease the affinity of the antibody for an Fc receptor (e.g., an activated Fc receptor) on the surface of an effector cell.
- an Fc receptor e.g., an activated Fc receptor
- Mutations in the Fc region of an antibody that decrease or increase the affinity of an antibody for an Fc receptor and techniques for introducing such mutations into the Fc receptor or fragment thereof are known to one of skill in the art. Examples of mutations in the Fc receptor of an antibody that can be made to alter the affinity of the antibody for an Fc receptor are described in, e.g., Smith P et al., (2012) PNAS 109: 6181-6186, U.S. Pat. No. 6,737,056, and International Publication Nos. WO 02/060919; WO 98/23289; and WO 97/34631, which are incorporated herein by reference.
- one, two or more mutations are introduced into the hinge region of the heavy chain constant region (CH1 domain) such that the number of cysteine residues in the hinge region are altered (e.g., increased or decreased) as described in, e.g., U.S. Pat. No. 5,677,425.
- the number of cysteine residues in the hinge region of the CH1 domain can be altered to, e.g., facilitate assembly of the light and heavy chains, or to alter (e.g., increase or decrease) the stability of the antibody or to facilitate linker conjugation.
- one, two or more amino acid mutations are introduced into an IgG constant domain, or FcRn-binding fragment thereof to alter (e.g., decrease or increase) half-life of the antibody in vivo.
- the one or more mutations are introduced into an Fc or hinge-Fc domain fragment. See, e.g., International Publication Nos. WO 02/060919; WO 98/23289; and WO 97/34631; and U.S. Pat. Nos. 5,869,046; 6,121,022; 6,277,375; and 6,165,745 for examples of mutations that will alter (e.g., decrease or increase) the half-life of an antibody in vivo.
- the constant region antibody described herein is an IgG1 constant region and comprises a methionine (M) to tyrosine (Y) substitution in position 252, a serine (S) to threonine (T) substitution in position 254, and a threonine (T) to glutamic acid (E) substitution in position 256, numbered according to the EU index as in Kabat. See U.S. Pat. No. 7,658,921, which is incorporated herein by reference.
- an antibody comprises an IgG constant domain comprising one, two, three or more amino acid substitutions of amino acid residues at positions 251-257, 285-290, 308-314, 385-389, and 428-436, numbered according to the EU index as in Kabat.
- one, two or more amino acid substitutions are introduced into an IgG constant domain Fc region to alter the effector function(s) of the antibody.
- the effector ligand to which affinity is altered can be, for example, an Fc receptor or the C1 component of complement. This approach is described in further detail in U.S. Pat. Nos. 5,624,821 and 5,648,260.
- the deletion or inactivation (through point mutations or other means) of a constant region domain can reduce Fc receptor binding of the circulating antibody thereby increasing tumor localization. See, e.g., U.S. Pat. Nos. 5,585,097 and 8,591,886 for a description of mutations that delete or inactivate the constant domain and thereby increase tumor localization.
- At least one amino acid substitutions may be introduced into the Fc region of an antibody described herein to remove potential glycosylation sites on Fc region, which may reduce Fc receptor binding (see, e.g., Shields R L et al., (2001) J Biol Chem 276: 6591-604).
- At least one amino acid in the constant region can be replaced with a different amino acid residue such that the antibody has altered Clq binding and/or reduced or abolished complement dependent cytotoxicity (CDC).
- CDC complement dependent cytotoxicity
- the Fc region of an antibody described herein is modified to increase the ability of the antibody to mediate antibody dependent cellular cytotoxicity (ADCC) and/or to increase the affinity of the antibody for an Fey receptor.
- ADCC antibody dependent cellular cytotoxicity
- the antibodies provided herein may comprise a stabilizing ‘Adair’ mutation (Angal S., et al., “A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody,” Mol Immunol 30, 105-108; 1993), where serine 228 (EU numbering; residue 241 Kabat numbering) is converted to proline resulting in an IgG1-like hinge sequence.
- Angal S., et al. “A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody,” Mol Immunol 30, 105-108; 1993
- serine 228 EU numbering; residue 241 Kabat numbering
- a L235E (EU numbering, corresponding to L248E in Kabat numbering) mutation is introduced to the heavy chain constant region, e.g., as described in Benhnia et al., JOURNAL OF VIROLOGY, December 2009, p. 12355-12367.
- the heavy chain constant region in any one of the humanized anti-C1s antibodies described herein is an IgG4 constant region, or a variant there of. Examples of IgG4 constant regions and variants are provided in Table 3.
- Heavy Chain Constant Region Amino Acid Sequence IgG4 ASTKGPSVFPLAPCSRSTSESTAALGCLVKD constant YFPEPVTVSWNSGALTSGVHTFPAVLQSSGL region WT YSLSSVVTVPSSSLGTKTYTCNVDHKPSNTK (also re- VDKRVESKYGPPCPSCPAPEFLGGPSVFLFP ferred to PKPKDTLMISRTPEVTCVVVDVSQEDPEVQF herein as NWYVDGVEVHNAKTKPREEQFNSTYRVVSVL “IgG4wt”) TVLHQDWLNGKEYKCKVSNKGLPSSIEKTIS KAKGQPREPQVYTLPPSQEEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLD SDGSFFLYSRLTVDKSRWQEGNVFSCSVMHE ALHNHYTQKSLSLSLGK (SEQ ID NO:
- the light chain of any of the humanized anti-C1s antibodies described herein may further comprise a light chain constant region (C L ).
- the C L is a kappa light chain.
- the C L is a lambda light chain.
- the C L is a kappa light chain, the sequence of which is provided below:
- An anti-C1s antibody is generally present in a composition, e.g., a pharmaceutical composition.
- a composition comprising an anti-C1s antibody comprises one or more of a salt, e.g., NaCl, MgCl 2 , KCl, MgSO 4 , etc.; a buffering agent, e.g., a Tris buffer, N-(2-Hydroxyethyl)piperazine-N′-(2-ethanesulfonic acid) (HEPES), 2-(N-Morpholino)ethanesulfonic acid (MES), 2-(N-Morpholino)ethanesulfonic acid sodium salt (MES), 3-(N-Morpholino)propanesulfonic acid (MOPS), N-tris[Hydroxymethyl]methyl-3-aminopropanesulfonic acid (TAPS), etc.; a solubilizing agent; a detergent, e.g., a non-ionic detergent such as Tween-20, etc.; a protease inhibitor; and
- an anti-C1s antibody may be administered to a subject using any convenient means capable of resulting in the desired therapeutic effect or diagnostic effect.
- the anti-C1s antibody may be incorporated into a variety of formulations for therapeutic administration.
- an anti-C1s antibody may be formulated into pharmaceutical compositions by combination with appropriate, pharmaceutically acceptable carriers, pharmaceutically acceptable diluents, or other pharmaceutically acceptable excipients and can be formulated into preparations in solid, semi solid, liquid or gaseous forms, such as tablets, capsules, powders, granules, ointments, solutions, suppositories, injections, inhalants and aerosols.
- a pharmaceutical composition comprises an anti-C1s antibody and a pharmaceutically acceptable excipient.
- an anti-C1s antibody in pharmaceutical dosage forms, can be administered in the form of their pharmaceutically acceptable salts, or they can also be used alone or in appropriate association, as well as in combination, with other pharmaceutically active compounds.
- an anti-C1s antibody can be used alone or in combination with appropriate additives to make tablets, powders, granules or capsules, for example, with conventional additives, such as lactose, mannitol, corn starch or potato starch; with binders, such as crystalline cellulose, cellulose derivatives, acacia, corn starch or gelatins; with disintegrators, such as corn starch, potato starch or sodium carboxymethylcellulose; with lubricants, such as talc or magnesium stearate; and if desired, with diluents, buffering agents, moistening agents, preservatives and flavoring agents.
- conventional additives such as lactose, mannitol, corn starch or potato starch
- binders such as crystalline cellulose, cellulose derivatives, acacia, corn starch or gelatins
- disintegrators such as corn starch, potato starch or sodium carboxymethylcellulose
- lubricants such as talc or magnesium stearate
- An anti-C1s antibody can be formulated into preparations for injection by dissolving, suspending or emulsifying the antibody in an aqueous or nonaqueous solvent, such as vegetable or other similar oils, propylene glycol, synthetic aliphatic acid glycerides, injectable organic esters (e.g., ethyl oleate), esters of higher aliphatic acids or propylene glycol; and if desired, with conventional additives such as solubilizers, isotonic agents, suspending agents, emulsifying agents, stabilizers and preservatives.
- Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils.
- Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like.
- the pharmaceutical composition of the present disclosure can comprise further agents such as dopamine or psychopharmacologic drugs, depending on the intended use of the pharmaceutical composition.
- compositions comprising an anti-C1s antibody are prepared by mixing a subject antibody having the desired degree of purity with optional physiologically acceptable carriers, other excipients, stabilizers, surfactants, buffers and/or tonicity agents.
- Acceptable carriers, other excipients and/or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid, glutathione, cysteine, methionine and citric acid; preservatives (such as ethanol, benzyl alcohol, phenol, m-cresol, p-chlor-m-cresol, methyl or propyl parabens, benzalkonium chloride, or combinations thereof); amino acids such as arginine, glycine, ornithine, lysine, histidine, glutamic acid, aspartic acid, isoleucine, leucine, alanine, phenylalanine, ty
- the pharmaceutical composition can be in a liquid form, a lyophilized form or a liquid form reconstituted from a lyophilized form, wherein the lyophilized preparation is to be reconstituted with a sterile solution prior to administration.
- the standard procedure for reconstituting a lyophilized composition is to add back a volume of pure water (typically equivalent to the volume removed during lyophilization); however solutions comprising antibacterial agents can be used for the production of pharmaceutical compositions for parenteral administration; see also Chen (1992) Drug Dev Ind Pharm 18, 1311-54.
- Exemplary antibody concentrations in a pharmaceutical composition suitable for use in a method of the present disclosure can range from about 1 mg/mL to about 200 mg/mL or from about 50 mg/mL to about 200 mg/mL, or from about 150 mg/mL to about 200 mg/mL.
- the antibody concentration is from about 10 mg/mL to about 60 mg/mL, from about 12 mg/mL to about 58 mg/mL, from about 14 mg/mL to about 56 mg/mL, from about 16 mg/mL to about 54 mg/mL, from about 17 mg/mL to about 52 mg/mL, or from about 18 mg/mL to about 50 mg/mL.
- the antibody concentration is 18 mg/mL.
- the antibody concentration is 50 mg/mL.
- An aqueous formulation of an anti-C1s antibody can be prepared in a pH-buffered solution, e.g., at pH ranging from about 4.0 to about 7.0, or from about 5.0 to about 6.0, or alternatively about 5.5.
- buffers that are suitable for a pH within this range include phosphate-, histidine-, citrate-, succinate-, acetate-buffers and other organic acid buffers.
- the buffer concentration can be from about 1 mM to about 100 mM, or from about 5 mM to about 50 mM, depending, e.g., on the buffer and the desired tonicity of the formulation.
- a tonicity agent can be included in the antibody formulation to modulate the tonicity of the formulation.
- exemplary tonicity agents include sodium chloride, potassium chloride, glycerin and any component from the group of amino acids, sugars as well as combinations thereof.
- the aqueous formulation is isotonic, although hypertonic or hypotonic solutions can be suitable.
- isotonic denotes a solution having the same tonicity as some other solution with which it is compared, such as a physiological salt solution or serum.
- Tonicity agents can be used in an amount of about 5 mM to about 350 mM, e.g., in an amount of 100 mM to 350 nM.
- a surfactant can also be added to the antibody formulation to reduce aggregation of the formulated antibody and/or minimize the formation of particulates in the formulation and/or reduce adsorption.
- exemplary surfactants include polyoxyethylensorbitan fatty acid esters (Tween), polyoxyethylene alkyl ethers (Brij), alkylphenylpolyoxyethylene ethers (Triton-X), polyoxyethylene-polyoxypropylene copolymer (Poloxamer, Pluronic), and sodium dodecyl sulfate (SDS).
- polyoxyethylenesorbitan-fatty acid esters examples include polysorbate 20, (sold under the trademark Tween 20TM) and polysorbate 80 (sold under the trademark TWEEN 80TM).
- suitable polyethylene-polypropylene copolymers examples include those sold under the names PLURONIC® F68 or POLOXAMER 188TM.
- suitable Polyoxyethylene alkyl ethers are those sold under the trademark BRIJTM.
- Exemplary concentrations of surfactant can range from about 0.001% to about 1% w/v.
- a lyoprotectant can also be added in order to protect the labile active ingredient (e.g. a protein) against destabilizing conditions during the lyophilization process.
- lyoprotectants include sugars (including glucose and sucrose); polyols (including mannitol, sorbitol and glycerol); and amino acids (including alanine, glycine and glutamic acid). Lyoprotectants can be included in an amount of about 10 mM to 500 nM.
- a suitable formulation includes an anti-C1s antibody, and one or more of the above-identified agents (e.g., a surfactant, a buffer, a stabilizer, a tonicity agent) and is essentially free of one or more preservatives, such as ethanol, benzyl alcohol, phenol, m-cresol, p-chlor-m-cresol, methyl or propyl parabens, benzalkonium chloride, and combinations thereof.
- a preservative is included in the formulation, e.g., at concentrations ranging from about 0.001 to about 2% (w/v).
- a suitable formulation can be a liquid or lyophilized formulation suitable for parenteral administration, and can comprise: about 1 mg/mL to about 200 mg/mL of a subject antibody; about 0.001% to about 1% of at least one surfactant; about 1 mM to about 100 mM of a buffer; optionally about 10 mM to about 500 mM of a stabilizer; and about 5 mM to about 305 mM of a tonicity agent; and has a pH of about 4.0 to about 7.0.
- a suitable parenteral formulation is a liquid or lyophilized formulation comprising: about 1 mg/mL to about 200 mg/mL of an anti-C1s antibody; 0.04% Tween 20 w/v; 20 mM L-histidine; and 250 mM sucrose; and has a pH of 5.5.
- a subject parenteral formulation comprises a lyophilized formulation comprising: 1) 15 mg/mL of an anti-C1s antibody; 0.04% Tween 20 w/v; 20 mM L-histidine; and 250 mM sucrose; and has a pH of 5.5; or 2) 75 mg/mL of a subject antibody; 0.04% Tween 20 w/v; 20 mM L-histidine; and 250 mM sucrose; and has a pH of 5.5; or 3) 75 mg/mL of an anti-C1s antibody; 0.02% Tween 20 w/v; 20 mM L-histidine; and 250 mM sucrose; and has a pH of 5.5; or 4) 75 mg/mL of an anti-C1s antibody; 0.04% Tween 20 w/v; 20 mM L-histidine; and 250 mM trehalose; and has a pH of 5.5; or 5) 75 mg/mL of an anti-C1s antibody
- a suitable parenteral formulation is a liquid formulation comprising: 1) 7.5 mg/mL of an anti-C1s antibody; 0.02% Tween 20 w/v; 120 mM L-histidine; and 250 125 mM sucrose; and has a pH of 5.5; or 2) 37.5 mg/mL of an anti-C1s antibody; 0.02% Tween 20 w/v; 10 mM L-histidine; and 125 mM sucrose; and has a pH of 5.5; or 3) 37.5 mg/mL of an anti-C1s antibody; 0.01% Tween 20 w/v; 10 mM L-histidine; and 125 mM sucrose; and has a pH of 5.5; or 4) 37.5 mg/mL of an anti-C1s antibody; 0.02% Tween 20 w/v; 10 mM L-histidine; 125 mM trehalose; and has a pH of 5.5; or 5) 37.5 mg/m
- Suitable excipient vehicles are, for example, water, saline, dextrose, glycerol, ethanol, or the like, and combinations thereof.
- the vehicle can contain minor amounts of auxiliary substances such as wetting or emulsifying agents or pH buffering agents.
- auxiliary substances such as wetting or emulsifying agents or pH buffering agents.
- Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in the art. See, e.g., Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pennsylvania, 17th edition, 1985.
- the composition or formulation to be administered will, in any event, contain a quantity of a subject antibody adequate to achieve the desired state in the subject being treated.
- the pharmaceutically acceptable excipients such as vehicles, adjuvants, carriers or diluents, are readily available to the public.
- pharmaceutically acceptable auxiliary substances such as pH adjusting and buffering agents, tonicity adjusting agents, stabilizers, wetting agents and the like, are readily available to the public.
- the present disclosure provides a method of treating a complement-mediated disease in an individual, the method comprising administering an anti-C1s antibody to the individual, where the anti-C1s antibody is administered in an effective amount of at least 4 g, at least 4.5 g, at least 5 g, at least 5.5 g, at least 6 g, at least 6.5 g, at least 7 g, at least 7.5 g, at least 8 g, at least 8.5 g, at least 9 g, at least 9.5 g, or at least 10 g.
- the anti-C1s antibody is administered in an effective amount between about 5.5 g and about 10 g, about 5.5 g and about 9.5 g, about 5.5 g and about 9 g, about 5.5 g and about 8.5 g, about 5.5 g and about 8 g, about 5.5 g and about 7.5 g, about 5.5 g and about 7 g, about 5.5 g and about 6.5 g, or about 5.5 g and about 6 g.
- the anti-C1s antibody is administered in an amount between about 4.5 g and about 8.5 g, about 4.5 g and about 8 g, about 4.5 g and about 7.5 g, about 4.5 g and about 7 g, about 4.5 g and about 6.5 g, about 4.5 g and about 6 g, about 4.5 g and about 5.5 g, or about 4.5 g and about 5 g.
- the anti-C1s antibody is administered in an amount between about 7.5 g and about 12 g, about 7.5 g and about 11.5 g, about 7.5 g and about 11 g, about 7.5 g and about 10.5 g, about 7.5 g and about 10 g, about 7.5 g and about 9.5 g, about 7.5 g and about 9 g, about 7.5 g and about 8.5 g, or about 7.5 g and about 8 g.
- the present disclosure provides a method of treating a complement-mediated disease in an individual, the method comprising administering an anti-C1s antibody to the individual, where the anti-C1s antibody is administered in an amount of 5.5 g.
- a dose of 5.5 g of the anti-C1s antibody is administered to the individual every other week.
- the method comprises: a) administering 5.5 g of the anti-C1s antibody on Day 1; b) administering 5.5 g of the anti-C1s antibody on Day 8; and c) administering 5.5 g of the anti-C1s antibody every other week following the Day 8 administration.
- a dose of 5.5 g of the anti-C1s antibody is administered to the individual every other week for a period of time from about 4 weeks to 1 year, e.g., from about 4 weeks to about 8 weeks, from about 2 months to about 6 months, or from about 6 months to 1 year. In some embodiments, a dose of 5.5 g of the anti-C1s antibody is administered to the individual every other week for a period of time of more than 1 year.
- a dose of 5.5 g of the anti-C1s antibody is administered to the individual every other week for a period of time from 1 year to 50 years, e.g., from 1 year to 2 years, from 2 years to 5 years, from 5 years to 10 years, from 10 years to 20 years, from 20 years to 30 years, from 30 years to 40 years, or from 40 years to 50 years.
- the individual for the present method weighs 75 kg or more and the anti-C1s antibody is administered at an effective dose of about 7.5 g. In other aspects, the individual for the present method weighs less than 75 kg and the anti-C1s antibody is administered at an effective dose of about 6.5 g.
- the present disclosure also provides a method of treating a complement-mediated disease in an individual, the method comprising administering an anti-C1s antibody to the individual, where the anti-C1s antibody is administered in an effective dose of about 6.5 g. In some embodiments, an effective dose of about 6.5 g of the anti-C1s antibody is administered to the individual every other week. In some embodiments, the method comprises: a) administering an effective dose of about 6.5 g of the anti-C1s antibody on Day 1; b) administering an effective dose of about 6.5 g of the anti-C1s antibody on Day 8; and c) administering an effective dose of about 6.5 g of the anti-C1s antibody every other week following the Day 8 administration.
- an effective dose of about 6.5 g of the anti-C1s antibody is administered to the individual every other week for a period of time from about 4 weeks to 1 year, e.g., from about 4 weeks to about 8 weeks, from about 2 months to about 6 months, or from about 6 months to 1 year. In some embodiments, an effective dose of about 6.5 g of the anti-C1s antibody is administered to the individual every other week for a period of time of more than 1 year.
- an effective dose of about 6.5 g of the anti-C1s antibody is administered to the individual every other week for a period of time from 1 year to 50 years, e.g., from 1 year to 2 years, from 2 years to 5 years, from 5 years to 10 years, from 10 years to 20 years, from 20 years to 30 years, from 30 years to 40 years, or from 40 years to 50 years.
- the present disclosure also provides a method of treating a complement-mediated disease in an individual, the method comprising administering an anti-C1s antibody to the individual, where the anti-C1s antibody is administered in an effective dose of about 7.5 g. In some embodiments, an effective dose of about 7.5 g of the anti-C1s antibody is administered to the individual every other week. In some embodiments, the method comprises: a) administering an effective dose of about 7.5 g of the anti-C1s antibody on Day 1; b) administering an effective dose of about 7.5 g of the anti-C1s antibody on Day 8; and c) administering an effective dose of about 7.5 g of the anti-C1s antibody every other week following the Day 8 administration.
- an effective dose of about 7.5 g of the anti-C1s antibody is administered to the individual every other week for a period of time from about 4 weeks to 1 year, e.g., from about 4 weeks to about 8 weeks, from about 2 months to about 6 months, or from about 6 months to 1 year. In some embodiments, an effective dose of about 7.5 g of the anti-C1s antibody is administered to the individual every other week for a period of time of more than 1 year.
- an effective dose of about 7.5 g of the anti-C1s antibody is administered to the individual every other week for a period of time from 1 year to 50 years, e.g., from 1 year to 2 years, from 2 years to 5 years, from 5 years to 10 years, from 10 years to 20 years, from 20 years to 30 years, from 30 years to 40 years, or from 40 years to 50 years.
- the present disclosure provides a method of treating a complement-mediated disease in an individual, the method comprising administering an anti-C1s antibody to the individual, where the anti-C1s antibody is administered in an effective dose between about 6.5 g and about 7.5 g. In some embodiments, an effective dose between about 6.5 g to about 7.5 g of the anti-C1s antibody is administered to the individual every other week. In some embodiments, the method comprises administering an effective dose between about 6.5 g and about 7.5 g of the anti-C1s antibody on Days 0 and 7 and then every other week thereafter.
- an effective dose between about 6.5 g and 7.5 g of the anti-C1s antibody is administered to the individual every other week for a period of time from about 4 weeks to 1 year, e.g., from about 4 weeks to about 8 weeks, from about 2 months to about 6 months, or from about 6 months to 1 year. In some embodiments, an effective dose between about 6.5 g and 7.5 g of the anti-C1s antibody is administered to the individual every other week for a period of time of more than 1 year.
- the present disclosure provides a method of treating a complement-mediated disease in a subject in need thereof, the method comprising administering an effective dose of an anti-C1s antibody to the subject, where the serum concentration of the anti-C1s antibody after the administration is at least about 20 ⁇ g/mL, at least about 25 ⁇ g/mL, at least about 30 ⁇ g/mL, at least about 35 ⁇ g/mL, at least about 40 ⁇ g/mL, at least about 45 ⁇ g/mL, at least about 50 ⁇ g/mL, at least about 55 ⁇ g/mL, at least about 60 ⁇ g/mL, at least about 65 ⁇ g/mL, at least about 70 ⁇ g/mL, at least about 75 ⁇ g/mL, at least about 80 ⁇ g/mL, at least about 85 ⁇ g/mL, at least about 90 ⁇ g/mL, at least about 95 ⁇ g/mL, or at least about 100 ⁇ g/mL.
- the serum concentration of the anti-C1s antibody after the administration is between about 20 ⁇ g/mL and about 100 ⁇ g/mL, about 20 ⁇ g/mL and about 90 ⁇ g/mL, about 20 ⁇ g/mL and about 80 ⁇ g/mL, about 20 ⁇ g/mL and about 70 ⁇ g/mL, about 20 ⁇ g/mL and about 70 ⁇ g/mL, about 20 ⁇ g/mL and about 60 ⁇ g/mL, about 20 ⁇ g/mL and about 50 ⁇ g/mL, about 20 ⁇ g/mL and about 40 ⁇ g/mL, or about 20 ⁇ g/mL and about 30 ⁇ g/mL. In some embodiments, the serum concentration of the anti-C1s antibody after the administration is at least about 20 ⁇ g/mL.
- the serum concentration of the anti-C1s antibody in the subject can be measured using techniques known in the art.
- the anti-C1s antibody is measured using a direct binding Enzyme-Linked Immunosorbent Assay (ELISA).
- ELISA Enzyme-Linked Immunosorbent Assay
- the anti-C1s antibody is measured using an indirect ELISA.
- the anti-C1s antibody is measured using a sandwich ELISA.
- the anti-C1s antibody is measured using a competitive ELISA.
- the present disclosure provides a method of treating a complement-mediated disease in a subject in need thereof, the method comprising administering an effective dose of an anti-C1s antibody to the subject, wherein the effective dose of the anti-C1s antibody is at least about 45 mg/kg, at least about 50 mg/kg, at least about 55 mg/kg, at least about 60 mg/kg, at least about 65 mg/kg, at least about 70 mg/kg, at least about 75 mg/kg, at least about 80 mg/kg, at least about 85 mg/kg, at least about 90 mg/kg, at least about 95 mg/kg, or at least about 100 mg/kg.
- the effective dose of the anti-C1s antibody is at least about 60 mg/kg.
- the effective dose of the anti-C1s antibody is between about 60 mg/kg and about 100 mg/kg, about 60 mg/kg and about 95 mg/kg, about 60 mg/kg and about 90 mg/kg, about 60 mg/kg and about 85 mg/kg, about 60 mg/kg and about 80 mg/kg, about 60 mg/kg and about 75 mg/kg, about 60 mg/kg and about 70 mg/kg, or about 60 mg/kg and about 65 mg/kg.
- the effective dose of the anti-C1s antibody is between about 45 mg/kg and about 85 mg/kg, about 45 mg/kg and about 80 mg/kg, about 45 mg/kg and about 75 mg/kg, about 45 mg/kg and about 70 mg/kg, about 45 mg/kg and about 65 mg/kg, about 45 mg/kg and about 60 mg/kg, or about 45 mg/kg and about 50 mg/kg.
- the effective dose of the anti-C1s antibody is between about 85 mg/kg and about 150 mg/kg, about 85 mg/kg and about 145 mg/kg, about 85 mg/kg and about 140 mg/kg, about 85 mg/kg and about 135 mg/kg, about 85 mg/kg and about 130 mg/kg, about 85 mg/kg and about 125 mg/kg, about 85 mg/kg and about 125 mg/kg, about 85 mg/kg and about 120 mg/kg, about 85 mg/kg and about 115 mg/kg, about 85 mg/kg and about 110 mg/kg, about 85 mg/kg and about 105 mg/kg, about 85 mg/kg and about 100 mg/kg, about 85 mg/kg and about 95 mg/kg, or about 85 mg/kg and about 90 mg/kg.
- the effective dose for the present methods is about 45 mg/kg, about 50 mg/kg, about 55 mg/kg, about 60 mg/kg, about 65 mg/kg, about 70 mg/kg, about 75 mg/kg, about 80 mg/kg, about 85 mg/kg, about 90 mg/kg, about 95 mg/kg, about 100 mg/kg, about 105 mg/kg, about 110 mg/kg, about 115 mg/kg, about 120 mg/kg, about 125 mg/kg, about 130 mg/kg, about 135 mg/kg, about 140 mg/kg, about 145 mg/kg, or about 150 mg/kg.
- the present disclosure provides a method of treating a complement-mediated disease in a subject in need thereof, the method comprising administering an effective dose of an anti-C1s antibody to the subject, wherein the anti-C1s antibody is administered at a dosing interval of five days, six days, seven days, eight days, nine days, ten days, eleven days, twelve days, thirteen days, fourteen days, fifteen days, sixteen days, seventeen days, eighteen days, nineteen days, twenty days, twenty one days, twenty two days, twenty three days, twenty four days, twenty five days, twenty six days, twenty seven days, twenty eight days, twenty nine days, thirty days, or thirty one days.
- the anti-C1s antibody is administered at a dosing interval of one week, two weeks, three weeks, four weeks, one month, two months, three months, or four months. In some embodiments, the anti-C1s antibody increases the number of reticulocytes in the subject's blood after the administration of the anti-C1s antibody.
- the anti-C1s antibody is administered as one or more loading doses followed by dosing at dosing intervals.
- the loading doses can be administered about 7 days apart, about 14 days apart, about 21 days apart, about 28 days apart, about two months apart, about three months apart, or about four months apart.
- the loading dose for the present disclosure is about 45 mg/kg, about 50 mg/kg, about 55 mg/kg, about 60 mg/kg, about 65 mg/kg, about 70 mg/kg, about 75 mg/kg, about 80 mg/kg, about 85 mg/kg, about 90 mg/kg, about 95 mg/kg, about 100 mg/kg, about 105 mg/kg, about 110 mg/kg, about 115 mg/kg, about 120 mg/kg, about 125 mg/kg, about 130 mg/kg, about 135 mg/kg, about 140 mg/kg, about 145 mg/kg, or about 150 mg/kg.
- the loading dose is a different dosage amount than the dose administered at dosing intervals.
- the loading dose is the same dosage amount as the dose administered at dosing intervals.
- the anti-C1s antibody is administered as two weekly loading doses of 60 mg/kg followed by doses of 60 mg/kg administered every other week.
- An anti-C1s antibody is administered to an individual using any available method and route suitable for drug delivery, including in vivo and ex vivo methods, as well as systemic and localized routes of administration.
- routes of administration include intranasal, intramuscular, intratracheal, intrathecal, intracranial, subcutaneous, intradermal, topical, intravenous, intraperitoneal, intraarterial (e.g., via the carotid artery), spinal or brain delivery, rectal, nasal, oral, and other enteral and parenteral routes of administration. Routes of administration can be combined, if desired, or adjusted depending upon the antibody and/or the desired effect.
- An anti-C1s antibody composition can be administered in a single dose or in multiple doses. In some embodiments, an anti-C1s antibody is administered orally. In some embodiments, an anti-C1s antibody is administered subcutaneously. In some embodiments, an anti-C1s antibody is administered intramuscularly. In some embodiments, an anti-C1s antibody is administered intravenously.
- An anti-C1s antibody can be administered to a host using any available conventional methods and routes suitable for delivery of conventional drugs, including systemic or localized routes.
- routes of administration contemplated by the disclosure include, but are not necessarily limited to, enteral, parenteral, or inhalational routes.
- Parenteral routes of administration other than inhalation administration include, but are not necessarily limited to, topical, transdermal, subcutaneous, intramuscular, intraorbital, intracapsular, intraspinal, intrasternal, intrathecal, and intravenous routes, i.e., any route of administration other than through the alimentary canal.
- Parenteral administration can be carried to effect systemic or local delivery of a subject antibody. Where systemic delivery is desired, administration typically involves invasive or systemically absorbed topical or mucosal administration of pharmaceutical preparations.
- treatment is meant at least an amelioration of the symptoms associated with the pathological condition afflicting the host, where amelioration is used in a broad sense to refer to at least a reduction in the magnitude of a parameter, e.g., symptom, associated with the pathological condition being treated, such as a complement-mediated disease.
- amelioration also includes situations where the pathological condition, or at least symptoms associated therewith, are completely inhibited, e.g., prevented from happening, or stopped, e.g., terminated, such that the host no longer suffers from the pathological condition, or at least the symptoms that characterize the pathological condition.
- an anti-C1s antibody is administered by injection and/or delivery, e.g., to a site in a brain artery or directly into brain tissue.
- An anti-C1s antibody can also be administered directly to a target site e.g., by biolistic delivery to the target site.
- hosts are treatable according to the subject methods.
- hosts are “mammals” or “mammalian,” where these terms are used broadly to describe organisms which are within the class mammalia, including the orders carnivore (e.g., cats), herbivores (e.g., cattle, horses, and sheep), omnivores (e.g., dogs, goats, and pigs), rodentia (e.g., mice, guinea pigs, and rats), and primates (e.g., humans, chimpanzees, and monkeys).
- carnivore e.g., cats
- herbivores e.g., cattle, horses, and sheep
- omnivores e.g., dogs, goats, and pigs
- rodentia e.g., mice, guinea pigs, and rats
- primates e.g., humans, chimpanzees, and monkeys.
- the host is an individual that has a complement system, such as a mammal, fish, or invertebrate.
- a complement system such as a mammal, fish, or invertebrate.
- the host is a complement system-containing mammal, fish, or invertebrate companion animal, agricultural animal, work animal, zoo animal, or lab animal.
- the individual is human.
- a complement-mediated disease is characterized by the presence in a cell, a tissue, or a fluid of an elevated (higher than normal) amount of C1s or of an elevated level of complement C1s activity.
- a complement-mediated disease is characterized by the presence in brain tissue and/or cerebrospinal fluid of an elevated amount and/or an elevated activity of C1s.
- a “higher than normal” amount of C1s in a cell, a tissue, or a fluid indicates that the amount of C1s in the cell, tissue or fluid is higher than a normal, control level, e.g., higher than a normal, control level for an individual or population of individuals of the same age group.
- a “higher than normal” level of C1s activity in a cell, a tissue, or a fluid indicates that the proteolytic cleavage effected by C1s in the cell, tissue or fluid is higher than a normal, control level, e.g., higher than a normal, control level for an individual or population of individuals of the same age group.
- an individual having a complement-mediated disease exhibits one or more additional symptoms of such a disease.
- the term “disease” encompasses “disorders.” The two terms may be used interchangeably.
- a complement-mediated disease is a classical complement-mediated disease.
- a complement-mediated disease is characterized by the presence in a cell, a tissue, or a fluid of a lower than normal amount of C1s or of a lower level of complement C1s activity.
- a complement-mediated disease is characterized by the presence in brain tissue and/or cerebrospinal fluid of a lower amount and/or a lower activity of C1s.
- a “lower than normal” amount of C1s in a cell, a tissue, or a fluid indicates that the amount of C1s in the cell, tissue or fluid is lower than a normal, control level, e.g., lower than a normal, control level for an individual or population of individuals of the same age group.
- a “lower than normal” level of C1s activity in a cell, a tissue, or a fluid indicates that the proteolytic cleavage effected by C1s in the cell, tissue or fluid is lower than a normal, control level, e.g., lower than a normal, control level for an individual or population of individuals of the same age group.
- a normal, control level e.g., lower than a normal, control level for an individual or population of individuals of the same age group.
- an individual having a complement-mediated disease exhibits one or more additional symptoms of such a disease.
- a complement-mediated disease is a disease in which the amount or activity of complement C1s is such as to cause disease in an individual.
- complement-mediated diseases include cold agglutinin disease (CAD), bullous pemphigoid, multifocal motor neuropathy (MMN), autoantibody mediated peripheral neuropathy, Myasthenia Gravis, lupus nephritis, mucous membrane pemphigoid, cicatricial pemphigoid, ocular pemphigoid, and antineutrophil cytoplasmic autoantibody (ANCA) associated vasculitis.
- CAD cold agglutinin disease
- MNN multifocal motor neuropathy
- ANCA antineutrophil cytoplasmic autoantibody
- the present method includes treatment of primary CAD in a subject in need thereof comprising administering an effective dose between about 6.5 g and about 7.5 g, e.g., about 6.5 g for subjects with less than 75 kg of bodyweight and 7.5 g for subjects with 75 kg or more of bodyweight, of an anti-C1s antibody, e.g., sutimlimab.
- the present methods have no limitation of use associated with anemia severity, transfusion history, or prior treatment experience.
- the dose is administered as intravenous infusion over 1 hour on Day 0, Day 7, and every 14 days ⁇ 2 days thereafter starting on Day 21.
- Intravenous infusion can take place within clinic or home setting.
- the anti-C1s antibody can improve anemia and associated clinical symptoms, eliminate transfusion, prevent hemolysis, rapid onset of action, improve fatigue and quality of life, and/or any combination thereof.
- the treatment shows no drug related serious or severe adverse events; no discontinuations due to adverse events, no serious infections; no REMS requirement, most commonly reported adverse events were similar to placebo, or any combination thereof.
- the anti-C1s antibody prevents chronic hemolysis, resulting in improvement in anemia, elimination of transfusion, improvement of quality of life, and ultimately reduction of risk of life-threatening thromboembolic events, morbidity, and mortality, and reduced healthcare utilization. In some embodiments, the anti-C1s antibody improves fatigue.
- the complement-mediated disease is bullous pemphigoid. In some embodiments, the complement-mediated disease is antibody-mediated rejection of organ transplant. In some embodiments, the complement-mediated disease is cold agglutinin disease. In some embodiments, the complement-mediated disease is warm autoimmune hemolytic anemia. In some embodiments, the complement-mediated disease antibody-mediated transplant rejection. In some embodiments, the classical complement-mediated disease is immunothrombocytopenic purpura. In some embodiments, the complement-mediated disease is neuromyelitis optica.
- the complement-mediated disease is multifocal motor neuropathy (MMN). In some embodiments, the complement-mediated disease is myasthenia gravis. In some embodiments, the complement-mediated disease is chronic inflammatory demyelinating polyneuropathy. In some embodiments, the complement-mediated disease is lupus nephritis. In some embodiments, the complement-mediated disease is mucous membrane pemphigoid. In some embodiments, the complement-mediated disease is cicatricial pemphigoid. In some embodiments, the complement-mediated disease is ocular pemphigoid. In some embodiments, the complement-mediated disease is antineutrophil cytoplasmic autoantibody (ANCA) associated vasculitis.
- MNN multifocal motor neuropathy
- the complement-mediated disease is myasthenia gravis. In some embodiments, the complement-mediated disease is chronic inflammatory demyelinating polyneuropathy. In some embodiments, the complement-mediated disease is lupus nephritis
- the complement-mediated disease is an autoantibody mediated peripheral neuropathy including, but not limited to, Guillain-Barré syndrome, Myasthenia Gravis, acute inflammatory demyelinating polyneuropathy (AIDP), chronic inflammatory demyelinating polyneuropathy (CIDP), acute motor axonal neuropathy (AMAN), acute motor and sensory axonal neuropathy (AMSAN), pharyngeal-cervical brachial variant, Miller Fisher syndrome, or any combination thereof.
- the complement-mediated disease is Guillain-Barré syndrome, which presents as rapid-onset muscle weakness, beginning in the feet and hands that spreads to the arms and upper body. During the acute phase, it can be fatal as respiratory failure can occur, and other autonomic functions (such as heart rate) can be affected. ⁇ 7.5% of all cases are fatal. Incidence: 1-2/100,000.
- the complement-mediated disease is Myasthenia Gravis, which exhibits weakness, fatigue that becomes progressively worse during periods of physical activity, generally starts with ocular weakness; progressing to a more severe form, characterized by weakness in the extremities and performing basic life functions (chewing, swallowing, breathing).
- myasthenic crisis respiratory paralysis occurs, necessitating assisted ventilation to sustain life.
- the complement-mediated disease is multifocal motor neuropathy (MMN), which is an inflammatory autoimmune disease of the lower nervous system.
- MMN is a pure motor neuropathy, which has the mean age onset of 40 years.
- MMN is characterized by: slowly progressive, asymmetric distal limb weakness; conduction block (CB), often affecting ulnar, median, radial or tibial nerves; and/or atrophic muscles.
- CB conduction block
- Other clinical features include muscle cramps, fasciculations, and an increase of weakness in cold conditions.
- GM1-specific IgM antibodies are present in the serum of ⁇ half of all patients, titers of which correlate with their in vitro complement-activating capacity and disease severity.
- Intravenous immunoglobulin (IVIg) is effective in MMN. Nevertheless, patients still undergo slowly progressive axonal degeneration and muscle weakness that cannot be fully prevented with chronic IVIg therapy.
- a complement-mediated disease useful for treatment is neuromyelitis optica (NMO).
- NMO is caused by anti-Aquaporin-4 IgG autoantibody (NMO-IgG) which activates complement and kills astrocytes resulting in death of oligodendrocytes that myelinate the optic nerve and spinal cord. Vision loss and paralysis occur following attacks.
- a complement-mediated disease useful for treatment is systemic lupus erythematosus (SLE).
- SLE Systemic lupus erythematosus
- SLE is an autoimmune disease that affects 0.04% of the population of developed countries. SLE is believed to arise as a result of an impairment in the body's waste disposal system, in which complement plays a key role.
- congenital deficiencies of the complement proteins in the C1 complex as well as C2 and C4 are associated with an increased risk of developing SLE.
- a substantial number of patients with SLE develop hypocomplementemia with depletion of C1q and other components of the classical pathway: e.g., complement deposition on RBCs and/or C1q deposition in affected tissues.
- a complement-mediated disease useful for treatment is lupus nephritis (LN).
- LN is the renal manifestation of SLE that occurs in 25-50% of patients and is the primary cause of morbidity and mortality.
- C1q antibodies are closely associated with renal involvement and are highly predictive of and present during flares. Active LN is rarely observed in the absence of C1q Abs. Multiple studies have shown a negative correlation with C1q Ab titers and serum C1q, and a positive correlation with C1q deposition in the glomeruli in patients with LN.
- a complement-mediated disease useful for treatment is membranoproliferative glomerulonephritis (type I) (Mixed Cryoglobulinemia).
- Mixed Cryoglobulinemia is a systemic vasculitis mediated by immune complexes (IC). It appears most often in the context of chronic infections (HCV—80% of MC cases).
- IC immune complexes
- HCV chronic infections
- cryoglobulinemia manifests itself with symptoms like weakness and arthralgias and variable cutaneous and visceral organ involvement. Steroids suppress inflammation with success in some patients, but additional plasmapheresis to remove circulating cryoglobulins and immunosuppressive treatment to inhibit the formation of new cryoglobulins are often necessary.
- Cytokine profiles and functional assessment of chronic illness therapy-fatigue (FACIT-F) scores were evaluated from baseline to follow-up timepoints at weeks 1, 3, 5 and 25 as represented by the treatment assessment timepoint (TAT) post-sutimlimab treatment. Summary statistics describing IL-6 and IL-10 changes at each week were reported. Changes from baseline to the TAT were analyzed using the Mixed Model for Repeated Measures (MMRM). A 3- to 10-point score improvement in FACIT-F was considered a meaningful difference in patient fatigue (based on FACIT-F data in autoimmune or oncologic diseases; Lai et al. J Rheumatol. 2011 and Reddy et al. J Palliat Med. 2007).
- MMRM Mixed Model for Repeated Measures
- Mean IL-6 level (mean pg/mL [standard error of the mean (SEM)]) steadily decreased from baseline (3.21 [0.958]; normal values IL-6 ⁇ 3.2 pg/mL.) to follow up at all time points after initiating sutimlimab treatment ( FIG. 1 ), showing rapid onset and durable pattern of decline as early as Week 1 (2.70 [0.839]).
- Mean IL-6 level was reduced by more than half by Week 3 (1.56 [0.297]), slightly rose at Week 5 (1.88 [0.383]) and was lowest at TAT (1.31 [0.201]).
- Mean IL-10 level (pg/mL [SEM]) also decreased in a time-dependent manner from baseline (1.36 [0.310]) initially at Week 1 (0.99 [0.250]).
- mean (SEM) FACIT-F score was 32.5 (2.265) ( FIGS. 1 - 2 ).
- FIGS. 3 and 4 Additional time points and parameters are presented in FIGS. 3 and 4 .
- Cytokine profiles for IL-6 and IL-10, FACIT-F scores, and hemoglobin (Hb) levels were evaluated from baseline to Weeks 1, 3, 5, 9, 13, and 25 after the first sutimlimab dose (Week 25 represented the treatment assessment time point [TAT]).
- FACIT-F is a patient-reported quality of life (QOL) outcome that is a validated assessment tool for measuring fatigue in patients with CAD (Roth A et al. N Engl J Med. 384(14):1323-1334 (2021) and Hill Q A et al. EHA 2021; Poster).
- FACIT-Fatigue scale range is 0 (worst fatigue) to 52 (no fatigue); a 3-point increase from baseline is considered a clinically meaningful improvement (Röth A et al. N Engl J Med. 384(14):1323-1334 (2021)).
- Activity of the classical complement pathway was measured via the Wieslab CP assay. Descriptive summary statistics of changes in IL-6, IL-10, FACIT-Fatigue, Hb, C4 and classical complement pathway activity were reported at each time point.
- Mean (SEM) IL-6 level was lower than baseline (3.21 [0.958] pg/mL) as early as Week 1 (2.70 [0.839] pg/mL) and at all other timepoints after initiating sutimlimab treatment ( FIG. 3 ).
- mean IL-6 level decreased by more than half at Week 3 (1.56 [0.297] pg/mL), a level that was maintained at Week 13 (1.57 [0.201] pg/mL), and lower still at the TAT (1.31 [0.201] pg/mL).
- Mean (SEM) IL-10 level also declined from baseline (1.36 [0.310] pg/mL) to follow-up during sutimlimab treatment ( FIG.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Provided herein are methods for treating complement-mediated diseases and associated conditions.
Description
- This application claims priority to U.S. provisional application Ser. No. 63/062,243, filed Aug. 6, 2020, the entire content of which is incorporated herein by reference.
- The present application relates to methods for treating complement-mediated diseases and associated conditions.
- Cold agglutinin disease (CAD) is a rare, chronic type of autoimmune hemolytic anemia, where hemolysis is driven by classical complement pathway activation. Complement activation assures the rapid initiation of the complement cascade as a part of an early immune response.
- A pro-inflammatory state secondary to complement activation has been demonstrated in other hemolytic diseases such as paroxysmal nocturnal hemoglobinuria and atypical-hemolytic uremic syndrome. Complement cascade activation stimulates cytokine production (TNF, IL-6, IL-8, IL-17) via anaphylatoxins C3a and C5a and increases vascular inflammatory markers, consistent with complement-mediated inflammation. In addition, complement activation and chronic inflammation may contribute to patient fatigue in cold agglutinin disease (CAD), apart from anemia.
- Classical complement activation resulting in a proinflammatory state has not been formally studied in CAD patients. Also, the interplay between complement-mediated inflammation, and fatigue has not been explored in patients with CAD. Results from the study described herein demonstrate a relationship between inflammatory cytokine expression (e.g., IL-6 and IL-10) and fatigue in CAD patients treated with the humanized monoclonal anti-C1s antibody, sutimlimab.
- Some aspects of the present disclosure provide a method comprising administering to a subject an anti-C1s antibody (e.g., the anti-C1s antibody of Table 1 or Table 2) and measuring a level of C reactive protein (CRP), IL-6, and/or IL-10 in a sample (e.g., blood, e.g., serum) from the subject. In some embodiments, the method further comprises assessing fatigue (e.g., measuring FACIT-F score) in the subject.
- Other aspects of the present disclosure provide a method comprising measuring a level of CRP, IL-6, and/or IL-10 in a sample from a subject being treated with an anti-C1s antibody (e.g., sutimlimab). In some embodiments, the method further comprises assessing fatigue in the subject.
- In some embodiments, a level of CRP is measured. CRP, in some embodiments, is used as a surrogate for IL-6. In some embodiments, a level of IL-6 is measured. In some embodiments, IL-10 is measured.
- In some embodiments, the subject has a complement-mediated disease. In some embodiments, the subject has CAD.
- In some embodiments, the subject has fatigue.
- Yet other aspects of the present disclosure provide a method comprising treating a subject with an anti-C1s antibody therapy (e.g., sutimlimab therapy), wherein the subject has fatigue, and measuring a level of CRP, IL-6, and/or IL-10 in a sample from the subject. In some embodiments, the method further comprises assessing fatigue in the subject. In some embodiments, the subject has a complement-mediated disease, for example, CAD.
- Further aspects of the present disclosure provide a method comprising treating a subject with an anti-C1s antibody therapy (e.g., sutimlimab therapy), wherein the subject has a complement mediated disease, for example, CAD, and measuring a level of CRP, IL-6, and/or IL-10 in a sample from the subject. In some embodiments, the method further comprises assessing fatigue in the subject. In some embodiments, the subject has fatigue.
- In some embodiments, the subject has a baseline level of CRP, IL-6, and/or IL-10 prior to treatment with an anti-C1s antibody (e.g., sutimlimab), and/or wherein the subject has a baseline level of fatigue prior to treatment with an anti-C1s antibody. In some embodiments, if the level of CRP, IL-6, and/or IL-10 in the sample is reduced, for example, by at least 5% or at least 10% (e.g., at least 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50%), relative to baseline and/or fatigue in the subject is improved relative to baseline, the method further comprises continuing with a current anti-C1s antibody treatment (e.g., sutimlimab treatment). In some embodiments, if the level of CRP, IL-6, and/or IL-10 in the sample is within 5% or within 10% of baseline and/or fatigue the subject is maintained or worsens relative to baseline, the method further comprises altering a current anti-C1s antibody treatment. In some embodiments, if the level of CRP, IL-6, and/or IL-10 in the sample is within 5% or within 10% of baseline, the method further comprises altering a current anti-C1s antibody treatment. In some embodiments, if fatigue the subject is maintained or worsens relative to baseline, the method further comprises altering a current anti-C1s antibody treatment.
- In some embodiments, altering the current anti-C1s antibody treatment comprises adjusting the dosage and/or frequency of the treatment with the anti-C1s antibody.
- In some embodiments, altering the current anti-C1s antibody treatment comprises further treatment of the subject with an anti-inflammatory agent.
- In some embodiments, altering the current anti-C1s antibody treatment comprises further treatment of the subject to improve fatigue.
- In some embodiments, a method further comprises monitoring levels (e.g., reassessing levels) of CRP, IL-6, and/or IL-10 in the subject over a period of time (e.g., hours, days, weeks, or months).
- In some embodiments, the subject has undergone a blood transfusion. In some embodiments, the subject has undergone a blood transfusion prior to commencing treatment with an anti-C1s antibody, e.g., within a month, within 3 weeks, within 2 weeks, or within 1 week.
- In some embodiments, the fatigue is assessed based on a Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) score. In some embodiments, an improvement in fatigue is a change by at least 3 (e.g., at least 4, 5, 6, 7, 8, 9, or 10) points on a FACIT-F score relative to baseline.
- In some embodiments, the anti-C1s antibody comprises a heavy chain (HC) complementarity determining region 1 (CDR1) comprising the amino acid sequence of SEQ ID NO: 5, an HC complementarity determining region 2 (CDR2) comprising the amino acid sequence of SEQ ID NO: 6, an HC complementarity determining region 3 (CDR3) comprising the amino acid sequence of SEQ ID NO: 7, a light chain (LC) CDR1 that comprises the amino acid sequence of SEQ ID NO: 8, an LC CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and an LC CDR3 comprising the amino acid sequence of SEQ ID NO: 10.
- In some embodiments, the anti-C1s antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 3 and comprises a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 4.
- In some embodiments, the anti-C1s antibody comprises an HC comprising the amino acid sequence of SEQ ID NO: 1 and an LC comprising the amino acid sequence of SEQ ID NO: 2.
- In some embodiments, the anti-C1s antibody comprises an HC CDR1 comprising the amino acid sequence of SEQ ID NO: 15, an HC CDR2 comprising the amino acid sequence of SEQ ID NO: 16, an HC CDR3 comprising the amino acid sequence of SEQ ID NO: 17, an LC CDR1 comprising the amino acid sequence of SEQ ID NO: 18, an LC CDR2 comprising the amino acid sequence of SEQ ID NO: 19, and an LC CDR3 comprising the amino acid sequence of SEQ ID NO: 20.
- In some embodiments, the anti-C1s antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 13 and comprises a VL comprising the amino acid sequence of SEQ ID NO: 14.
- In some embodiments, the anti-C1s antibody comprises an HC comprising the amino acid sequence of SEQ ID NO: 11 and an LC comprising the amino acid sequence of SEQ ID NO: 12.
- In some embodiments, the anti-C1s antibody comprises an IgG4 constant region. Each of International Publication Nos. WO 2014/071206, filed Nov. 2, 2012, entitled Anti-Complement C1s Antibodies and Uses Thereof, WO 2016/164358, filed Apr. 6, 2015, entitled Humanized Anti-C1s Antibodies and Methods of Use Thereof, and in WO 2018/170145, filed Mar. 14, 2017, entitled Methods for Treating Complement-Mediated Diseases and Disorders is herein incorporated by reference in its entirety.
-
FIG. 1 shows changes in proinflammatory cytokine IL-6 levels (B) and FACIT-F (A) scores at baseline and over time in patients with cold agglutinin disease (CAD). FACIT-F, functional assessment of chronic illness therapy-fatigue; SEM, standard error of the mean; TAT, treatment assessment timepoint. Mean and SEM values fromweek 25 were used to represent the TAT. Normal control values for IL-6 were <3.2 pg/mL. -
FIG. 2 shows changes in regulatory cytokine IL-10 levels (B) and FACIT-F (A) scores at baseline and over time in patients with CAD. FACIT-F, functional assessment of chronic illness therapy-fatigue; SEM, standard error of the mean; TAT, treatment assessment timepoint. Mean and SEM values fromweek 25 were used to represent the TAT. -
FIG. 3 shows effect of sutimlimab treatment on mean IL-6 level (A), fatigue (B), mean total C4 (C), and classical complement pathway activity (D) in patients with CAD. Mean and SEM values fromWeek 25 were used to represent the TAT. Normal values for IL-6 were <3.2 pg/mL. CAD, cold agglutinin disease; CP, classical complement pathway; FACIT-Fatigue, Functional Assessment of Chronic Illness Therapy-Fatigue; IL, interleukin; SEM, standard error of the mean; TAT, treatment assessment time point. -
FIG. 4 shows effect of sutimlimab treatment on mean IL-10 level (A), fatigue (B), mean total C4 (C), and classical complement pathway activity (D) in patients with CAD. Mean and SEM values fromWeek 25 were used to represent the TAT. CAD, cold agglutinin disease; CP, classical complement pathway; FACIT-Fatigue, Functional Assessment of Chronic Illness Therapy-Fatigue; IL, interleukin; SEM, standard error of the mean; TAT, treatment assessment time point. - The complement system is a well-known effector mechanism of the immune response, providing not only protection against pathogens and other harmful agents but also recovery from injury. The complement pathway comprises proteins that typically exist in the body in inactive form. The classical complement pathway is triggered by activation of the first component of complement, referred to as the C1 complex, which includes C1q, C1r, and C1s proteins. Upon binding of C1 to an immune complex or other activator, the C1s component, a diisopropyl fluorophosphate (DFP)-sensitive serine protease, cleaves complement components C4 and C2 to initiate activation of the classical complement pathway. The classical complement pathway plays a role in cold agglutinin disease, for example.
- Cold agglutinin disease (CAD) is a form of chronic autoimmune hemolytic anemia (AIHA) accompanied by classical component-dependent hemolysis (see Berentsen S. Semin Hematol. 2018; 55(3):141-149; and Noris M, Remuzzi G. Semin Nephrol. 2013; 33(6):479-492, each of which is herein incorporated by reference). Symptoms of CAD can include chronic hemolysis, anemia and related symptoms (e.g., dyspnea), hemoglobinuria, jaundice, and circulatory symptoms. Some people who have cold agglutinin disease also may get a cold, numb feeling and loss of color in their fingers or toes, known as Raynaud's phenomenon.
- The data provided herein demonstrated a relationship between inflammatory cytokine expression (e.g., IL-6 and IL-10) and fatigue in CAD patients treated with the humanized monoclonal anti-C1s antibody, sutimlimab.
- IL-6 is a pro-inflammatory cytokine featuring pleiotropic activity; it induces synthesis of acute phase proteins such as CRP, serum amyloid A, fibrinogen, and hepcidin in hepatocytes, whereas it inhibits production of albumin. IL-6 also plays an important role on acquired immune response by stimulation of antibody production and of effector T-cell development. Moreover, IL-6 can promote differentiation or proliferation of several nonimmune cells. Because of the pleiotropic activity, dysregulated continual production of IL-6 leads to the onset or development of various diseases.
- IL-10, formerly known as cytokine synthesis inhibitory factor and namesake of the corresponding cytokine family, is regarded as a key immunoregulatory cytokine capable of curbing overt inflammation in various pathophysiological settings. In addition to influencing the cytokine network, IL-10 has the capability to curb production of key effector mediators involved in development of tissue damage, among others reactive oxygen species (and matrix metalloproteinases.
- Fatigue is a common symptom of CAD. While not solely caused by anemia, the fatigue in CAD is presumed to be secondary to the hemolytic anemia, which refers to low numbers of RBCs as a result of their destruction. RBCs are responsible for delivering oxygen to all parts of the body, and for removing carbon dioxide that is generated because of metabolic activity. When RBC numbers are low due to hemolytic anemia, the organs receive less oxygen than required for their normal function. This affects all organs of the body, especially those that require high energy for their function. The result is tiredness and fatigue because the body is not able to keep up with the energy demand of daily tasks.
- The present disclosure is based in part, on the observation that subjects with a complement-mediated disease (e.g., CAD), who are receiving treatment with an anti-C1s antibody, show a decrease in the levels of inflammatory cytokines along with a concomitant improvement in symptoms of fatigue.
- Accordingly, the present disclosure provides methods of monitoring and/or treating inflammation and/or fatigue in subjects with complement-mediated disorders, by analyzing the status of one or more inflammatory cytokines (e.g., IL-6, IL-8, IL-10, IL-12, IL-17, IL-18, IL-1β, IFN-γ, TNF-α, TNF-receptor, etc.) in said patients. In some embodiments, the status of one or more inflammatory cytokines is determined by measuring the level of one or more biomarkers of inflammation. In some embodiments, the levels of inflammatory cytokines and/or biomarkers of inflammation provide an objective measure of fatigue. Methods of measuring levels of inflammatory cytokines and/or biomarkers of inflammation are known in the art. The level of an inflammatory cytokine or biomarker of inflammation may be measured using standard electrophoretic and immunodiagnostic techniques, including but not limited to immunoassays such as competition, direct reaction, or sandwich type assays. Such techniques include, but are not limited to, Western blots; agglutination tests; enzyme-labeled and mediated immunoassays, such as an ELISA; biotin/avidin assays; radioimmunoassays; immunoelectrophoresis; immunoprecipitation, etc. The methods may include plasmon resonance methods, or any method that detects the presence of an inflammatory cytokine or biomarker of inflammation by the binding of an antibody, aptamer, or other binding molecule.
- In one aspect, the present disclosure provides a method comprising administering to a subject an anti-C1s antibody (e.g., the anti-C1s antibody of Table 1 or Table 2); measuring a level of one or more biomarkers of inflammation (e.g., CRP), or one or more inflammatory cytokines (e.g., IL-6, and/or IL-10) in a sample (e.g., blood, e.g., serum) from the subject. In some embodiments, the subject has a complement-mediated disease, such as CAD. In some embodiments, the subject has fatigue.
- In another aspect, the present disclosure provides a method comprising measuring a level of one or more biomarkers of inflammation (e.g., CRP), or one or more inflammatory cytokines (e.g., IL-6, and/or IL-10) in a sample from a subject being treated with an anti-C1s antibody (e.g., the anti-C1s antibody of Table 1 or Table 2). The subject, in some embodiments, has a complement-mediated disease (e.g., CAD). In some embodiments, the subject has fatigue.
- Yet other aspects of the present disclosure provide a method comprising treating a subject with an anti-C1s antibody (e.g., the anti-C1s antibody of Table 1 or Table 2), wherein the subject has fatigue, and measuring a level of one or more biomarkers of inflammation (e.g., CRP), or one or more inflammatory cytokines (e.g., IL-6, and/or IL-10) in a sample from the subject. In some embodiments, the subject has a complement-mediated disease, such as CAD.
- Further aspects of the present disclosure provide a method comprising treating a subject with an anti-C1s antibody (e.g., the anti-C1s antibody of Table 1 or Table 2), wherein the subject has a complement mediated disease (e.g., CAD), and measuring a level of one or more biomarkers of inflammation (e.g., CRP), or one or more inflammatory cytokines (e.g., IL-6, and/or IL-10) in a sample from the subject. The subject, in some embodiments, has fatigue.
- In some embodiments, a level of CRP is measured. CRP, in some embodiments, is used as a surrogate for IL-6. In some embodiments, a level of IL-6 is measured. In some embodiments, a level of IL-10 is measured.
- In some embodiments, a method of the present disclosure further comprises assessing fatigue in the subject. In some embodiments, the fatigue is assessed based on a FACIT-F score. The FACIT-F is a 13-item patient-reported outcome instrument that was designed to assess fatigue-related symptoms and impacts on daily functioning (Cella et al. Cancer 94(2):528-238 (2002)); Yellen et al., J Pain Symptom Manage 13(2):63-74 (1997); Lai et al., J Rheumatol 38(4):672-9 (2011); Reddy et al., J Palliat Med 19(5):1068-75 (2007)). Other methods of assessing fatigue may be used. A number of fatigue-measurement scales are known in the art (e.g., Fatigue Severity Scale (FSS), Fatigue Impact Scale (FIS), Brief Fatigue Inventory (BFI), Fatigue Symptom Inventory (FSI), Multidimensional Assessment of Fatigue (MAF), and Multidimensional Fatigue Symptom Inventory (MFSI), etc. (Whitehead, J Pain Symptom Manage 37(1):10-7-28 (2009)). Fatigue may be assessed as part of a multi-symptom scale or a fatigue specific scale (Hjollund et al., Health Qual Life Outcomes 5:12 (2007)).
- In some embodiments, the subject has a baseline level of CRP, IL-6, and/or IL-10 prior to treatment with an anti-C1s antibody. In some embodiments, the subject has a baseline level of CRP of greater than 3 mg/mL (e.g., greater than 4 mg/mL, greater than 5 mg/mL, greater than 6 mg/mL, greater than 7 mg/mL, greater than 8 mg/mL, greater than 9 mg/mL, or greater than 10 mg/mL, greater than 20 mg/mL, greater than 50 mg/mL, etc.). In some embodiments, the subject has a baseline level of IL-6 of greater than 1.8 pg/mL (e.g., greater than 2 pg/mL, greater than 2.5 pg/mL, greater than 3 pg/mL, between about 1.8 pg/mL and about 2 pg/mL, between about 2 pg/mL to about 2.5 pg/mL, between about 2.5 to about 3 pg/mL, between about 3 pg/mL to about 3.5 pg/mL, between about 3.5 pg/mL to about 4 pg/mL, etc.). In some embodiments, the subject has a baseline level of IL-10 of greater than 1 pg/mL (e.g., greater than 1.1 pg/mL, greater than 1.2 pg/mL, greater than 1.3 pg/mL, greater than 1.4 pg/mL, greater than 1.5 pg/mL, 2 pg/mL, greater than 2.5 pg/mL, greater than 3 pg/mL, between about 1 pg/mL to about 1.5 pg/mL, between about 1 pg/mL and about 2 pg/mL, between about 2 pg/mL to about 2.5 pg/mL, between about 2.5 to about 3 pg/mL, between about 3 pg/mL to about 3.5 pg/mL, between about 3.5 pg/mL to about 4 pg/mL, etc.). In some embodiments, the subject has a baseline level of fatigue prior to treatment with an anti-C1s antibody. In some embodiments, the baseline level of fatigue is assessed based on a FACIT-F score. In some embodiments, the baseline FACIT-F score of a subject ranges from 20-25, 25-30, 30-35, or 35-40. In some embodiments, the baseline FACIT-F score of a subject is 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40.
- It is demonstrated herein that a reduction in the levels of inflammatory cytokines correlates with an improvement in fatigue in subjects who are receiving treatment with an anti-C1s antibody. Accordingly, the levels of the inflammatory cytokines tested have been shown to be indicative of the efficacy of the treatment, for example, to improve fatigue.
- In some embodiments, the levels of one or more biomarkers of inflammation (e.g., CRP), or one or more inflammatory cytokines (e.g., IL-6, and/or IL-10) are monitored over a period of time (e.g., 1 week, one month, 6-8 weeks, three months, six months, a year, two years, etc.). In some embodiments, the levels are assessed once a week, biweekly, bimonthly, or monthly over the course of several months (e.g., at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, etc.) or over the course of several years (e.g., at least 2, 3, 4, 5, etc.).
- In some embodiments, if the level of one or more biomarkers of inflammation (e.g., CRP), or one or more inflammatory cytokines (e.g., IL-6, and/or IL-10) in the sample is reduced, for example, by at least 5%, or by at least 10% (e.g., at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, or at least 80%, between about 5% to about 10%, between about 10% to about 15%, between about 15% to about 20%, between about 20% to about 25%, between about 25% to about 30%, between about 30% to about 40%, between about 40% to about 50%, between about 50% to about 60%, between about 60% to about 80%, etc., or if the levels are reduced to a level that is within the normal range for that biomarker or inflammatory cytokine) relative to baseline and/or fatigue in the subject is improved relative to baseline, the method further comprises continuing with a current anti-C1s antibody treatment. In some embodiments, an improvement in fatigue is an improvement of at least at 3 points (e.g., at least 4 points, at least 5 points, at least 6 points, at least 7 points, at least 8 points, at least 9 points, at least 10 points, at least 11 points, at least 12 points, at least 13 points, at least 14 points, at least 15 points, 3-15 points, 3-10 points, 3-5 points, 5-15 points, 5-10 points, etc.) on the FACIT-F score relative to baseline. In some embodiments, if the level of one or more biomarkers of inflammation (e.g., CRP), or one or more inflammatory cytokines (e.g., IL-6, and/or IL-10) in the sample is within 5% or 10% of baseline and/or fatigue the subject is maintained or worsens relative to baseline, the method further comprises altering a current anti-C1s antibody treatment. In some embodiments, the fatigue is assessed based on a FACIT-F score. In some embodiments, a worsening in fatigue is a decrease of at least at 3 points (e.g., at least 4 points, at least 5 points, at least 6 points, at least 7 points, at least 8 points, at least 9 points, at least 10 points, at least 11 points, at least 12 points, at least 13 points, at least 14 points, at least 15 points, 3-15 points, 3-10 points, 3-5 points, 5-15 points, 5-10 points, etc.) on the FACIT-F score relative to baseline.
- In some embodiments, the levels of one or more biomarkers of inflammation (e.g., CRP), or one or more inflammatory cytokines (e.g., IL-6, and/or IL-10) are measured at a first point in time and a second point in time after commencing treatment with the anti-C1s antibody. In some embodiments, the first point in time and the second point in time are a few days apart (e.g., less than 1 week), 1 week apart, 2 weeks apart, 3 weeks apart, 1 month apart, 2 months apart, or several months apart (e.g., at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, etc.). In some embodiments, if the level of one or more biomarkers of inflammation (e.g., CRP), or one or more inflammatory cytokines (e.g., IL-6, and/or IL-10) in the sample is reduced, for example, by at least 5% or by at least 10% (e.g., at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, or at least 80%, between about 5% to about 10%, between about 10% to about 15%, between about 15% to about 20%, between about 20% to about 25%, between about 25% to about 30%, between about 30% to about 40%, between about 40% to about 50%, between about 50% to about 60%, between about 60% to about 80%, etc., or if the levels are reduced to a level that is within the normal range for that biomarker or inflammatory cytokine) at the second time point relative to the first time point and/or fatigue in the subject is improved relative to the first time point, the method further comprises continuing with a current anti-C1s antibody treatment. In some embodiments, if the level of one or more biomarkers of inflammation (e.g., CRP), or one or more inflammatory cytokines (e.g., IL-6, and/or IL-10) in the sample at the second time point is within 5% or 10% of the level at the first time point and/or fatigue the subject is maintained or worsens relative to the first time point, the method further comprises altering a current anti-C1s antibody treatment. In some embodiments, a worsening in fatigue is a decrease of at least at 3 points (e.g., at least 4 points, at least 5 points, at least 6 points, at least 7 points, at least 8 points, at least 9 points, at least 10 points, at least 11 points, at least 12 points, at least 13 points, at least 14 points, at least 15 points, 3-15 points, 3-10 points, 3-5 points, 5-15 points, 5-10 points, etc.) on the FACIT-F score relative to baseline.
- In some embodiments, where a patient weighs <75 kg, continuing with a current anti-C1s antibody treatment comprises: a) administering an effective dose of about 6.5 g of the anti-C1s antibody on
Day 1; b) administering an effective dose of about 6.5 g of the anti-C1s antibody onDay 8; and c) administering an effective dose of about 6.5 g of the anti-C1s antibody every other week following theDay 8 administration. In some embodiments, an effective dose of about 6.5 g of the anti-C1s antibody is administered to the individual every other week for a period of time from about 4 weeks to 1 year, e.g., from about 4 weeks to about 8 weeks, from about 2 months to about 6 months, or from about 6 months to 1 year. In some embodiments, an effective dose of about 6.5 g of the anti-C1s antibody is administered to the individual every other week for a period of time of more than 1 year. For example, in some embodiments, an effective dose of about 6.5 g of the anti-C1s antibody is administered to the individual every other week for a period of time from 1 year to 50 years, e.g., from 1 year to 2 years, from 2 years to 5 years, from 5 years to 10 years, from 10 years to 20 years, from 20 years to 30 years, from 30 years to 40 years, or from 40 years to 50 years. In some embodiments, where a patient weighs ≥75 kg, continuing with a current anti-C1s antibody treatment comprises: a) administering an effective dose of about 7.5 g of the anti-C1s antibody onDay 1; b) administering an effective dose of about 7.5 g of the anti-C1s antibody onDay 8; and c) administering an effective dose of about 7.5 g of the anti-C1s antibody every other week following theDay 8 administration. In some embodiments, an effective dose of about 7.5 g of the anti-C1s antibody is administered to the individual every other week for a period of time from about 4 weeks to 1 year, e.g., from about 4 weeks to about 8 weeks, from about 2 months to about 6 months, or from about 6 months to 1 year. In some embodiments, an effective dose of about 7.5 g of the anti-C1s antibody is administered to the individual every other week for a period of time of more than 1 year. For example, in some embodiments, an effective dose of about 7.5 g of the anti-C1s antibody is administered to the individual every other week for a period of time from 1 year to 50 years, e.g., from 1 year to 2 years, from 2 years to 5 years, from 5 years to 10 years, from 10 years to 20 years, from 20 years to 30 years, from 30 years to 40 years, or from 40 years to 50 years. - In some embodiments, altering treatment with the anti-C1s antibody comprises adjusting the dosage and/or frequency of the treatment with the anti-C1s antibody. In some embodiments, adjusting the dosage and/or frequency of the treatment with the anti-C1s antibody involves increasing the dosage and/or frequency of the treatment with the anti-C1s antibody. In some embodiments, the effective dose of the anti-C1s antibody is increased by about 0.1 g to about 0.5 g, about 0.5 g to about 1 g, about 1 g to about 1.5 g, about 1.5 g to about 2.0 g, about 2.0 to about 2.5 g, about 2.5 g to about 3 g, or about 3 g to about 3.5 g. In some embodiments, the effective dose of the anti-C1s antibody is increased by about 0.1 g, about 0.2 g, about 0.3 g, about 0.4 g, about 0.5 g, about 0.6 g, about 0.7 g, about 0.8 g, about 0.9 g, about 1 g, about 1.5 g, about 2 g, about 2.5 g, about 3 g, or about 3.5 g. In some embodiments, the frequency of the treatment is increased to monthly, bi-weekly, weekly, every other day, or daily. In some embodiments, the anti-C1s antibody is administered as one or more loading doses followed by dosing at dosing intervals. In some embodiments, the frequency of the loading doses is increased to monthly, bi-weekly, weekly, every other day, or daily. In some embodiments, the dosing interval following the initial one or more loading doses is reduced (e.g., reduced to monthly, bi-weekly, weekly, every other day, daily, etc.). In some embodiments, the number of loading doses is increased (e.g., by 1, 2, 3, 4, or more).
- In some embodiments, altering treatment with the anti-C1s antibody comprises further treatment of the subject with an anti-inflammatory agent. In some embodiments, an anti-inflammatory agent is selected from one or more of: a glucocorticoid (e.g., cortisol, prednisolone, methyl-prednisolone, dexamethasone); a nonsteroidal anti-inflammatory drug (NSAID) (e.g., aspirin, ibuprofen, fenoprofen, naproxen, sulindac, diclofenac, piroxicam, ketoprofen, diflunisal, nabumetone, etodolac, or oxaprozin, indomethacin); Cox-2 inhibitors (e.g., rofecoxib and celecoxib); interferon, interferon derivatives including betaseron, beta-interferon; soluble TNF-receptors; anti-TNF-antibodies; soluble receptors of interleukins or other cytokines (e.g., receptors of IL-6, IL-8, IL-10, IL-12, IL-17, IL-18, IL-1β, or IFN-γ); antibodies against interleukins or other cytokines (e.g., IL-6, IL-8, IL-10, IL-12, IL-17, IL-18, IL-1β, or IFN-γ); and antibodies against receptors of interleukins or other cytokines (e.g., receptors of IL-6, IL-8, IL-10, IL-12, IL-17, IL-18, IL-1β, or IFN-γ). In some embodiments, the anti-inflammatory agent is an IL-6 antagonist (e.g., an anti-IL-6 antibody). In some embodiments, the anti-inflammatory agent is an IL-10 antagonist (e.g., an anti-IL-10 antibody).
- In some embodiments, altering treatment with the anti-C1s antibody comprises further treatment of the subject to improve fatigue. In some embodiments, the further treatment to improve fatigue comprises administering one or more of: an NSAID (e.g., aspirin, ibuprofen, fenoprofen, naproxen, sulindac, diclofenac, piroxicam, ketoprofen, diflunisal, nabumetone, etodolac, oxaprozin, or indomethacin); an antihistamine (diphenhydramine or doxylamine); a stimulant (e.g., modafinil, armodafinil, methylphenidate, dexamphetamine, or amphetamine salts); a sleep aid (e.g., melatonin, cyclobenzaprine, clonazepam, zolpidem, zopiclone, or promethazine), an antiseizure drug (e.g., gabapentin, or pregabalin); an antidepressant (e.g., amitriptyline, doxepin, nortriptyline, trazodone, or mirtazapine); a pain reliever (e.g., acetaminophen, oxycodone, hydrocodone, morphine, fentanyl, buprenorphine, tapendatol, or tramadol).
- In some embodiments, the subject has undergone a blood transfusion. In some embodiments, the subject has undergone a blood transfusion prior to commencing treatment with an anti-C1s antibody, e.g., within a month, within 3 weeks, within 2 weeks, or within 1 week.
- An exemplary humanized anti-C1s antibody sequence is provided in Table 1 below.
-
TABLE 1 Anti-C1s Antibody #1 (Sutimlimab) Anti- SEQ body ID Region Sequence NO: HC EVQLVESGGGLVKPGGSLRLSCAASGFTFSNYAMSWVR 1 QAPGKGLEWVATISSGGSHTYYLDSVKGRFTISRDNSK NTLYLQMNSLRAEDTALYYCARLFTGYAMDYWGQGTLV TVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFP EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP SSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCP APEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQ EDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVL TVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPR EPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEG NVFSCSVMHEALHNHYTQKSLSLSLGK LC QIVLTQSPATLSLSPGERATMSCTASSSVSSSYLHWYQ 2 QKPGKAPKLWIYSTSNLASGVPSRFSGSGSGTDYTLTI SSLQPEDFATYYCHQYYRLPPITFGQGTKLEIKRTVAA PSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKV DNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEK HKVYACEVTHQGLSSPVTKSFNRGEC VH EVQLVESGGGLVKPGGSLRLSCAASGFTFSNYAMSWVR 3 QAPGKGLEWVATISSGGSHTYYLDSVKGRFTISRDNSK NTLYLQMNSLRAEDTALYYCARLFTGYAMDYWGQGTLV TVSS VL QIVLTQSPATLSLSPGERATMSCTASSSVSSSYLHWYQ 4 QKPGKAPKLWIYSTSNLASGVPSRFSGSGSGTDYTLTI SSLQPEDFATYYCHQYYRLPPITFGQGTKLEIK HC NYAMS 5 CDR1 HC TISSGGSHTYYLDSVKG 6 CDR2 HC LFTGYAMDY 7 CDR3 LC TASSSVSSSYLH 8 CDR1 LC STSNLAS 9 CDR2 LC HQYYRLPPIT 10 CDR3 Residue numbering follows the nomenclature of Kabat et al., U.S. Dept. of Health and Human Services, “Sequences of proteins of immunological interest” (1991). - In some embodiments, a humanized anti-C1s antibody comprises a heavy chain complementarity determining region 1 (HC CDR1) comprising the amino acid sequence of SEQ ID NO: 5. In some embodiments, a humanized anti-C1s antibody comprises a heavy chain complementarity determining region 2 (HC CDR2) comprising the amino acid sequence of SEQ ID NO: 6. In some embodiments, a humanized anti-C1s antibody comprises a heavy chain complementarity determining region 3 (HC CDR3) comprising the amino acid sequence of SEQ ID NO: 7. In some embodiments, a humanized anti-C1s antibody comprises an HC CDR1 comprising the amino acid sequence of SEQ ID NO: 5, an HC CDR2 comprising the amino acid sequence of SEQ ID NO: 6, and an HC CDR3 comprising the amino acid sequence of SEQ ID NO: 7.
- In some embodiments, a humanized anti-C1s antibody comprises a light chain complementarity determining region 1 (LC CDR1) comprising the amino acid sequence of SEQ ID NO: 8. In some embodiments, a humanized anti-C1s antibody comprises a light chain complementarity determining region 2 (LC CDR2) comprising the amino acid sequence of SEQ ID NO: 9. In some embodiments, a humanized anti-C1s antibody comprises a light chain complementarity determining region 3 (LC CDR3) comprising the amino acid sequence of SEQ ID NO: 10. In some embodiments, a humanized anti-C1s antibody comprises an LC CDR1 comprising the amino acid sequence of SEQ ID NO: 8, an LC CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and an LC CDR3 comprising the amino acid sequence of SEQ ID NO: 10.
- In some embodiments, a humanized anti-C1s antibody comprises an HC CDR1 comprising the amino acid sequence of SEQ ID NO: 5, an HC CDR2 comprising the amino acid sequence of SEQ ID NO: 6, an HC CDR3 comprising the amino acid sequence of SEQ ID NO: 7, an LC CDR1 comprising the amino acid sequence of SEQ ID NO: 8, an LC CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and an LC CDR3 comprising the amino acid sequence of SEQ ID NO: 10.
- In some embodiments, a humanized anti-C1s antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 3.
- In some embodiments, a humanized anti-C1s antibody comprises a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 4.
- In some embodiments, a humanized anti-C1s antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 3 and a VL comprising the amino acid sequence of SEQ ID NO: 4.
- In some embodiments, a humanized anti-C1s antibody comprises a heavy chain (HC) comprising the amino acid sequence of SEQ ID NO: 1.
- In some embodiments, a humanized anti-C1s antibody comprises a light chain (LC) comprising the amino acid sequence of SEQ ID NO: 2.
- In some embodiments, a humanized anti-C1s antibody comprises a HC comprising the amino acid sequence of SEQ ID NO: 1 and a LC comprising the amino acid sequence of SEQ ID NO: 2.
- In some embodiments, a humanized anti-C1s antibody comprises an HC CDR1 comprising an amino acid sequence containing no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation(s)) relative to the HC CDR1 amino acid sequence of SEQ ID NO: 5. In some embodiments, a humanized anti-C1s antibody comprises an HC CDR2 comprising an amino acid sequence containing no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation(s)) relative to the HC CDR2 amino acid sequence of SEQ ID NO: 6. In some embodiments, a humanized anti-C1s antibody comprises an HC CDR3 comprising an amino acid sequence containing no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation(s)) relative to the HC CDR3 amino acid sequence of SEQ ID NO: 7. In some embodiments, affinity maturation may be used to identify CDR variations that preserve binding specificity.
- In some embodiments, a humanized anti-C1s antibody comprises an LC CDR1 comprising an amino acid sequence containing no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation(s)) relative to the LC CDR1 amino acid sequence of SEQ ID NO: 8. In some embodiments, a humanized anti-C1s antibody comprises an LC CDR2 comprising an amino acid sequence containing no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation(s)) relative to the LC CDR2 amino acid sequence of SEQ ID NO: 9. In some embodiments, a humanized anti-C1s antibody comprises an LC CDR3 comprising an amino acid sequence containing no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation(s)) relative to the LC CDR3 amino acid sequence of SEQ ID NO: 10.
- In some embodiments, a humanized anti-C1s antibody comprises a VH comprising an amino acid sequence containing no more than 20 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation(s)) relative to the VH amino acid sequence of SEQ ID NO: 3.
- In some embodiments, a humanized anti-C1s antibody comprises a VL comprising an amino acid sequence containing no more than 20 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation(s)) relative to the VL amino acid sequence of SEQ ID NO: 4.
- In some embodiments, a humanized anti-C1s antibody comprises a VH comprising an HC CDR1 comprising the amino acid sequence of SEQ ID NO: 5, an HC CDR2 comprising the amino acid sequence of SEQ ID NO: 6, an HC CDR3 comprising the amino acid sequence of SEQ ID NO: 7, and comprises framework regions that contain no more than 20 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation(s)) relative to the VH sequence of SEQ ID NO: 3.
- In some embodiments, a humanized anti-C1s antibody comprises a VL comprising an LC CDR1 comprising the amino acid sequence of SEQ ID NO: 8, an LC CDR2 comprising the amino acid sequence of SEQ ID NO: 9, an LC CDR3 comprising the amino acid sequence of SEQ ID NO: 10, and comprises framework regions that contain no more than 20 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation(s)) relative to the VL sequence of SEQ ID NO: 4.
- In some embodiments, a humanized anti-C1s antibody comprises (a) a VH comprising an HC CDR1 comprising the amino acid sequence of SEQ ID NO: 5, an HC CDR2 comprising the amino acid sequence of SEQ ID NO: 6, an HC CDR3 comprising the amino acid sequence of SEQ ID NO: 7, and comprises framework regions that contain no more than 20 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation(s)) relative to the VH sequence of SEQ ID NO: 3, and (b) a VL comprising an LC CDR1 comprising the amino acid sequence of SEQ ID NO: 8, an LC CDR2 comprising the amino acid sequence of SEQ ID NO: 9, an LC CDR3 comprising the amino acid sequence of SEQ ID NO: 10, and comprises framework regions that contain no more than 20 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation(s)) relative to the VL sequence of SEQ ID NO: 4.
- In some embodiments, a humanized anti-C1s antibody comprises a VH comprising an amino acid sequence having at least 80% (e.g., 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) identity to the VH amino acid sequence of SEQ ID NO: 3.
- In some embodiments, a humanized anti-C1s antibody comprises a VL comprising an amino acid sequence having at least 80% (e.g., 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) identity to the VL amino acid sequence of SEQ ID NO: 4.
- In some embodiments, a humanized anti-C1s antibody comprises a VH comprising an HC CDR1 comprising the amino acid sequence of SEQ ID NO: 5, an HC CDR2 comprising the amino acid sequence of SEQ ID NO: 6, an HC CDR3 comprising the amino acid sequence of SEQ ID NO: 7, and comprises framework regions that have at least 80% (e.g., 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) identity to the framework regions of the VH sequence of SEQ ID NO: 3.
- In some embodiments, a humanized anti-C1s antibody comprises a VL comprising an LC CDR1 comprising the amino acid sequence of SEQ ID NO: 8, an LC CDR2 comprising the amino acid sequence of SEQ ID NO: 9, an LC CDR3 comprising the amino acid sequence of SEQ ID NO: 10, and comprises framework regions that have at least 80% (e.g., 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) identity to the framework regions of the VL sequence of SEQ ID NO: 4.
- In some embodiments, a humanized anti-C1s antibody comprises (a) a VH comprising an HC CDR1 comprising the amino acid sequence of SEQ ID NO: 5, an HC CDR2 comprising the amino acid sequence of SEQ ID NO: 6, an HC CDR3 comprising the amino acid sequence of SEQ ID NO: 7, and comprises framework regions that have at least 80% (e.g., 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) identity to the framework regions of the VH sequence of SEQ ID NO: 3, and (b) a VL comprising an LC CDR1 comprising the amino acid sequence of SEQ ID NO: 8, an LC CDR2 comprising the amino acid sequence of SEQ ID NO: 9, an LC CDR3 comprising the amino acid sequence of SEQ ID NO: 10, and comprises framework regions that have at least 80% (e.g., 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) identity to the framework regions of the VL sequence of SEQ ID NO: 4.
- Another exemplary humanized anti-C1s antibody sequence is provided in Table 2 below.
-
TABLE 2 Anti-C1s Antibody # 2Anti- SEQ body ID Region Sequence NO: HC QVQLVQSGAEVKKPGASVKLSCTASGFNIKDDYIHWVK 11 QAPGQGLEWIGRIDPADGHTKYAPKFQVKVTITADTST STAYLELSSLRSEDTAVYYCARYGYGREVFDYWGQGTT VTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYF PEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTV PSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPC PAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS QEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSV LTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQP REPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEW ESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQE GNVFSCSVLHEALHSHYTQKSLSLSLGK LC DIVLTQSPDSLAVSLGERATISCKASQSVDYDGDSYMN 12 WYQQKPGQPPKILIYDASNLESGIPARFSGSGSGTDFT LTISSLEPEDFAIYYCQQSNEDPWTFGGGTKVEIKRTV AAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQW VDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKAD KYEKHKVYACEVTHQGLSSPVTKSFNRGEC VH QVQLVQSGAEVKKPGASVKLSCTASGFNIKDDYIHWVK 13 QAPGQGLEWIGRIDPADGHTKYAPKFQVKVTITADTST STAYLELSSLRSEDTAVYYCARYGYGREVFDYWGQGTT VTVSS VL DIVLTQSPDSLAVSLGERATISCKASQSVDYDGDSYMN 14 WYQQKPGQPPKILIYDASNLESGIPARFSGSGSGTDFT LTISSLEPEDFAIYYCQQSNEDPWTFGGGTKVEIK HC DDYIH 15 CDR1 HC RIDPADGHTKYAPKFQV 16 CDR2 HC YGYGREVFDY 17 CDR3 LC KASQSVDYDGDSYMN 18 CDR1 LC DASNLES 19 CDR2 LC QQSNEDPWT 20 CDR3 Residue numbering follows the nomenclature of Kabat et al., U.S. Dept. of Health and Human Services, “Sequences of proteins of immunological interest” (1991). - In some embodiments, a humanized anti-C1s antibody comprises a heavy chain complementarity determining region 1 (HC CDR1) comprising the amino acid sequence of SEQ ID NO: 15. In some embodiments, a humanized anti-C1s antibody comprises a heavy chain complementarity determining region 2 (HC CDR2) comprising the amino acid sequence of SEQ ID NO: 16. In some embodiments, a humanized anti-C1s antibody comprises a heavy chain complementarity determining region 3 (HC CDR3) comprising the amino acid sequence of SEQ ID NO: 17. In some embodiments, a humanized anti-C1s antibody comprises an HC CDR1 comprising the amino acid sequence of SEQ ID NO: 15, an HC CDR2 comprising the amino acid sequence of SEQ ID NO: 16, and an HC CDR3 comprising the amino acid sequence of SEQ ID NO: 17.
- In some embodiments, a humanized anti-C1s antibody comprises a light chain complementarity determining region 1 (LC CDR1) comprising the amino acid sequence of SEQ ID NO: 18. In some embodiments, a humanized anti-C1s antibody comprises a light chain complementarity determining region 2 (LC CDR2) comprising the amino acid sequence of SEQ ID NO: 19. In some embodiments, a humanized anti-C1s antibody comprises a light chain complementarity determining region 3 (LC CDR3) comprising the amino acid sequence of SEQ ID NO: 20. In some embodiments, a humanized anti-C1s antibody comprises an LC CDR1 comprising the amino acid sequence of SEQ ID NO: 18, an LC CDR2 comprising the amino acid sequence of SEQ ID NO: 19, and an LC CDR3 comprising the amino acid sequence of SEQ ID NO: 20.
- In some embodiments, a humanized anti-C1s antibody comprises an HC CDR1 comprising the amino acid sequence of SEQ ID NO: 15, an HC CDR2 comprising the amino acid sequence of SEQ ID NO: 16, an HC CDR3 comprising the amino acid sequence of SEQ ID NO: 17, an LC CDR1 comprising the amino acid sequence of SEQ ID NO: 18, an LC CDR2 comprising the amino acid sequence of SEQ ID NO: 19, and an LC CDR3 comprising the amino acid sequence of SEQ ID NO: 20.
- In some embodiments, a humanized anti-C1s antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 13.
- In some embodiments, a humanized anti-C1s antibody comprises a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 14.
- In some embodiments, a humanized anti-C1s antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 13 and a VL comprising the amino acid sequence of SEQ ID NO: 14.
- In some embodiments, a humanized anti-C1s antibody comprises a heavy chain (HC) comprising the amino acid sequence of SEQ ID NO: 11.
- In some embodiments, a humanized anti-C1s antibody comprises a light chain (LC) comprising the amino acid sequence of SEQ ID NO: 12.
- In some embodiments, a humanized anti-C1s antibody comprises a HC comprising the amino acid sequence of SEQ ID NO: 11 and a LC comprising the amino acid sequence of SEQ ID NO: 12.
- In some embodiments, a humanized anti-C1s antibody comprises an HC CDR1 comprising an amino acid sequence containing no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation(s)) relative to the HC CDR1 amino acid sequence of SEQ ID NO: 15. In some embodiments, a humanized anti-C1s antibody comprises an HC CDR2 comprising an amino acid sequence containing no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation(s)) relative to the HC CDR2 amino acid sequence of SEQ ID NO: 16. In some embodiments, a humanized anti-C1s antibody comprises an HC CDR3 comprising an amino acid sequence containing no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation(s)) relative to the HC CDR3 amino acid sequence of SEQ ID NO: 7.
- In some embodiments, a humanized anti-C1s antibody comprises an LC CDR1 comprising an amino acid sequence containing no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation(s)) relative to the LC CDR1 amino acid sequence of SEQ ID NO: 18. In some embodiments, a humanized anti-C1s antibody comprises an LC CDR2 comprising an amino acid sequence containing no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation(s)) relative to the LC CDR2 amino acid sequence of SEQ ID NO: 19. In some embodiments, a humanized anti-C1s antibody comprises an LC CDR3 comprising an amino acid sequence containing no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation(s)) relative to the LC CDR3 amino acid sequence of SEQ ID NO: 20.
- In some embodiments, a humanized anti-C1s antibody comprises a VH comprising an amino acid sequence containing no more than 20 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation(s)) relative to the VH amino acid sequence of SEQ ID NO: 13.
- In some embodiments, a humanized anti-C1s antibody comprises a VL comprising an amino acid sequence containing no more than 20 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation(s)) relative to the VL amino acid sequence of SEQ ID NO: 14.
- In some embodiments, a humanized anti-C1s antibody comprises a VH comprising an HC CDR1 comprising the amino acid sequence of SEQ ID NO: 15, an HC CDR2 comprising the amino acid sequence of SEQ ID NO: 16, an HC CDR3 comprising the amino acid sequence of SEQ ID NO: 17, and comprises framework regions that contain no more than 20 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation(s)) relative to the VH sequence of SEQ ID NO: 13.
- In some embodiments, a humanized anti-C1s antibody comprises a VL comprising an LC CDR1 comprising the amino acid sequence of SEQ ID NO: 18, an LC CDR2 comprising the amino acid sequence of SEQ ID NO: 19, an LC CDR3 comprising the amino acid sequence of SEQ ID NO: 20, and comprises framework regions that contain no more than 20 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation(s)) relative to the VL sequence of SEQ ID NO: 14.
- In some embodiments, a humanized anti-C1s antibody comprises (a) a VH comprising an HC CDR1 comprising the amino acid sequence of SEQ ID NO: 15, an HC CDR2 comprising the amino acid sequence of SEQ ID NO: 16, an HC CDR3 comprising the amino acid sequence of SEQ ID NO: 17, and comprises framework regions that contain no more than 20 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation(s)) relative to the VH sequence of SEQ ID NO: 13, and (b) a VL comprising an LC CDR1 comprising the amino acid sequence of SEQ ID NO: 18, an LC CDR2 comprising the amino acid sequence of SEQ ID NO: 19, an LC CDR3 comprising the amino acid sequence of SEQ ID NO: 20, and comprises framework regions that contain no more than 20 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation(s)) relative to the VL sequence of SEQ ID NO: 14.
- In some embodiments, a humanized anti-C1s antibody comprises a VH comprising an amino acid sequence having at least 80% (e.g., 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) identity to the VH amino acid sequence of SEQ ID NO: 13.
- In some embodiments, a humanized anti-C1s antibody comprises a VL comprising an amino acid sequence having at least 80% (e.g., 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) identity to the VL amino acid sequence of SEQ ID NO: 14.
- In some embodiments, a humanized anti-C1s antibody comprises a VH comprising an HC CDR1 comprising the amino acid sequence of SEQ ID NO: 15, an HC CDR2 comprising the amino acid sequence of SEQ ID NO: 16, an HC CDR3 comprising the amino acid sequence of SEQ ID NO: 17, and comprises framework regions that have at least 80% (e.g., 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) identity to the framework regions of the VH sequence of SEQ ID NO: 13.
- In some embodiments, a humanized anti-C1s antibody comprises a VL comprising an LC CDR1 comprising the amino acid sequence of SEQ ID NO: 18, an LC CDR2 comprising the amino acid sequence of SEQ ID NO: 19, an LC CDR3 comprising the amino acid sequence of SEQ ID NO: 20, and comprises framework regions that have at least 80% (e.g., 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) identity to the framework regions of the VL sequence of SEQ ID NO: 14.
- In some embodiments, a humanized anti-C1s antibody comprises (a) a VH comprising an HC CDR1 comprising the amino acid sequence of SEQ ID NO: 15, an HC CDR2 comprising the amino acid sequence of SEQ ID NO: 16, an HC CDR3 comprising the amino acid sequence of SEQ ID NO: 17, and comprises framework regions that have at least 80% (e.g., 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) identity to the framework regions of the VH sequence of SEQ ID NO: 13, and (b) a VL comprising an LC CDR1 comprising the amino acid sequence of SEQ ID NO: 18, an LC CDR2 comprising the amino acid sequence of SEQ ID NO: 19, an LC CDR3 comprising the amino acid sequence of SEQ ID NO: 20, and comprises framework regions that have at least 80% (e.g., 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) identity to the framework regions of the VL sequence of SEQ ID NO: 14.
- “Antibody” encompasses antibodies or immunoglobulins of any isotype, including but not limited to humanized antibodies and chimeric antibodies. An antibody may be a single-chain antibody (scAb) or a single domain antibody (dAb) (e.g., a single domain heavy chain antibody or a single domain light chain antibody; see Holt et al. (2003) Trends Biotechnol. 21:484). The term “antibody” also encompasses fragments of antibodies (antibody fragments) that retain specific binding to an antigen. “Antibody” further includes single-chain variable fragments (scFvs), which are fusion proteins of the variable regions of the heavy (VH) and light chains (VL) of antibodies, connected with a short linker peptide, and diabodies, which are noncovalent dimers of scFv fragments that include the VH and VL connected by a small peptide linker (Zapata et al., Protein Eng. 8(10): 1057-1062 (1995)). Other fusion proteins that comprise an antigen-binding portion of an antibody and a non-antibody protein are also encompassed by the term “antibody.”
- “Antibody fragments” comprise a portion of an intact antibody, for example, the antigen binding or variable region of the intact antibody. Examples of antibody fragments include an antigen-binding fragment (Fab), Fab′, F(ab′)2, a variable domain Fv fragment (Fv), an Fd fragment, and an antigen binding fragment of a chimeric antigen receptor.
- Papain digestion of antibodies produces two identical antigen-binding fragments, referred to as “Fab” fragments, each with a single antigen-binding site, and a residual “Fc” fragment, a designation reflecting the ability to crystallize readily. Pepsin treatment yields an F(ab′)2 fragment that has two antigen combining sites and is still capable of cross-linking antigen.
- “Fv” is the minimum antibody fragment that contains a complete antigen-recognition and -binding site. This region includes a dimer of one heavy-chain variable domain and one light-chain variable domain in tight, non-covalent association. It is in this configuration that the three CDRs of each variable domain interact to define an antigen-binding site on the surface of the VH-VL dimer. Collectively, the six CDRs confer antigen-binding specificity to the antibody. However, even a single variable domain (or half of an Fv comprising only three CDRs specific for an antigen) has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site.
- “Fab” fragments contain the constant domain of the light chain and the first constant domain (CH1) of the heavy chain. Fab fragments differ from Fab′ fragments by the addition of a few residues at the carboxyl terminus of the heavy chain CH1 domain including at least one cysteine from the antibody hinge region. Fab′-SH is the designation herein for Fab′ in which the cysteine residue(s) of the constant domains bear a free thiol group. F(ab′)2 antibody fragments originally were produced as pairs of Fab′ fragments which have hinge cysteines between them. Other chemical couplings of antibody fragments are also known.
- “scFv” antibody fragments comprise the VH and VL of an antibody, wherein these regions are present in a single polypeptide chain. In some embodiments, the Fv polypeptide further comprises a polypeptide linker between the VH and VL regions, which enables the scFv to form the desired structure for antigen binding. For a review of scFv, see Pluckthun in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., Springer-Verlag, New York, pp. 269-315 (1994).
- “Diabody” refers to a small antibody fragment with two antigen-binding sites, which fragments comprise a VH connected to a VL in the same polypeptide chain (VH-VL). By using a linker that is too short to allow pairing between the two domains on the same chain, the domains are forced to pair with the complementary domains of another chain and create two antigen-binding sites. Diabodies are described more fully in, for example, Hollinger et al. Proc. Natl. Acad. Sci. USA 90: 6444-6448 (1993).
- An antibody can be monovalent or bivalent. An antibody can be an Ig monomer, which is a “Y-shaped” molecule that consists of four polypeptide chains: two heavy chains and two light chains connected by disulfide bonds.
- Antibodies can be detectably labeled, e.g., with a radioisotope, an enzyme that generates a detectable product, and/or a fluorescent protein. Antibodies can be further conjugated to other moieties, such as members of specific binding pairs, e.g., biotin member of biotin-avidin specific binding pair. Antibodies can also be bound to a solid support, including, but not limited to, polystyrene plates and/or beads.
- An “isolated” antibody is one that has been identified and separated and/or recovered from a component of its natural environment (i.e., is not naturally occurring). Contaminant components of its natural environment are materials that would interfere with uses (e.g., diagnostic or therapeutic uses) of the antibody, and can include enzymes, hormones, and other proteinaceous or nonproteinaceous solutes. In some embodiments, an antibody is purified (1) to greater than 90%, greater than 95%, or greater than 98% by weight of antibody as determined by the Lowry method, for example, more than 99% by weight, (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (3) to homogeneity by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) under reducing or non-reducing conditions using Coomassie blue or silver stain. Isolated antibodies encompass antibodies in situ within recombinant cells, as at least one component of the antibody's natural environment will not be present. In some embodiments, an isolated antibody is prepared by at least one purification step.
- A “monoclonal antibody” is an antibody produced by a group of identical cells, all of which were produced from a single cell by repetitive cellular replication. That is, the clone of cells only produces a single antibody species. While a monoclonal antibody can be produced using hybridoma production technology, other production methods known to those skilled in the art can also be used (e.g., antibodies derived from antibody phage display libraries).
- A “complementarity determining region (CDR)” is the non-contiguous antigen combining sites found within the variable region of both heavy and light chain polypeptides. CDRs have been described by Lefranc et al. (2003) Developmental and Comparative Immunology 27:55; Kabat et al., J. Biol. Chem. 252:6609-6616 (1977); Kabat et al., U.S. Dept. of Health and Human Services, “Sequences of proteins of immunological interest” (1991); by Chothia et al., J. Mol. Biol. 196:901-917 (1987); and MacCallum et al., J. Mol. Biol. 262:732-745 (1996), where the definitions include overlapping or subsets of amino acid residues when compared against each other. Nevertheless, application of either definition to refer to a CDR of an antibody or grafted antibodies or variants thereof is intended to be within the scope of the term as defined and used herein.
- The terms “LC CDR1,” “LC CDR2,” and “LC CDR3” refer, respectively, to the first, second, and third CDRs in a light chain variable region. As used herein, the terms “HC CDR1”, “HC CDR2”, and “HC CDR3” refer, respectively, to the first, second, and third CDRs in a heavy chain variable region. As used herein, the terms “CDR1”, “CDR2”, and “CDR3” refer, respectively, to the first, second and third CDRs of either chain's variable region.
- A “framework” when used in reference to an antibody variable region includes all amino acid residues outside the CDR regions within the variable region of an antibody. A variable region framework is generally a discontinuous amino acid sequence that includes only those amino acids outside of the CDRs. A “framework region” includes each domain of the framework that is separated by the CDRs.
- A “humanized antibody” is an antibody comprising portions of antibodies of different origin, wherein at least one portion comprises amino acid sequences of human origin. For example, the humanized antibody can comprise portions derived from an antibody of nonhuman origin with the requisite specificity, such as a mouse, and from antibody sequences of human origin (e.g., chimeric immunoglobulin), joined together chemically by conventional techniques (e.g., synthetic) or prepared as a contiguous polypeptide using genetic engineering techniques (e.g., DNA encoding the protein portions of the chimeric antibody can be expressed to produce a contiguous polypeptide chain). Another example of a humanized antibody is an antibody containing at least one chain comprising a CDR derived from an antibody of nonhuman origin and a framework region derived from a light and/or heavy chain of human origin (e.g., CDR-grafted antibodies with or without framework changes). Chimeric or CDR-grafted single chain antibodies are also encompassed by the term humanized immunoglobulin. See, e.g., Cabilly et al., U.S. Pat. No. 4,816,567; Cabilly et al., European Patent No. 0,125,023 B1; Boss et al., U.S. Pat. No. 4,816,397; Boss et al., European Patent No. 0,120,694 B1; Neuberger, M. S. et al., WO 86/01533; Neuberger, M. S. et al., European Patent No. 0,194,276 B1; Winter, U.S. Pat. No. 5,225,539; Winter, European Patent No. 0,239,400 B1; Padlan, E. A. et al., European Patent Application No. 0,519,596 A1. See also, Ladner et al., U.S. Pat. No. 4,946,778; Huston, U.S. Pat. No. 5,476,786; and Bird, R. E. et al., Science, 242: 423-426 (1988)), regarding single chain antibodies.
- In some embodiments, a humanized antibody is produced using synthetic and/or recombinant nucleic acids to prepare genes (e.g., cDNA) encoding the desired humanized chain. For example, nucleic acid (e.g., DNA) sequences coding for humanized variable regions can be constructed using PCR mutagenesis methods to alter DNA sequences encoding a human or humanized chain, such as a DNA template from a previously humanized variable region (see e.g., Kamman, M., et al., Nucl. Acids Res., 17: 5404 (1989)); Sato, K., et al., Cancer Research, 53: 851-856 (1993); Daugherty, B. L. et al., Nucleic Acids Res., 19(9): 2471-2476 (1991); and Lewis, A. P. and J. S. Crowe, Gene, 101: 297-302 (1991)). Using these or other suitable methods, variants can also be readily produced. For example, cloned variable regions can be mutagenized, and sequences encoding variants with the desired specificity can be selected (e.g., from a phage library; see e.g., Krebber et al., U.S. Pat. No. 5,514,548; Hoogenboom et al., WO 93/06213, published Apr. 1, 1993).
- In some embodiments, a humanized anti-C1s antibody described herein is a full-length IgG, an Ig monomer, a Fab fragment, a F(ab′)2 fragment, a Fd fragment, a scFv, a scAb, or a Fv. In some embodiments, a humanized anti-C1s antibody described herein is a full-length IgG. In some embodiments, the heavy chain of any of the humanized anti-C1s antibodies as described herein comprises a heavy chain constant region (CH) or a portion thereof (e.g., CH1, CH2, CH3, or a combination thereof). The heavy chain constant region can of any suitable origin, e.g., human, mouse, rat, or rabbit. In some embodiments, the heavy chain constant region is from a human IgG (a gamma heavy chain), e.g., IgG1, IgG2, or IgG4.
- In some embodiments, mutations can be introduced into the heavy chain constant region of any one of the humanized anti-C1s antibodies described herein. In some embodiments, one, two or more mutations (e.g., amino acid substitutions) are introduced into the heavy chain constant region (e.g., in a CH2 domain (residues 231-340 of human IgG1) and/or CH3 domain (residues 341-447 of human IgG1) and/or the hinge region, with numbering according to the Kabat numbering system (e.g., the EU index in Kabat)) to increase or decrease the affinity of the antibody for an Fc receptor (e.g., an activated Fc receptor) on the surface of an effector cell. Mutations in the Fc region of an antibody that decrease or increase the affinity of an antibody for an Fc receptor and techniques for introducing such mutations into the Fc receptor or fragment thereof are known to one of skill in the art. Examples of mutations in the Fc receptor of an antibody that can be made to alter the affinity of the antibody for an Fc receptor are described in, e.g., Smith P et al., (2012) PNAS 109: 6181-6186, U.S. Pat. No. 6,737,056, and International Publication Nos. WO 02/060919; WO 98/23289; and WO 97/34631, which are incorporated herein by reference.
- In some embodiments, one, two or more mutations (e.g., amino acid substitutions) are introduced into the hinge region of the heavy chain constant region (CH1 domain) such that the number of cysteine residues in the hinge region are altered (e.g., increased or decreased) as described in, e.g., U.S. Pat. No. 5,677,425. The number of cysteine residues in the hinge region of the CH1 domain can be altered to, e.g., facilitate assembly of the light and heavy chains, or to alter (e.g., increase or decrease) the stability of the antibody or to facilitate linker conjugation.
- In some embodiments, one, two or more amino acid mutations (i.e., substitutions, insertions or deletions) are introduced into an IgG constant domain, or FcRn-binding fragment thereof to alter (e.g., decrease or increase) half-life of the antibody in vivo. In some embodiments, the one or more mutations are introduced into an Fc or hinge-Fc domain fragment. See, e.g., International Publication Nos. WO 02/060919; WO 98/23289; and WO 97/34631; and U.S. Pat. Nos. 5,869,046; 6,121,022; 6,277,375; and 6,165,745 for examples of mutations that will alter (e.g., decrease or increase) the half-life of an antibody in vivo.
- In some embodiments, the constant region antibody described herein is an IgG1 constant region and comprises a methionine (M) to tyrosine (Y) substitution in position 252, a serine (S) to threonine (T) substitution in position 254, and a threonine (T) to glutamic acid (E) substitution in position 256, numbered according to the EU index as in Kabat. See U.S. Pat. No. 7,658,921, which is incorporated herein by reference. This type of mutant IgG, referred to as “YTE mutant” has been shown to display fourfold increased half-life as compared to wild-type versions of the same antibody (see Dall'Acqua W F et al., (2006) J Biol Chem 281: 23514-24). In some embodiments, an antibody comprises an IgG constant domain comprising one, two, three or more amino acid substitutions of amino acid residues at positions 251-257, 285-290, 308-314, 385-389, and 428-436, numbered according to the EU index as in Kabat. Additional mutations that may be introduced to the heavy chain constant region that would increase the half-life of the antibody are known in the art, e.g., the M428L/N434S (EU numbering; M459L/N466S Kabat numbering) mutations as described in Zalevsky et al., Nat Biotechnol. 2010 February; 28(2): 157-159.
- In some embodiments, one, two or more amino acid substitutions are introduced into an IgG constant domain Fc region to alter the effector function(s) of the antibody. The effector ligand to which affinity is altered can be, for example, an Fc receptor or the C1 component of complement. This approach is described in further detail in U.S. Pat. Nos. 5,624,821 and 5,648,260. In some embodiments, the deletion or inactivation (through point mutations or other means) of a constant region domain can reduce Fc receptor binding of the circulating antibody thereby increasing tumor localization. See, e.g., U.S. Pat. Nos. 5,585,097 and 8,591,886 for a description of mutations that delete or inactivate the constant domain and thereby increase tumor localization. In some embodiments, at least one amino acid substitutions may be introduced into the Fc region of an antibody described herein to remove potential glycosylation sites on Fc region, which may reduce Fc receptor binding (see, e.g., Shields R L et al., (2001) J Biol Chem 276: 6591-604).
- In some embodiments, at least one amino acid in the constant region can be replaced with a different amino acid residue such that the antibody has altered Clq binding and/or reduced or abolished complement dependent cytotoxicity (CDC). This approach is described in further detail in U.S. Pat. No. 6,194,551 (Idusogie et al.). In some embodiments, at least one amino acid residue in the N-terminal region of the CH2 domain of an antibody described herein is altered to thereby alter the ability of the antibody to fix complement. This approach is described further in International Publication No. WO 94/29351. In some embodiments, the Fc region of an antibody described herein is modified to increase the ability of the antibody to mediate antibody dependent cellular cytotoxicity (ADCC) and/or to increase the affinity of the antibody for an Fey receptor. This approach is described further in International Publication No. WO 00/42072.
- In some embodiments, to avoid potential complications due to Fab-arm exchange, which is known to occur with native IgG4 mAbs, the antibodies provided herein may comprise a stabilizing ‘Adair’ mutation (Angal S., et al., “A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody,”
Mol Immunol 30, 105-108; 1993), where serine 228 (EU numbering; residue 241 Kabat numbering) is converted to proline resulting in an IgG1-like hinge sequence. In some embodiments, to reduce residual antibody-dependent cellular cytotoxicity, a L235E (EU numbering, corresponding to L248E in Kabat numbering) mutation is introduced to the heavy chain constant region, e.g., as described in Benhnia et al., JOURNAL OF VIROLOGY, December 2009, p. 12355-12367. - In some embodiments, the heavy chain constant region in any one of the humanized anti-C1s antibodies described herein is an IgG4 constant region, or a variant there of. Examples of IgG4 constant regions and variants are provided in Table 3.
-
TABLE 3 Examples of Heavy Chain Constant Regions Heavy Chain Constant Region Amino Acid Sequence IgG4 ASTKGPSVFPLAPCSRSTSESTAALGCLVKD constant YFPEPVTVSWNSGALTSGVHTFPAVLQSSGL region WT YSLSSVVTVPSSSLGTKTYTCNVDHKPSNTK (also re- VDKRVESKYGPPCPSCPAPEFLGGPSVFLFP ferred to PKPKDTLMISRTPEVTCVVVDVSQEDPEVQF herein as NWYVDGVEVHNAKTKPREEQFNSTYRVVSVL “IgG4wt”) TVLHQDWLNGKEYKCKVSNKGLPSSIEKTIS KAKGQPREPQVYTLPPSQEEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLD SDGSFFLYSRLTVDKSRWQEGNVFSCSVMHE ALHNHYTQKSLSLSLGK (SEQ ID NO: 21) IgG4 ASTKGPSVFPLAPCSRSTSESTAALGCLVKD constant YFPEPVTVSWNSGALTSGVHTFPAVLQSSGL region YSLSSVVTVPSSSLGTKTYTCNVDHKPSNTK variant VDKRVESKYGPPCPPCPAPEFEGGPSVFLFP 1 (also PKPKDTLMISRTPEVTCVVVDVSQEDPEVQF referred NWYVDGVEVHNAKTKPREEQFNSTYRVVSVL to herein TVLHQDWLNGKEYKCKVSNKGLPSSIEKTIS as KAKGQPREPQVYTLPPSQEEMTKNQVSLTCL “IgG4v1”) VKGFYPSDIAVEWESNGQPENNYKTTPPVLD SDGSFFLYSRLTVDKSRWQEGNVFSCSVMHE ALHNHYTQKSLSLSLGK (SEQ ID NO: 22) IgG4 ASTKGPSVFPLAPCSRSTSESTAALGCLVKD constant YFPEPVTVSWNSGALTSGVHTFPAVLQSSGL region YSLSSVVTVPSSSLGTKTYTCNVDHKPSNTK variant VDKRVESKYGPPCPPCPAPEFEGGPSVFLFP 2 (also PKPKDTLMISRTPEVTCVVVDVSQEDPEVQF referred NWYVDGVEVHNAKTKPREEQFNSTYRVVSVL to herein TVLHQDWLNGKEYKCKVSNKGLPSSIEKTIS as KAKGQPREPQVYTLPPSQEEMTKNQVSLTCL “IgG4v2”) VKGFYPSDIAVEWESNGQPENNYKTTPPVLD SDGSFFLYSRLTVDKSRWQEGNVFSCSVLHE ALHSHYTQKSLSLSLGK (SEQ ID NO: 23) - In some embodiments, the light chain of any of the humanized anti-C1s antibodies described herein may further comprise a light chain constant region (CL). In some examples, the CL is a kappa light chain. In other examples, the CL is a lambda light chain. In some embodiments, the CL is a kappa light chain, the sequence of which is provided below:
-
(SEQ ID NO: 24) RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSG NSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTK SFNRGEC - Other antibody heavy and light chain constant regions are well known in the art, e.g., those provided in the IMGT database (www.imgt.org) or at www.vbase2.org/vbstat.php., both of which are incorporated by reference herein.
- An anti-C1s antibody is generally present in a composition, e.g., a pharmaceutical composition.
- A composition comprising an anti-C1s antibody, in some embodiments, comprises one or more of a salt, e.g., NaCl, MgCl2, KCl, MgSO4, etc.; a buffering agent, e.g., a Tris buffer, N-(2-Hydroxyethyl)piperazine-N′-(2-ethanesulfonic acid) (HEPES), 2-(N-Morpholino)ethanesulfonic acid (MES), 2-(N-Morpholino)ethanesulfonic acid sodium salt (MES), 3-(N-Morpholino)propanesulfonic acid (MOPS), N-tris[Hydroxymethyl]methyl-3-aminopropanesulfonic acid (TAPS), etc.; a solubilizing agent; a detergent, e.g., a non-ionic detergent such as Tween-20, etc.; a protease inhibitor; and/or glycerol.
- An anti-C1s antibody may be administered to a subject using any convenient means capable of resulting in the desired therapeutic effect or diagnostic effect. Thus, the anti-C1s antibody may be incorporated into a variety of formulations for therapeutic administration. For example, an anti-C1s antibody may be formulated into pharmaceutical compositions by combination with appropriate, pharmaceutically acceptable carriers, pharmaceutically acceptable diluents, or other pharmaceutically acceptable excipients and can be formulated into preparations in solid, semi solid, liquid or gaseous forms, such as tablets, capsules, powders, granules, ointments, solutions, suppositories, injections, inhalants and aerosols. In some embodiments, a pharmaceutical composition comprises an anti-C1s antibody and a pharmaceutically acceptable excipient.
- In pharmaceutical dosage forms, an anti-C1s antibody can be administered in the form of their pharmaceutically acceptable salts, or they can also be used alone or in appropriate association, as well as in combination, with other pharmaceutically active compounds.
- For oral preparations, an anti-C1s antibody can be used alone or in combination with appropriate additives to make tablets, powders, granules or capsules, for example, with conventional additives, such as lactose, mannitol, corn starch or potato starch; with binders, such as crystalline cellulose, cellulose derivatives, acacia, corn starch or gelatins; with disintegrators, such as corn starch, potato starch or sodium carboxymethylcellulose; with lubricants, such as talc or magnesium stearate; and if desired, with diluents, buffering agents, moistening agents, preservatives and flavoring agents.
- An anti-C1s antibody can be formulated into preparations for injection by dissolving, suspending or emulsifying the antibody in an aqueous or nonaqueous solvent, such as vegetable or other similar oils, propylene glycol, synthetic aliphatic acid glycerides, injectable organic esters (e.g., ethyl oleate), esters of higher aliphatic acids or propylene glycol; and if desired, with conventional additives such as solubilizers, isotonic agents, suspending agents, emulsifying agents, stabilizers and preservatives. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Furthermore, the pharmaceutical composition of the present disclosure can comprise further agents such as dopamine or psychopharmacologic drugs, depending on the intended use of the pharmaceutical composition.
- Pharmaceutical compositions comprising an anti-C1s antibody are prepared by mixing a subject antibody having the desired degree of purity with optional physiologically acceptable carriers, other excipients, stabilizers, surfactants, buffers and/or tonicity agents. Acceptable carriers, other excipients and/or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid, glutathione, cysteine, methionine and citric acid; preservatives (such as ethanol, benzyl alcohol, phenol, m-cresol, p-chlor-m-cresol, methyl or propyl parabens, benzalkonium chloride, or combinations thereof); amino acids such as arginine, glycine, ornithine, lysine, histidine, glutamic acid, aspartic acid, isoleucine, leucine, alanine, phenylalanine, tyrosine, tryptophan, methionine, serine, proline and combinations thereof; monosaccharides, disaccharides and other carbohydrates; low molecular weight (less than about 10 residues) polypeptides; proteins, such as gelatin or serum albumin; chelating agents such as EDTA; sugars such as trehalose, sucrose, lactose, glucose, mannose, maltose, galactose, fructose, sorbose, raffinose, glucosamine, N-methylglucosamine, galactosamine, and neuraminic acid; and/or non-ionic surfactants such as Tween, Brij Pluronics, Triton-X, or polyethylene glycol (PEG).
- The pharmaceutical composition can be in a liquid form, a lyophilized form or a liquid form reconstituted from a lyophilized form, wherein the lyophilized preparation is to be reconstituted with a sterile solution prior to administration. The standard procedure for reconstituting a lyophilized composition is to add back a volume of pure water (typically equivalent to the volume removed during lyophilization); however solutions comprising antibacterial agents can be used for the production of pharmaceutical compositions for parenteral administration; see also Chen (1992) Drug
Dev Ind Pharm 18, 1311-54. - Exemplary antibody concentrations in a pharmaceutical composition suitable for use in a method of the present disclosure can range from about 1 mg/mL to about 200 mg/mL or from about 50 mg/mL to about 200 mg/mL, or from about 150 mg/mL to about 200 mg/mL. In some aspects, the antibody concentration is from about 10 mg/mL to about 60 mg/mL, from about 12 mg/mL to about 58 mg/mL, from about 14 mg/mL to about 56 mg/mL, from about 16 mg/mL to about 54 mg/mL, from about 17 mg/mL to about 52 mg/mL, or from about 18 mg/mL to about 50 mg/mL. In some aspects, the antibody concentration is 18 mg/mL. In some aspects, the antibody concentration is 50 mg/mL.
- An aqueous formulation of an anti-C1s antibody can be prepared in a pH-buffered solution, e.g., at pH ranging from about 4.0 to about 7.0, or from about 5.0 to about 6.0, or alternatively about 5.5. Examples of buffers that are suitable for a pH within this range include phosphate-, histidine-, citrate-, succinate-, acetate-buffers and other organic acid buffers. The buffer concentration can be from about 1 mM to about 100 mM, or from about 5 mM to about 50 mM, depending, e.g., on the buffer and the desired tonicity of the formulation.
- A tonicity agent can be included in the antibody formulation to modulate the tonicity of the formulation. Exemplary tonicity agents include sodium chloride, potassium chloride, glycerin and any component from the group of amino acids, sugars as well as combinations thereof. In some embodiments, the aqueous formulation is isotonic, although hypertonic or hypotonic solutions can be suitable. The term “isotonic” denotes a solution having the same tonicity as some other solution with which it is compared, such as a physiological salt solution or serum. Tonicity agents can be used in an amount of about 5 mM to about 350 mM, e.g., in an amount of 100 mM to 350 nM.
- A surfactant can also be added to the antibody formulation to reduce aggregation of the formulated antibody and/or minimize the formation of particulates in the formulation and/or reduce adsorption. Exemplary surfactants include polyoxyethylensorbitan fatty acid esters (Tween), polyoxyethylene alkyl ethers (Brij), alkylphenylpolyoxyethylene ethers (Triton-X), polyoxyethylene-polyoxypropylene copolymer (Poloxamer, Pluronic), and sodium dodecyl sulfate (SDS). Examples of suitable polyoxyethylenesorbitan-fatty acid esters are
polysorbate 20, (sold under thetrademark Tween 20™) and polysorbate 80 (sold under the trademark TWEEN 80™). Examples of suitable polyethylene-polypropylene copolymers are those sold under the names PLURONIC® F68 or POLOXAMER 188™. Examples of suitable Polyoxyethylene alkyl ethers are those sold under the trademark BRIJ™. Exemplary concentrations of surfactant can range from about 0.001% to about 1% w/v. - A lyoprotectant can also be added in order to protect the labile active ingredient (e.g. a protein) against destabilizing conditions during the lyophilization process. For example, known lyoprotectants include sugars (including glucose and sucrose); polyols (including mannitol, sorbitol and glycerol); and amino acids (including alanine, glycine and glutamic acid). Lyoprotectants can be included in an amount of about 10 mM to 500 nM.
- In some embodiments, a suitable formulation includes an anti-C1s antibody, and one or more of the above-identified agents (e.g., a surfactant, a buffer, a stabilizer, a tonicity agent) and is essentially free of one or more preservatives, such as ethanol, benzyl alcohol, phenol, m-cresol, p-chlor-m-cresol, methyl or propyl parabens, benzalkonium chloride, and combinations thereof. In other embodiments, a preservative is included in the formulation, e.g., at concentrations ranging from about 0.001 to about 2% (w/v).
- For example, a suitable formulation can be a liquid or lyophilized formulation suitable for parenteral administration, and can comprise: about 1 mg/mL to about 200 mg/mL of a subject antibody; about 0.001% to about 1% of at least one surfactant; about 1 mM to about 100 mM of a buffer; optionally about 10 mM to about 500 mM of a stabilizer; and about 5 mM to about 305 mM of a tonicity agent; and has a pH of about 4.0 to about 7.0.
- As another example, a suitable parenteral formulation is a liquid or lyophilized formulation comprising: about 1 mg/mL to about 200 mg/mL of an anti-C1s antibody; 0.04% Tween 20 w/v; 20 mM L-histidine; and 250 mM sucrose; and has a pH of 5.5.
- As another example, a subject parenteral formulation comprises a lyophilized formulation comprising: 1) 15 mg/mL of an anti-C1s antibody; 0.04% Tween 20 w/v; 20 mM L-histidine; and 250 mM sucrose; and has a pH of 5.5; or 2) 75 mg/mL of a subject antibody; 0.04% Tween 20 w/v; 20 mM L-histidine; and 250 mM sucrose; and has a pH of 5.5; or 3) 75 mg/mL of an anti-C1s antibody; 0.02% Tween 20 w/v; 20 mM L-histidine; and 250 mM sucrose; and has a pH of 5.5; or 4) 75 mg/mL of an anti-C1s antibody; 0.04% Tween 20 w/v; 20 mM L-histidine; and 250 mM trehalose; and has a pH of 5.5; or 5) 75 mg/mL of an anti-C1s antibody; 0.02% Tween 20 w/v; 20 mM L-histidine; and 250 mM trehalose; and has a pH of 5.5.
- As another example, a suitable parenteral formulation is a liquid formulation comprising: 1) 7.5 mg/mL of an anti-C1s antibody; 0.02% Tween 20 w/v; 120 mM L-histidine; and 250 125 mM sucrose; and has a pH of 5.5; or 2) 37.5 mg/mL of an anti-C1s antibody; 0.02% Tween 20 w/v; 10 mM L-histidine; and 125 mM sucrose; and has a pH of 5.5; or 3) 37.5 mg/mL of an anti-C1s antibody; 0.01% Tween 20 w/v; 10 mM L-histidine; and 125 mM sucrose; and has a pH of 5.5; or 4) 37.5 mg/mL of an anti-C1s antibody; 0.02% Tween 20 w/v; 10 mM L-histidine; 125 mM trehalose; and has a pH of 5.5; or 5) 37.5 mg/mL of an anti-C1s antibody; 0.01% Tween 20 w/v; 10 mM L-histidine; and 125 mM trehalose; and has a pH of 5.5; or 6) 5 mg/mL of an anti-C1s antibody; 0.02% Tween 20 w/v; 20 mM L-histidine; and 250 mM trehalose; and has a pH of 5.5; or 7) 75 mg/mL of an anti-C1s antibody; 0.02% Tween 20 w/v; 20 mM L-histidine; and 250 mM mannitol; and has a pH of 5.5; or 8) 75 mg/mL of an anti-C1s antibody; 0.02% Tween 20 w/v; 20 mM L histidine; and 140 mM sodium chloride; and has a pH of 5.5; or 9) 150 mg/mL of an anti-C1s antibody; 0.02% Tween 20 w/v; 20 mM L-histidine; and 250 mM trehalose; and has a pH of 5.5; or 10) 150 mg/mL of an anti-C1s antibody; 0.02% Tween 20 w/v; 20 mM L-histidine; and 250 mM mannitol; and has a pH of 5.5; or 11) 150 mg/mL of an anti-C1s antibody; 0.02% Tween 20 w/v; 20 mM L-histidine; and 140 mM sodium chloride; and has a pH of 5.5; or 12) 10 mg/mL of an anti-C1s antibody; 0.01% Tween 20 w/v; 20 mM L-histidine; and 40 mM sodium chloride; and has a pH of 5.5.
- Suitable excipient vehicles are, for example, water, saline, dextrose, glycerol, ethanol, or the like, and combinations thereof. In addition, if desired, the vehicle can contain minor amounts of auxiliary substances such as wetting or emulsifying agents or pH buffering agents. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in the art. See, e.g., Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pennsylvania, 17th edition, 1985. The composition or formulation to be administered will, in any event, contain a quantity of a subject antibody adequate to achieve the desired state in the subject being treated.
- The pharmaceutically acceptable excipients, such as vehicles, adjuvants, carriers or diluents, are readily available to the public. Moreover, pharmaceutically acceptable auxiliary substances, such as pH adjusting and buffering agents, tonicity adjusting agents, stabilizers, wetting agents and the like, are readily available to the public.
- The present disclosure provides a method of treating a complement-mediated disease in an individual, the method comprising administering an anti-C1s antibody to the individual, where the anti-C1s antibody is administered in an effective amount of at least 4 g, at least 4.5 g, at least 5 g, at least 5.5 g, at least 6 g, at least 6.5 g, at least 7 g, at least 7.5 g, at least 8 g, at least 8.5 g, at least 9 g, at least 9.5 g, or at least 10 g.
- In some embodiments, the anti-C1s antibody is administered in an effective amount between about 5.5 g and about 10 g, about 5.5 g and about 9.5 g, about 5.5 g and about 9 g, about 5.5 g and about 8.5 g, about 5.5 g and about 8 g, about 5.5 g and about 7.5 g, about 5.5 g and about 7 g, about 5.5 g and about 6.5 g, or about 5.5 g and about 6 g. In some embodiments, the anti-C1s antibody is administered in an amount between about 4.5 g and about 8.5 g, about 4.5 g and about 8 g, about 4.5 g and about 7.5 g, about 4.5 g and about 7 g, about 4.5 g and about 6.5 g, about 4.5 g and about 6 g, about 4.5 g and about 5.5 g, or about 4.5 g and about 5 g. in some embodiments, the anti-C1s antibody is administered in an amount between about 7.5 g and about 12 g, about 7.5 g and about 11.5 g, about 7.5 g and about 11 g, about 7.5 g and about 10.5 g, about 7.5 g and about 10 g, about 7.5 g and about 9.5 g, about 7.5 g and about 9 g, about 7.5 g and about 8.5 g, or about 7.5 g and about 8 g.
- In one aspect, the present disclosure provides a method of treating a complement-mediated disease in an individual, the method comprising administering an anti-C1s antibody to the individual, where the anti-C1s antibody is administered in an amount of 5.5 g. In some embodiments, a dose of 5.5 g of the anti-C1s antibody is administered to the individual every other week. In some embodiments, the method comprises: a) administering 5.5 g of the anti-C1s antibody on
Day 1; b) administering 5.5 g of the anti-C1s antibody onDay 8; and c) administering 5.5 g of the anti-C1s antibody every other week following theDay 8 administration. In some embodiments, a dose of 5.5 g of the anti-C1s antibody is administered to the individual every other week for a period of time from about 4 weeks to 1 year, e.g., from about 4 weeks to about 8 weeks, from about 2 months to about 6 months, or from about 6 months to 1 year. In some embodiments, a dose of 5.5 g of the anti-C1s antibody is administered to the individual every other week for a period of time of more than 1 year. For example, in some embodiments, a dose of 5.5 g of the anti-C1s antibody is administered to the individual every other week for a period of time from 1 year to 50 years, e.g., from 1 year to 2 years, from 2 years to 5 years, from 5 years to 10 years, from 10 years to 20 years, from 20 years to 30 years, from 30 years to 40 years, or from 40 years to 50 years. - In some embodiments, the individual for the present method weighs 75 kg or more and the anti-C1s antibody is administered at an effective dose of about 7.5 g. In other aspects, the individual for the present method weighs less than 75 kg and the anti-C1s antibody is administered at an effective dose of about 6.5 g.
- In another aspect, the present disclosure also provides a method of treating a complement-mediated disease in an individual, the method comprising administering an anti-C1s antibody to the individual, where the anti-C1s antibody is administered in an effective dose of about 6.5 g. In some embodiments, an effective dose of about 6.5 g of the anti-C1s antibody is administered to the individual every other week. In some embodiments, the method comprises: a) administering an effective dose of about 6.5 g of the anti-C1s antibody on
Day 1; b) administering an effective dose of about 6.5 g of the anti-C1s antibody onDay 8; and c) administering an effective dose of about 6.5 g of the anti-C1s antibody every other week following theDay 8 administration. In some embodiments, an effective dose of about 6.5 g of the anti-C1s antibody is administered to the individual every other week for a period of time from about 4 weeks to 1 year, e.g., from about 4 weeks to about 8 weeks, from about 2 months to about 6 months, or from about 6 months to 1 year. In some embodiments, an effective dose of about 6.5 g of the anti-C1s antibody is administered to the individual every other week for a period of time of more than 1 year. For example, in some embodiments, an effective dose of about 6.5 g of the anti-C1s antibody is administered to the individual every other week for a period of time from 1 year to 50 years, e.g., from 1 year to 2 years, from 2 years to 5 years, from 5 years to 10 years, from 10 years to 20 years, from 20 years to 30 years, from 30 years to 40 years, or from 40 years to 50 years. - In another aspect, the present disclosure also provides a method of treating a complement-mediated disease in an individual, the method comprising administering an anti-C1s antibody to the individual, where the anti-C1s antibody is administered in an effective dose of about 7.5 g. In some embodiments, an effective dose of about 7.5 g of the anti-C1s antibody is administered to the individual every other week. In some embodiments, the method comprises: a) administering an effective dose of about 7.5 g of the anti-C1s antibody on
Day 1; b) administering an effective dose of about 7.5 g of the anti-C1s antibody onDay 8; and c) administering an effective dose of about 7.5 g of the anti-C1s antibody every other week following theDay 8 administration. In some embodiments, an effective dose of about 7.5 g of the anti-C1s antibody is administered to the individual every other week for a period of time from about 4 weeks to 1 year, e.g., from about 4 weeks to about 8 weeks, from about 2 months to about 6 months, or from about 6 months to 1 year. In some embodiments, an effective dose of about 7.5 g of the anti-C1s antibody is administered to the individual every other week for a period of time of more than 1 year. For example, in some embodiments, an effective dose of about 7.5 g of the anti-C1s antibody is administered to the individual every other week for a period of time from 1 year to 50 years, e.g., from 1 year to 2 years, from 2 years to 5 years, from 5 years to 10 years, from 10 years to 20 years, from 20 years to 30 years, from 30 years to 40 years, or from 40 years to 50 years. - In other aspects, the present disclosure provides a method of treating a complement-mediated disease in an individual, the method comprising administering an anti-C1s antibody to the individual, where the anti-C1s antibody is administered in an effective dose between about 6.5 g and about 7.5 g. In some embodiments, an effective dose between about 6.5 g to about 7.5 g of the anti-C1s antibody is administered to the individual every other week. In some embodiments, the method comprises administering an effective dose between about 6.5 g and about 7.5 g of the anti-C1s antibody on
Days - The present disclosure provides a method of treating a complement-mediated disease in a subject in need thereof, the method comprising administering an effective dose of an anti-C1s antibody to the subject, where the serum concentration of the anti-C1s antibody after the administration is at least about 20 μg/mL, at least about 25 μg/mL, at least about 30 μg/mL, at least about 35 μg/mL, at least about 40 μg/mL, at least about 45 μg/mL, at least about 50 μg/mL, at least about 55 μg/mL, at least about 60 μg/mL, at least about 65 μg/mL, at least about 70 μg/mL, at least about 75 μg/mL, at least about 80 μg/mL, at least about 85 μg/mL, at least about 90 μg/mL, at least about 95 μg/mL, or at least about 100 μg/mL. In some embodiments of the disclosure, the serum concentration of the anti-C1s antibody after the administration is between about 20 μg/mL and about 100 μg/mL, about 20 μg/mL and about 90 μg/mL, about 20 μg/mL and about 80 μg/mL, about 20 μg/mL and about 70 μg/mL, about 20 μg/mL and about 70 μg/mL, about 20 μg/mL and about 60 μg/mL, about 20 μg/mL and about 50 μg/mL, about 20 μg/mL and about 40 μg/mL, or about 20 μg/mL and about 30 μg/mL. In some embodiments, the serum concentration of the anti-C1s antibody after the administration is at least about 20 μg/mL.
- The serum concentration of the anti-C1s antibody in the subject can be measured using techniques known in the art. In some embodiments, the anti-C1s antibody is measured using a direct binding Enzyme-Linked Immunosorbent Assay (ELISA). In some embodiments, the anti-C1s antibody is measured using an indirect ELISA. In some embodiments, the anti-C1s antibody is measured using a sandwich ELISA. In some embodiments the anti-C1s antibody is measured using a competitive ELISA.
- The present disclosure provides a method of treating a complement-mediated disease in a subject in need thereof, the method comprising administering an effective dose of an anti-C1s antibody to the subject, wherein the effective dose of the anti-C1s antibody is at least about 45 mg/kg, at least about 50 mg/kg, at least about 55 mg/kg, at least about 60 mg/kg, at least about 65 mg/kg, at least about 70 mg/kg, at least about 75 mg/kg, at least about 80 mg/kg, at least about 85 mg/kg, at least about 90 mg/kg, at least about 95 mg/kg, or at least about 100 mg/kg. In some embodiments, the effective dose of the anti-C1s antibody is at least about 60 mg/kg.
- In some embodiments, the effective dose of the anti-C1s antibody is between about 60 mg/kg and about 100 mg/kg, about 60 mg/kg and about 95 mg/kg, about 60 mg/kg and about 90 mg/kg, about 60 mg/kg and about 85 mg/kg, about 60 mg/kg and about 80 mg/kg, about 60 mg/kg and about 75 mg/kg, about 60 mg/kg and about 70 mg/kg, or about 60 mg/kg and about 65 mg/kg. In some embodiments, the effective dose of the anti-C1s antibody is between about 45 mg/kg and about 85 mg/kg, about 45 mg/kg and about 80 mg/kg, about 45 mg/kg and about 75 mg/kg, about 45 mg/kg and about 70 mg/kg, about 45 mg/kg and about 65 mg/kg, about 45 mg/kg and about 60 mg/kg, or about 45 mg/kg and about 50 mg/kg. In some embodiments, the effective dose of the anti-C1s antibody is between about 85 mg/kg and about 150 mg/kg, about 85 mg/kg and about 145 mg/kg, about 85 mg/kg and about 140 mg/kg, about 85 mg/kg and about 135 mg/kg, about 85 mg/kg and about 130 mg/kg, about 85 mg/kg and about 125 mg/kg, about 85 mg/kg and about 125 mg/kg, about 85 mg/kg and about 120 mg/kg, about 85 mg/kg and about 115 mg/kg, about 85 mg/kg and about 110 mg/kg, about 85 mg/kg and about 105 mg/kg, about 85 mg/kg and about 100 mg/kg, about 85 mg/kg and about 95 mg/kg, or about 85 mg/kg and about 90 mg/kg.
- In some embodiments, the effective dose for the present methods is about 45 mg/kg, about 50 mg/kg, about 55 mg/kg, about 60 mg/kg, about 65 mg/kg, about 70 mg/kg, about 75 mg/kg, about 80 mg/kg, about 85 mg/kg, about 90 mg/kg, about 95 mg/kg, about 100 mg/kg, about 105 mg/kg, about 110 mg/kg, about 115 mg/kg, about 120 mg/kg, about 125 mg/kg, about 130 mg/kg, about 135 mg/kg, about 140 mg/kg, about 145 mg/kg, or about 150 mg/kg.
- The present disclosure provides a method of treating a complement-mediated disease in a subject in need thereof, the method comprising administering an effective dose of an anti-C1s antibody to the subject, wherein the anti-C1s antibody is administered at a dosing interval of five days, six days, seven days, eight days, nine days, ten days, eleven days, twelve days, thirteen days, fourteen days, fifteen days, sixteen days, seventeen days, eighteen days, nineteen days, twenty days, twenty one days, twenty two days, twenty three days, twenty four days, twenty five days, twenty six days, twenty seven days, twenty eight days, twenty nine days, thirty days, or thirty one days.
- In some embodiments, the anti-C1s antibody is administered at a dosing interval of one week, two weeks, three weeks, four weeks, one month, two months, three months, or four months. In some embodiments, the anti-C1s antibody increases the number of reticulocytes in the subject's blood after the administration of the anti-C1s antibody.
- In some embodiments, the anti-C1s antibody is administered as one or more loading doses followed by dosing at dosing intervals. The loading doses can be administered about 7 days apart, about 14 days apart, about 21 days apart, about 28 days apart, about two months apart, about three months apart, or about four months apart. In some embodiments, the loading dose for the present disclosure is about 45 mg/kg, about 50 mg/kg, about 55 mg/kg, about 60 mg/kg, about 65 mg/kg, about 70 mg/kg, about 75 mg/kg, about 80 mg/kg, about 85 mg/kg, about 90 mg/kg, about 95 mg/kg, about 100 mg/kg, about 105 mg/kg, about 110 mg/kg, about 115 mg/kg, about 120 mg/kg, about 125 mg/kg, about 130 mg/kg, about 135 mg/kg, about 140 mg/kg, about 145 mg/kg, or about 150 mg/kg. In some embodiments, the loading dose is a different dosage amount than the dose administered at dosing intervals. In some embodiments, the loading dose is the same dosage amount as the dose administered at dosing intervals. In one aspect, the anti-C1s antibody is administered as two weekly loading doses of 60 mg/kg followed by doses of 60 mg/kg administered every other week.
- An anti-C1s antibody is administered to an individual using any available method and route suitable for drug delivery, including in vivo and ex vivo methods, as well as systemic and localized routes of administration.
- Conventional and pharmaceutically acceptable routes of administration include intranasal, intramuscular, intratracheal, intrathecal, intracranial, subcutaneous, intradermal, topical, intravenous, intraperitoneal, intraarterial (e.g., via the carotid artery), spinal or brain delivery, rectal, nasal, oral, and other enteral and parenteral routes of administration. Routes of administration can be combined, if desired, or adjusted depending upon the antibody and/or the desired effect. An anti-C1s antibody composition can be administered in a single dose or in multiple doses. In some embodiments, an anti-C1s antibody is administered orally. In some embodiments, an anti-C1s antibody is administered subcutaneously. In some embodiments, an anti-C1s antibody is administered intramuscularly. In some embodiments, an anti-C1s antibody is administered intravenously.
- An anti-C1s antibody can be administered to a host using any available conventional methods and routes suitable for delivery of conventional drugs, including systemic or localized routes. In general, routes of administration contemplated by the disclosure include, but are not necessarily limited to, enteral, parenteral, or inhalational routes.
- Parenteral routes of administration other than inhalation administration include, but are not necessarily limited to, topical, transdermal, subcutaneous, intramuscular, intraorbital, intracapsular, intraspinal, intrasternal, intrathecal, and intravenous routes, i.e., any route of administration other than through the alimentary canal. Parenteral administration can be carried to effect systemic or local delivery of a subject antibody. Where systemic delivery is desired, administration typically involves invasive or systemically absorbed topical or mucosal administration of pharmaceutical preparations.
- By “treatment” is meant at least an amelioration of the symptoms associated with the pathological condition afflicting the host, where amelioration is used in a broad sense to refer to at least a reduction in the magnitude of a parameter, e.g., symptom, associated with the pathological condition being treated, such as a complement-mediated disease. As such, treatment also includes situations where the pathological condition, or at least symptoms associated therewith, are completely inhibited, e.g., prevented from happening, or stopped, e.g., terminated, such that the host no longer suffers from the pathological condition, or at least the symptoms that characterize the pathological condition.
- In some embodiments, an anti-C1s antibody is administered by injection and/or delivery, e.g., to a site in a brain artery or directly into brain tissue. An anti-C1s antibody can also be administered directly to a target site e.g., by biolistic delivery to the target site.
- A variety of hosts (wherein the term “host” is used interchangeably herein with the terms “subject,” “individual,” and “patient”) are treatable according to the subject methods. Generally such hosts are “mammals” or “mammalian,” where these terms are used broadly to describe organisms which are within the class mammalia, including the orders carnivore (e.g., cats), herbivores (e.g., cattle, horses, and sheep), omnivores (e.g., dogs, goats, and pigs), rodentia (e.g., mice, guinea pigs, and rats), and primates (e.g., humans, chimpanzees, and monkeys). In some embodiments, the host is an individual that has a complement system, such as a mammal, fish, or invertebrate. In some embodiments, the host is a complement system-containing mammal, fish, or invertebrate companion animal, agricultural animal, work animal, zoo animal, or lab animal. In some embodiments, the individual is human.
- In some embodiments, a complement-mediated disease is characterized by the presence in a cell, a tissue, or a fluid of an elevated (higher than normal) amount of C1s or of an elevated level of complement C1s activity. For example, in some embodiments, a complement-mediated disease is characterized by the presence in brain tissue and/or cerebrospinal fluid of an elevated amount and/or an elevated activity of C1s. A “higher than normal” amount of C1s in a cell, a tissue, or a fluid indicates that the amount of C1s in the cell, tissue or fluid is higher than a normal, control level, e.g., higher than a normal, control level for an individual or population of individuals of the same age group. A “higher than normal” level of C1s activity in a cell, a tissue, or a fluid indicates that the proteolytic cleavage effected by C1s in the cell, tissue or fluid is higher than a normal, control level, e.g., higher than a normal, control level for an individual or population of individuals of the same age group. In some embodiments, an individual having a complement-mediated disease exhibits one or more additional symptoms of such a disease. It should be understood that the term “disease” encompasses “disorders.” The two terms may be used interchangeably. In some embodiments, a complement-mediated disease is a classical complement-mediated disease.
- In some embodiments, a complement-mediated disease is characterized by the presence in a cell, a tissue, or a fluid of a lower than normal amount of C1s or of a lower level of complement C1s activity. For example, in some embodiments, a complement-mediated disease is characterized by the presence in brain tissue and/or cerebrospinal fluid of a lower amount and/or a lower activity of C1s. A “lower than normal” amount of C1s in a cell, a tissue, or a fluid indicates that the amount of C1s in the cell, tissue or fluid is lower than a normal, control level, e.g., lower than a normal, control level for an individual or population of individuals of the same age group. A “lower than normal” level of C1s activity in a cell, a tissue, or a fluid indicates that the proteolytic cleavage effected by C1s in the cell, tissue or fluid is lower than a normal, control level, e.g., lower than a normal, control level for an individual or population of individuals of the same age group. In some embodiments, an individual having a complement-mediated disease exhibits one or more additional symptoms of such a disease.
- A complement-mediated disease is a disease in which the amount or activity of complement C1s is such as to cause disease in an individual. Non-limiting examples of complement-mediated diseases include cold agglutinin disease (CAD), bullous pemphigoid, multifocal motor neuropathy (MMN), autoantibody mediated peripheral neuropathy, Myasthenia Gravis, lupus nephritis, mucous membrane pemphigoid, cicatricial pemphigoid, ocular pemphigoid, and antineutrophil cytoplasmic autoantibody (ANCA) associated vasculitis.
- In some embodiments, the present method includes treatment of primary CAD in a subject in need thereof comprising administering an effective dose between about 6.5 g and about 7.5 g, e.g., about 6.5 g for subjects with less than 75 kg of bodyweight and 7.5 g for subjects with 75 kg or more of bodyweight, of an anti-C1s antibody, e.g., sutimlimab. In some embodiments, the present methods have no limitation of use associated with anemia severity, transfusion history, or prior treatment experience. In some embodiments, there is no REMS requirement prior to dosing; vaccinate patients according to local guidelines prior to treatment initiation to reduce risk of serious infection. In some embodiments, the dose is administered as intravenous infusion over 1 hour on
Day 0,Day 7, and every 14 days±2 days thereafter starting onDay 21. Intravenous infusion can take place within clinic or home setting. As a result of the treatment, the anti-C1s antibody can improve anemia and associated clinical symptoms, eliminate transfusion, prevent hemolysis, rapid onset of action, improve fatigue and quality of life, and/or any combination thereof. In other embodiments, the treatment shows no drug related serious or severe adverse events; no discontinuations due to adverse events, no serious infections; no REMS requirement, most commonly reported adverse events were similar to placebo, or any combination thereof. In other embodiments, as a result of the treatment, the anti-C1s antibody prevents chronic hemolysis, resulting in improvement in anemia, elimination of transfusion, improvement of quality of life, and ultimately reduction of risk of life-threatening thromboembolic events, morbidity, and mortality, and reduced healthcare utilization. In some embodiments, the anti-C1s antibody improves fatigue. - In some embodiments, the complement-mediated disease is bullous pemphigoid. In some embodiments, the complement-mediated disease is antibody-mediated rejection of organ transplant. In some embodiments, the complement-mediated disease is cold agglutinin disease. In some embodiments, the complement-mediated disease is warm autoimmune hemolytic anemia. In some embodiments, the complement-mediated disease antibody-mediated transplant rejection. In some embodiments, the classical complement-mediated disease is immunothrombocytopenic purpura. In some embodiments, the complement-mediated disease is neuromyelitis optica.
- In some embodiments, the complement-mediated disease is multifocal motor neuropathy (MMN). In some embodiments, the complement-mediated disease is myasthenia gravis. In some embodiments, the complement-mediated disease is chronic inflammatory demyelinating polyneuropathy. In some embodiments, the complement-mediated disease is lupus nephritis. In some embodiments, the complement-mediated disease is mucous membrane pemphigoid. In some embodiments, the complement-mediated disease is cicatricial pemphigoid. In some embodiments, the complement-mediated disease is ocular pemphigoid. In some embodiments, the complement-mediated disease is antineutrophil cytoplasmic autoantibody (ANCA) associated vasculitis.
- In other embodiments, the complement-mediated disease is an autoantibody mediated peripheral neuropathy including, but not limited to, Guillain-Barré syndrome, Myasthenia Gravis, acute inflammatory demyelinating polyneuropathy (AIDP), chronic inflammatory demyelinating polyneuropathy (CIDP), acute motor axonal neuropathy (AMAN), acute motor and sensory axonal neuropathy (AMSAN), pharyngeal-cervical brachial variant, Miller Fisher syndrome, or any combination thereof. In some embodiments, the complement-mediated disease is Guillain-Barré syndrome, which presents as rapid-onset muscle weakness, beginning in the feet and hands that spreads to the arms and upper body. During the acute phase, it can be fatal as respiratory failure can occur, and other autonomic functions (such as heart rate) can be affected. ˜7.5% of all cases are fatal. Incidence: 1-2/100,000.
- In other embodiments, the complement-mediated disease is Myasthenia Gravis, which exhibits weakness, fatigue that becomes progressively worse during periods of physical activity, generally starts with ocular weakness; progressing to a more severe form, characterized by weakness in the extremities and performing basic life functions (chewing, swallowing, breathing). In a myasthenic crisis, respiratory paralysis occurs, necessitating assisted ventilation to sustain life.
- In other embodiments, the complement-mediated disease is multifocal motor neuropathy (MMN), which is an inflammatory autoimmune disease of the lower nervous system. MMN is a pure motor neuropathy, which has the mean age onset of 40 years. MMN is characterized by: slowly progressive, asymmetric distal limb weakness; conduction block (CB), often affecting ulnar, median, radial or tibial nerves; and/or atrophic muscles. Other clinical features include muscle cramps, fasciculations, and an increase of weakness in cold conditions. GM1-specific IgM antibodies are present in the serum of ˜half of all patients, titers of which correlate with their in vitro complement-activating capacity and disease severity. Intravenous immunoglobulin (IVIg) is effective in MMN. Nevertheless, patients still undergo slowly progressive axonal degeneration and muscle weakness that cannot be fully prevented with chronic IVIg therapy.
- In other embodiments, a complement-mediated disease useful for treatment is neuromyelitis optica (NMO). NMO is caused by anti-Aquaporin-4 IgG autoantibody (NMO-IgG) which activates complement and kills astrocytes resulting in death of oligodendrocytes that myelinate the optic nerve and spinal cord. Vision loss and paralysis occur following attacks.
- In other embodiments, a complement-mediated disease useful for treatment is systemic lupus erythematosus (SLE). Systemic lupus erythematosus (SLE) is an autoimmune disease that affects 0.04% of the population of developed countries. SLE is believed to arise as a result of an impairment in the body's waste disposal system, in which complement plays a key role. In humans, congenital deficiencies of the complement proteins in the C1 complex as well as C2 and C4 are associated with an increased risk of developing SLE. However, a substantial number of patients with SLE develop hypocomplementemia with depletion of C1q and other components of the classical pathway: e.g., complement deposition on RBCs and/or C1q deposition in affected tissues.
- In other embodiment, a complement-mediated disease useful for treatment is lupus nephritis (LN). LN is the renal manifestation of SLE that occurs in 25-50% of patients and is the primary cause of morbidity and mortality. C1q antibodies are closely associated with renal involvement and are highly predictive of and present during flares. Active LN is rarely observed in the absence of C1q Abs. Multiple studies have shown a negative correlation with C1q Ab titers and serum C1q, and a positive correlation with C1q deposition in the glomeruli in patients with LN.
- In some embodiments, a complement-mediated disease useful for treatment is membranoproliferative glomerulonephritis (type I) (Mixed Cryoglobulinemia). Mixed Cryoglobulinemia is a systemic vasculitis mediated by immune complexes (IC). It appears most often in the context of chronic infections (HCV—80% of MC cases). Clinically, cryoglobulinemia manifests itself with symptoms like weakness and arthralgias and variable cutaneous and visceral organ involvement. Steroids suppress inflammation with success in some patients, but additional plasmapheresis to remove circulating cryoglobulins and immunosuppressive treatment to inhibit the formation of new cryoglobulins are often necessary.
- In a
Phase 3, pivotal, open-label, multicenter study to assess the efficacy and safety of sutimlimab in patients with primary cold agglutinin disease (CAD) who have a recent history of blood transfusion (ClinicalTrials.gov Identifier: NCT03347396; EudraCT No. 2017-003538-10; EFC16215), patients with CAD received intravenous doses of sutimlimab onDays weeks - Mean IL-6 level (mean pg/mL [standard error of the mean (SEM)]) steadily decreased from baseline (3.21 [0.958]; normal values IL-6<3.2 pg/mL.) to follow up at all time points after initiating sutimlimab treatment (
FIG. 1 ), showing rapid onset and durable pattern of decline as early as Week 1 (2.70 [0.839]). Mean IL-6 level was reduced by more than half by Week 3 (1.56 [0.297]), slightly rose at Week 5 (1.88 [0.383]) and was lowest at TAT (1.31 [0.201]). Mean IL-10 level (pg/mL [SEM]) also decreased in a time-dependent manner from baseline (1.36 [0.310]) initially at Week 1 (0.99 [0.250]). Mean IL-10 marginally increased at Week 3 (1.07 [0.306]) but dropped at Week 5 (0.83 [0.142]) and was lowest by TAT (0.82 [0.129]) with sutimlimab treatment (FIG. 2 ). At baseline, mean (SEM) FACIT-F score was 32.5 (2.265) (FIGS. 1-2 ). Patient FACIT-F scores showed early and late improvements with mean score increases at Week 1 (39.67 [1.740]), Week 3 (40.70 [1.542]), Week 5 (43.75 [1.191]), and at TAT (41.86 [1.958]). Decreased inflammation, as demonstrated by IL-6 and IL-10 activity, correlated inversely with FACIT-F score improvements over time. - In this
Phase 3 study, decrease from baseline to TAT in proinflammatory cytokine IL-6 levels and regulatory cytokine IL-10 levels were observed during sutimlimab treatment, highlighting the influence of complement inhibition on inflammation in CAD. Improved FACIT-F scores are concurrent with sutimlimab treatment and inhibition of the classical complement pathway. An inverse correlation was noted between select inflammatory cytokines and meaningful improvements in patients' fatigue, suggesting complement-mediated inflammation may additionally contribute to manifestation of fatigue in patients with CAD. - Additional time points and parameters are presented in
FIGS. 3 and 4 . Cytokine profiles for IL-6 and IL-10, FACIT-F scores, and hemoglobin (Hb) levels were evaluated from baseline toWeeks Week 25 represented the treatment assessment time point [TAT]). FACIT-F is a patient-reported quality of life (QOL) outcome that is a validated assessment tool for measuring fatigue in patients with CAD (Roth A et al. N Engl J Med. 384(14):1323-1334 (2021) and Hill Q A et al. EHA 2021; Poster). FACIT-Fatigue scale range is 0 (worst fatigue) to 52 (no fatigue); a 3-point increase from baseline is considered a clinically meaningful improvement (Röth A et al. N Engl J Med. 384(14):1323-1334 (2021)). Activity of the classical complement pathway was measured via the Wieslab CP assay. Descriptive summary statistics of changes in IL-6, IL-10, FACIT-Fatigue, Hb, C4 and classical complement pathway activity were reported at each time point. - Mean (SEM) IL-6 level was lower than baseline (3.21 [0.958] pg/mL) as early as Week 1 (2.70 [0.839] pg/mL) and at all other timepoints after initiating sutimlimab treatment (
FIG. 3 ). Compared to baseline, mean IL-6 level decreased by more than half at Week 3 (1.56 [0.297] pg/mL), a level that was maintained at Week 13 (1.57 [0.201] pg/mL), and lower still at the TAT (1.31 [0.201] pg/mL). Mean (SEM) IL-10 level also declined from baseline (1.36 [0.310] pg/mL) to follow-up during sutimlimab treatment (FIG. 4 ), with a reduction observed as early as Week 1 (0.99 [0.250] pg/mL). Mean (SEM) IL-10 was 0.83 (0.132) pg/mL atWeek 13 and was lowest at the TAT (0.82 [0.129] pg/mL). Decreased levels of IL-6 and IL-10 coincided with rapid and durable increases in mean FACIT-Fatigue score (i.e., decreased fatigue). At baseline, mean (SEM) FACIT-Fatigue score was 32.5 (2.3), consistent with the level of fatigue reported for patients with paroxysmal nocturnal hemoglobinuria (Schrezenmeier H et al. Haematologica 99(5):922-929 (2014)) and cancer (Escalante C P et al. Cancer Med. 8(2):543-553 (2019)). Clinically meaningful improvements in fatigue were observed at Week 1 (7-point mean score improvement) and TAT (10-point mean score improvement) and coincided with inhibition of the classical complement pathway. Sutimlimab treatment led to rapid suppression of Wieslab CP activity and normalization of mean total C4 level, effects that were maintained over the treatment period. - Thus, treatment with sutimlimab, a selective C1s inhibitor, was associated with rapid and durable decreases in inflammatory cytokines (IL-6, IL-10) from baseline to follow up at the TAT, highlighting the effects of classical complement pathway inhibition (i.e., suppression of Wieslab CP activity and normalized total C4 level) in patients with CAD. Concurrent inverse changes over time were observed for these select inflammatory/regulatory cytokines and fatigue; these results suggest that, in addition to anemia, complement-mediated inflammation may contribute to fatigue in patients with CAD and further support C1s inhibition as an effective therapeutic target for this disorder.
Claims (22)
1. A method comprising administering to a subject an anti-C1s antibody; measuring a level of IL-6, and/or IL-10 in a sample from the subject; and optionally assessing fatigue in the subject.
2. (canceled)
3. The method of claim 1 , wherein the subject has a complement-mediated disease, optionally a classical complement-mediated disease, further optionally cold agglutinin disease (CAD).
4. The method of claim 1 , wherein the subject has fatigue.
5. A method comprising treating a subject with an anti-C1s antibody, wherein the subject has fatigue; measuring a level of IL-6, and/or IL-10 in a sample from the subject; and optionally assessing fatigue in the subject.
6. The method of claim 5 , wherein the subject has a complement-mediated disease, optionally a classical complement-mediated disease, further optionally cold agglutinin disease (CAD).
7. A method comprising treating a subject with an anti-C1s antibody, wherein the subject has a complement mediated disease, optionally cold agglutinin disease (CAD); measuring a level of IL-6, and/or IL-10 in a sample from the subject; and optionally assessing fatigue in the subject.
8. The method of claim 7 , wherein the subject has fatigue.
9. The method of claim 1 , wherein the subject has a baseline level of IL-6, and/or IL-10 prior to treatment with the anti-C1s antibody, and/or wherein the subject has a baseline level of fatigue prior to treatment with the anti-C1s antibody.
10. The method of claim 9 , wherein:
(a) if the level of IL-6, and/or IL-10 in the sample is reduced, optionally by at least 10%, relative to baseline and/or fatigue in the subject is improved relative to baseline, the method further comprises continuing with the current anti-C1s antibody treatment; or
(b) if the level of IL-6, and/or IL-10 in the sample is within 10% of baseline and/or fatigue the subject is maintained or worsens relative to baseline, the method further comprises altering the current anti-C1s antibody treatment.
11. The method of claim 10 , wherein altering the current anti-C1s antibody treatment comprises: (i) adjusting the dosage and/or frequency of the treatment with the anti-C1s antibody, (ii) further treatment of the subject with an anti-inflammatory agent, or (iii) further treatment of the subject to improve fatigue.
12.-13. (canceled)
14. The method of claim 1 , further comprising monitoring levels of IL-6, and/or IL-10 in the subject over a period of time.
15. The method of claim 1 , wherein the subject has undergone a blood transfusion.
16. The method of claim 1 , wherein the fatigue is assessed based on a Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) score, optionally wherein an improvement in fatigue is a change by at least 3 points on a FACIT-F score relative to baseline.
17. The method of claim 1 , wherein the anti-C1s antibody comprises a heavy chain (HC) complementarity determining region 1 (CDR1) comprising the amino acid sequence of SEQ ID NO: 5, an HC complementarity determining region 2 (CDR2) comprising the amino acid sequence of SEQ ID NO: 5 6, an HC complementarity determining region 3 (CDR3) comprising the amino acid sequence of SEQ ID NO: 7, a light chain (LC) CDR1 that comprises the amino acid sequence of SEQ ID NO: 8, an LC CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and an LC CDR3 comprising the amino acid sequence of SEQ ID NO: 10.
18. The method of claim 17 , wherein the anti-C1s antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 3 and comprises a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 4.
19. The method of claim 18 , wherein the anti-C1s antibody comprises an HC comprising the amino acid sequence of SEQ ID NO: 1 and an LC comprising the amino acid sequence of SEQ ID NO: 2.
20. The method of claim 1 , wherein the anti-C1s antibody comprises a heavy chain (HC) complementarity determining region 1 (CDR1) comprising the amino acid sequence of SEQ ID NO: 15, an HC CDR2 comprising the amino acid sequence of SEQ ID NO: 16, an HC CDR3 comprising the amino acid sequence of SEQ ID NO: 17, a light chain (LC) complementarity determining region 1 (CDR1) comprising the amino acid sequence of SEQ ID NO: 18, an LC CDR2 comprising the amino acid sequence of SEQ ID NO: 19, and an LC CDR3 comprising the amino acid sequence of SEQ ID NO: 20.
21. The method of claim 20 , wherein the anti-C1s antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 13 and comprises a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 14.
22. The method of claim 21 , wherein the anti-C1s antibody comprises an HC comprising the amino acid sequence of SEQ ID NO: 11 and an LC comprising the amino acid sequence of SEQ ID NO: 12.
23. The method of claim 1 , wherein the anti-C1s antibody comprises an IgG4 constant region.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/164,521 US20230357433A1 (en) | 2020-08-06 | 2023-02-03 | Inflammatory cytokines and fatigue in subject with a complement mediated disease |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063062243P | 2020-08-06 | 2020-08-06 | |
PCT/US2021/044761 WO2022031978A1 (en) | 2020-08-06 | 2021-08-05 | Inflammatory cytokines and fatigue in subject with a complement mediated disease |
US18/164,521 US20230357433A1 (en) | 2020-08-06 | 2023-02-03 | Inflammatory cytokines and fatigue in subject with a complement mediated disease |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2021/044761 Continuation WO2022031978A1 (en) | 2020-08-06 | 2021-08-05 | Inflammatory cytokines and fatigue in subject with a complement mediated disease |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230357433A1 true US20230357433A1 (en) | 2023-11-09 |
Family
ID=77750323
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/164,521 Pending US20230357433A1 (en) | 2020-08-06 | 2023-02-03 | Inflammatory cytokines and fatigue in subject with a complement mediated disease |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230357433A1 (en) |
EP (1) | EP4193153A1 (en) |
JP (1) | JP2023536904A (en) |
KR (1) | KR20230044312A (en) |
CN (1) | CN116724236A (en) |
AU (1) | AU2021320870A1 (en) |
BR (1) | BR112023001942A2 (en) |
CA (1) | CA3187866A1 (en) |
IL (1) | IL300376A (en) |
MX (1) | MX2023001492A (en) |
WO (1) | WO2022031978A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202304508A (en) * | 2021-03-31 | 2023-02-01 | 美商百歐維拉提夫美國公司 | Reducing surgery-associated hemolysis in cold agglutinin disease patients |
WO2023245048A1 (en) * | 2022-06-15 | 2023-12-21 | Bioverativ Usa Inc. | Anti-complement c1s antibody formulation |
WO2023250507A1 (en) * | 2022-06-24 | 2023-12-28 | Bioverativ Usa Inc. | Methods for treating complement-mediated diseases |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
DE3856559T2 (en) | 1987-05-21 | 2004-04-29 | Micromet Ag | Multifunctional proteins with predetermined objectives |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
AU665025B2 (en) | 1991-09-23 | 1995-12-14 | Cambridge Antibody Technology Limited | Production of chimeric antibodies - a combinatorial approach |
GB9206422D0 (en) | 1992-03-24 | 1992-05-06 | Bolt Sarah L | Antibody preparation |
AU4116793A (en) | 1992-04-24 | 1993-11-29 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
CA2115811A1 (en) | 1993-02-17 | 1994-08-18 | Claus Krebber | A method for in vivo selection of ligand-binding proteins |
JPH08511420A (en) | 1993-06-16 | 1996-12-03 | セルテック・セラピューテイクス・リミテッド | Body |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
KR100940380B1 (en) | 1999-01-15 | 2010-02-02 | 제넨테크, 인크. | Polypeptide Variants with Altered Effector Function |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
ES2649037T3 (en) | 2000-12-12 | 2018-01-09 | Medimmune, Llc | Molecules with prolonged half-lives, compositions and uses thereof |
US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
EP2175884B8 (en) | 2007-07-12 | 2017-02-22 | GITR, Inc. | Combination therapies employing gitr binding molecules |
RS63212B1 (en) | 2012-11-02 | 2022-06-30 | Bioverativ Usa Inc | Anti-complement c1s antibodies and uses thereof |
EP2997045A4 (en) * | 2013-05-15 | 2016-11-23 | Annexon Inc | Anti-complement factor c1s antibodies and uses thereof |
EP4212175A1 (en) | 2015-04-06 | 2023-07-19 | Bioverativ USA Inc. | Humanized anti-c1s antibodies and methods of use thereof |
TWI773695B (en) * | 2016-10-12 | 2022-08-11 | 美商生物維瑞提夫美國公司 | ANTI-C1s ANTIBODIES AND METHODS OF USE THEREOF |
CA3055781A1 (en) | 2017-03-14 | 2018-09-20 | Bioverativ Usa Inc. | Methods for treating complement-mediated diseases and disorders |
AU2019250403A1 (en) * | 2018-04-13 | 2020-11-19 | Chugai Seiyaku Kabushiki Kaisha | Anti-complement component antibodies and methods of use |
-
2021
- 2021-08-05 JP JP2023507563A patent/JP2023536904A/en active Pending
- 2021-08-05 AU AU2021320870A patent/AU2021320870A1/en active Pending
- 2021-08-05 CA CA3187866A patent/CA3187866A1/en active Pending
- 2021-08-05 KR KR1020237007908A patent/KR20230044312A/en unknown
- 2021-08-05 EP EP21770091.3A patent/EP4193153A1/en active Pending
- 2021-08-05 BR BR112023001942A patent/BR112023001942A2/en unknown
- 2021-08-05 MX MX2023001492A patent/MX2023001492A/en unknown
- 2021-08-05 WO PCT/US2021/044761 patent/WO2022031978A1/en active Application Filing
- 2021-08-05 CN CN202180056699.1A patent/CN116724236A/en active Pending
- 2021-08-05 IL IL300376A patent/IL300376A/en unknown
-
2023
- 2023-02-03 US US18/164,521 patent/US20230357433A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20230044312A (en) | 2023-04-03 |
CN116724236A (en) | 2023-09-08 |
WO2022031978A1 (en) | 2022-02-10 |
JP2023536904A (en) | 2023-08-30 |
BR112023001942A2 (en) | 2023-02-28 |
MX2023001492A (en) | 2023-03-08 |
EP4193153A1 (en) | 2023-06-14 |
IL300376A (en) | 2023-04-01 |
AU2021320870A1 (en) | 2023-04-06 |
CA3187866A1 (en) | 2022-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230357433A1 (en) | Inflammatory cytokines and fatigue in subject with a complement mediated disease | |
JP7293122B2 (en) | Methods for treating complement-mediated diseases and disorders | |
TWI391401B (en) | Humanized anti-factor d antibodies and uses thereof | |
JP6790304B2 (en) | BTLA agonist antibody and its use | |
JP2020525411A (en) | Immunotherapy for hepatocellular carcinoma | |
JP7419262B2 (en) | Preparations containing anti-PCSK9 antibodies and uses thereof | |
JP2021515039A (en) | Compositions and Methods for Treating Severe Asthma | |
KR20180020296A (en) | How to treat autoimmune and allogeneic immune disorders | |
CA3161801A1 (en) | Methods of treating lupus nephritis using interleukin-17 (il-17) antagonists | |
US20240052062A1 (en) | Reducing surgery-associated hemolysis in cold agglutinin disease patients | |
US20240025978A1 (en) | Methods for treating complement-mediated diseases | |
RU2796586C2 (en) | Antibodies to cd6 for the treatment of severe asthma | |
JP2024503432A (en) | Use of anti-CD38 antibodies and anti-CD38 antibodies | |
WO2023237928A2 (en) | Igf1r antibodies | |
CN114786717A (en) | Stable aqueous anti-TFPI antibody formulations | |
JP2023503105A (en) | IGFBP3 Antibodies and Their Therapeutic Uses | |
TW202017595A (en) | Dosing regimens for use with pcsk9 inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BIOVERATIV USA INC., MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ARIAS, JAIME MORALES;PATEL, PARIJA S.;HOBBS, WILLIAM E.;AND OTHERS;SIGNING DATES FROM 20210723 TO 20210802;REEL/FRAME:063842/0036 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |